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DEFINITIONS OF TERMS 
 
 
Percutaneous 
Absorption 
 
A general term which describes the passage of a compound 
through the skin but does not necessarily indicate its eventual 
fate. The process can be subdivided into the following steps. 
1. Penetration The entry of a compound into a particular layer. 
2. Permeation The diffusion of a compound through a particular layer. 
 
Transdermal 
formulation 
 
A formulation which after local application to the skin surface 
allows active drug to reach the systemic circulation. 
 
Topical formulation 
 
A formulation designed for local delivery i.e. after local 
application to the skin no drug should reach the systemic 
circulation. 
 
Cosmetics  
(MESH Term) 
 
Formulations containing compounds designed to remain on the 
skin surface. 
Substances designated for application to the human body for 
cleansing, beautifying, promoting attractiveness or altering the 
appearance without affecting the skin’s structure or functions. 
Included in this definition are skin creams, lotions, perfumes, 
lipsticks, fingernail polishes, eye and facial makeup 
preparations, permanent waves, hair colors, toothpastes and 
deodorants as well as any material intended for use as a 
component of a cosmetic product . 
 
Sunscreening agent 
(MESH Term) 
 
A chemical or physical agent that protects the skin from 
sunburn and erythema by absorbing or blocking ultraviolet 
radiation. 
Synonym: UV filter, sunscreen agent 
 
Sunscreen product 
 
Formulation (emulsion, oil, gel, mousse, aerosol, stick and 
ointment) that contains sunscreening agents and that is used to 
protect the skin from excessive ultraviolet radiation.  
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1 Abstract 
 
The objective of this thesis was to develop a spectrophotometric methodology for 
simultaneous determination of a sunscreening agent and relative stratum corneum tissue 
density in skin tape strips. This methodology was then employed to investigate the effect of 
different vehicles and their application time on the penetration of the sunscreening agent into 
the stratum corneum (SC) and the ability of these vehicles to create a reservoir. Tape 
stripping of the stratum corneum from the skin is a relatively non-invasive and useful 
technique used for bioavailability and dermatopharmacokinetic studies of topically-applied 
drugs. 
 
As model compound the sunscreening agent 3-(4-Methylbenzylidene)camphor (4-MBC) was 
chosen because of its high absorbance potential (A
 
    930-990 at 299 nm) and its high affinity 
to the SC which may be inferred by its low solubility in water (0.00013 g in 100 mL). To be 
able to conduct SC measurements directly on a tape by UV/VIS spectroscopy, a Perkin 
Elmer UV/VIS spectrophotometer was modified providing a uniform measurement area of     
1 cm2 to measure the absorbance through the sample as a result of light scattering by the SC 
on the tapes.  
A spectroscopic UV/VIS method determining the model compound 4-MBC and SC 
simultaneously in skin tape strips was then developed directly on tape strips and validated 
according to the International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) guidelines. For SC measurements this 
technique has distinct advantages in terms of facile sample handling procedures when 
compared with previously described methods such as tape strip weighing, protein 
determination and extraction procedures which are laborious and are susceptible to analytical 
artifacts. The validation parameters of the UV/VIS method were compared to those of a 
conventional solvent extraction/HPLC method. The data of the two analytical methods were 
found to be equally accurate and precise in determining sunscreen abundance in the 
corneocyte layers removed by tape stripping. However, the direct spectrophotometric 
technique obviates the need for any tape extraction process prior to analysis of 4-MBC and 
SC, and is sensitive enough for the accurate determination of low analyte concentrations on 
the tape strips since there is no loss of analyte in the sample handling protocol. 
 
The validation was further completed by comparing the data of an in vivo tape stripping 
1% 
1 cm 
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experiment measured by the UV/VIS method and the solvent extraction/HPLC method. For 
this purpose the tape stripping procedure has been optimized and standardized using a strict 
protocol to minimize the variability of the tape stripping data. The 4-MBC delivery from a 2% 
and 4% 4-MBC emulsions was then investigated in vivo using five human volunteers. A dose 
of 2 mg/cm2 was applied to the volar forearm for one hour. The tapes were analyzed be the 
new UV/VIS method by determining simultaneously the 4-MBC abundance and the relative 
density of SC. The tapes were then extracted and the 4-MBC concentrations obtained by 
direct spectrophotometric quantification were verified by HPLC. The linear correlation factor 
was 0.974 and statistical analysis confirmed that there was no statistical difference (p>0.05) 
between the two analytical procedures. The total mass of compound delivered from a vehicle 
was calculated by summating the 4-MBC abundance determined per tape and area of tape 
strip. Thereby, the first tape was always discarded. The results showed a statistically 
significant (p<0.05) influence of the dosing strength (2% vs 4%) of the formulations on the 
penetration of 4-MBC.  
This investigation revealed that the newly developed spectroscopic method is rapid, precise 
and as accurate as a conventional HPLC method for the in vivo determination of 
sunscreening agent delivery from topical applied formulations.  
 
Finally, the delivery of 4-MBC from several representative vehicles was compared using the 
direct spectrophotometric determination method and according to GCP procedures. To be 
able to detect vehicle effects on the penetration of 4-MBC into the SC, all vehicles used in the 
study were saturated with 4-MBC.  
In the first experiment the influence of propylene glycol and mineral oil and of their application 
time on 4-MBC penetration was investigated in five volunteers. Although the solubility of      
4-MBC was approximately 3.5 times lower in propylene glycol than in mineral oil, the 4-MBC 
delivery into the SC was significantly higher from propylene glycol. This observation can be 
explained by the ability of propylene glycol to decrease SC permeability. The number of tape 
strips required to completely remove the SC in the presence of the propylene glycol was 
significantly lower revealing a loosening of corneocytes and thus a facilitated penetration of 
4-MBC into the SC. The application time showed no influence on the 4-MBC penetration.  
In a further experiment, PEG 400 vehicles containing 0%, 10% and 50% Transcutol®CG were 
evaluated in ten subjects for their ability to create a reservoir of 4-MBC in the skin. This was 
evaluated seven hours post vehicle application. The solubility of 4-MBC increased with 
increasing Transcutol®CG concentration in the vehicle. The 4-MBC delivery from the three 
1 Abstract  
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vehicles was proportional to the 4-MBC concentration in the vehicle. The vehicles containing 
0% and 10% Transcutol®CG showed no difference in the 4-MBC amount measured in the SC 
seven hours post application compared to the 4-MBC amount measured in the SC one hour 
post application. For PEG 400 containing 50% Transcutol®CG the 4-MBC amount remaining 
in the SC seven hours post application was smaller than one hour post application.  
This study clearly demonstrated that this methodology is, therefore, capable of detecting 
differences in the extent of reservoir formation of the sunscreen when applied to the skin in 
different delivery vehicles. 
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2 Introduction 
 
Tape stripping of the stratum corneum from the skin is a relatively non-invasive and useful 
technique that has been used widely in recent years for bioavailability and 
dermatopharmacokinetic studies of topically-applied drugs [1]. The numerous problems 
associated with the standardization of the tape stripping methodology have been 
documented at length [2, 3]. The general technique used to date involves topical dosing, 
followed by application and subsequent removal of adhesive tape strips from the skin; 
corneocytes adhering to the tape strips are thereby removed from the underlying tissue. Each 
tape used in the stripping process (often 30-50 strips in total from each stripped skin site) is 
usually then solvent extracted to isolate the analyte of interest, prior to high sensitivity 
analysis.  However, the adhesive tape stripping of the stratum corneum is not a linear 
process in terms of the thickness of the layer of corneocytes removed from one strip to the 
next, and is not uniform in thickness across the entire field of each tape area (see electron 
micrographs) [2]. This procedure, therefore, relates the mass of permeant found on each strip 
to the tape strip number analyzed, and not (strictly) to stratum corneum depth or volume [4-
7]. A modification of this methodology that has been researched involves the weighing of the 
tape strips on a high-sensitivity balance before and after stripping to obtain a mass of tissue 
removed with each strip [8-11]. Alternatively, tissue mass on the tape strips has been 
determined in terms of protein content using the Lowry method [8]. These tape strip 
weighing, protein determination and extraction procedures are laborious and are susceptible 
to analytical artefacts (e.g. vaporization of volatile components of the tape matrix, static 
charges on the tape strip, etc.). Alternatively, a technique has been researched recently that 
allows the simultaneous analysis of corneocyte density and xenobiotic abundance using 
ultraviolet and visible (UV/VIS) spectroscopy [12-14]. This technique has distinct advantages 
in terms of facile sample handling procedures when compared with previously described 
methods. We have used the principle of this technique as a basis for the fully-validated 
studies reported here. 
 
The purpose of this research was: firstly, to develop a standardized method for the direct 
assessment of tapes removed from the skin without the need to conduct any preparative 
procedures (such as extraction or weighing) that may introduce artefacts into the analysis. 
Secondly, to develop a method capable of the simultaneous, accurate and simple, UV/VIS 
spectrophotometric determination of both analyte concentration and relative corneocyte 
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density on each tape strip.  Thirdly, to fully validate both the new, direct UV/VIS analysis of 
tapes and the conventional sample extraction/HPLC analysis procedure as a reference, 
according to current guidelines, in order to assure that either technique may be deemed fit for 
purpose.  The new UV/VIS method must be shown to be as good as the HPLC technique if it 
is to be used for routine analysis. 
 
A validated direct spectrophotometric technique would obviate the need for an extraction 
process prior to analysis, but would have to be sensitive enough for determination of low 
analyte concentrations.  Moreover, simultaneously obtaining the relative fraction of stratum 
corneum adhering to each tape would allow the mass of analyte found to be related directly 
to the relative amount of tissue removed by each tape strip, thereby providing a method for 
depicting a generalized penetration profile of the analyte into, or retention in, the stratum 
corneum layers. 
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Background, Rational and Purpose 
In topical bioavailability studies, tape stripping is a simple, useful technique to quantify drugs 
in the stratum corneum. In addition, it has the further advantage of being non-invasive.  
Despite these advantages, High Performance Liquid Chromatography (HPLC) is currently 
considered the standard method for quantifying the amount of drug on tapes. However, with 
HPLC, the final results can not be obtained in one step. Here, the stratum corneum (SC) as 
well as the drugs, must first of all be extracted before they can be quantified. 
To date, the extraction procedures employed are not only laborious but also susceptible to 
analytical artefacts. Thus, it would be both desirable and optimal if the standard multistep 
method requiring extraction and HPLC analysis of SC and drugs could be replaced by a 
simple, accurate and reliable one-step method. 
Weigmann and Lademann [12] recently developed an ultraviolet/visible (UV/VIS) 
spectroscopic method for directly determining the amount of SC on tapes. However, to obtain 
a drug penetration profile of the SC, an extraction of drug from the tapes was required in 
another step.  
Thus, the purpose of the present thesis was to develop a direct, one-step UV/VIS 
spectroscopic method for quantifying both the SC and sunscreening agent such as                
4-methylbenzylidene camphor (4-MBC) on tapes (Figure 1). 
 
This new, one-step method should not only be simple and efficient but also reliable and 
reproducible and, in addition, should be equally as sensitive as the standard multistep 
method.  
 
Validation and Verification of the Method 
Chapter 8.1 concerns validation of two methods: - the one-step UV/VIS spectroscopic 
method and the multistep HPLC method requiring extraction procedures. The validation 
parameters were performed according to the International Conference on Harmonization of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guidelines 
and the Food and Drug Administration (FDA) Guidance for Industry.  
Chapter 8.2 concerns verification of drug concentrations obtained from the direct one-step 
method by the multistep method after topical application of a 2% and 4% 4-MBC formulation.  
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Influence of Vehicle on Topical Bioavailability of 4-MBC 
Chapter 8.3 describes the influence of vehicles such as mineral oil and propylene glycol and 
their duration of application on the topical bioavailability of 4-MBC.  
Chapter 8.3 concerns also a clinical study in which the concentration of Transcutol®CG on 
the substantivity of 4-MBC was investigated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  Scheme illustrating distribution of 4-MBC in SC obtained by a new, direct one-step 
spectroscopic method vs. an established, multistep method.
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In the experimental part of this thesis, 4-MBC, a sunscreening agent, is the drug of interest. 
Thus, in Chapters 3-7 which describe important aspects of topical bioavailability in relation to 
the present work examples, whenever possible, are given concerning sunscreening agents. 
 
 
3 Structure and function of the human skin 
 
The skin is the largest organ of the body covering 15'000-20’000 cm2 and weighing several 
kilograms. It is the interface of the body with an environment and barrier for minimizing 
transport of harmful materials into the body. The skin is a highly organized, heterogeneous 
and multilayered organ. The upper region called the SC, the non-viable part of the epidermis, 
is between 10-20 µm thick. Underlying this region is the viable epidermis (20-100 µm) and 
then the dermis (1-2 mm) [15]. The sum of these various layers together with their 
appendages and underlying microvasculature constitute a living envelope surrounding the 
body (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic representation of the structure of the skin.  
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3.1 Anatomy of the skin 
 
3.1.1 Stratum corneum  
The SC is the final product of epidermal differentiation and forms a highly resistant, compact, 
horny layer made up of approximately 15-25 cell layers. Each day, roughly one layer of the 
SC is lost in a process termed desquamation and one layer is synthesized by the underlying 
epidermis. 
The main elements of the SC are the corneocytes - flat polyhedral-shaped, enucleated, 
dehydrated, keratinized cells - which are embedded in a matrix of lipid bilayers often 
described using the analogy of the bricks and mortar of a brick wall [16]. The corneocytes are 
approximately 20-40 µm in diameter and differ in their thickness depending on the body site 
and the location within the stratum corneum [17, 18]. The corneocyte cytosol is filled with 
keratin filaments and is encased by a chemically resistant yet flexible shell the cornified 
envelope. This cell envelope is composed and stabilized by cross-linked proteins (involucrin, 
loricrin) and covalently bound lipids (hydroxyceramides) [19-23]. 
The structure of the cell envelope consists of two parts: (1) a thick layer adjacent to the 
cytoplasm and composed of structural proteins and; (2) a thin layer on the exterior of the 
protein part which is composed of lipids. 
The principal factors responsible for maintaining attachment between corneocytes is not the 
intercellular lipid matrix but corneodesmosomes [24]. These junctions are crucial for the 
structural integrity of the SC barrier. In the lower SC, called stratum compactum, corneocytes 
are tightly superimposed and hold together by several corneodesmosomes. Further towards 
the SC surface, the corneocytes are characterized by a loss of corneodesmosomes. The 
cells detach at these regions forming a much looser SC structure, the stratum disjunctum, 
where the corneocytes are in a process of desquamation [25, 26].  
The SC is composed of approximately 70% protein, 15% lipid and only 15% water, compared 
to the average 70% water for the viable epidermis [27, 28]. The water content is variable and 
is controlled by the environmental conditions and the evaporative flux from lower skin layers. 
SC is extremely hygroscopic: it can absorb up to 500% of its dry weight in less than 1h 
following immersion in water, swelling vertically to 4-5 times its original width [29]. 
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3.1.2 Epidermis 
The cells of the SC originate in the viable epidermis, a layered epithelium made up of four 
distinct cell layers which correspond to various stages of epidermal keratinocyte 
differentiation.  
The stratum basale or stratum germinativum is a continuous monolayer consisting of 
cuboidal keratinocytes. This cell layer constantly divides by mitosis forming daughter cells 
that are displaced outward and then migrate across successive overlaying layers - the 
stratum spinosum, the stratum granulosum, the stratum lucidum – to finally enter the SC.  
During their migration toward corneocytes, the shape of the keratinocytes changes 
dramatically. The cells flatten considerably and reduce in volume. This progressive altering of 
keratinocytes is accompanied by biochemical developments, formation of keratins, formation 
and hydrolysis of lipids, loss of water and cross-linking of cell envelopes. 
Although keratinocytes are the major cells within the epidermis, melanocytes involved in skin 
pigmentation, Langerhans cells which are important for antigen presentation and the immune 
response - and Merkel cells, the latter of which are thought to be touch receptors, are also 
found in the epidermis [15, 30]. 
 
3.1.3 Dermis 
Below the epidermis lies the dermis, a hydrous connective tissue with collagen fibers and 
elastin both of which are embedded in glycosaminoglycans networks. This tissue determines 
the tensile strength and the elasticity of the skin. The dermis contains a sparse cell 
population; the main cells are fibroblasts which produce the connective tissue components: 
collagen, laminin, fibronectin and vitronectin. In addition to fibroblasts, mast cells which are 
involved in the immune and inflammatory responses and melanocytes which are involved in 
the production of melanin are also present in the dermis. The hair follicles and sweat ducts 
(skin appendages) originate deep within the dermis and terminate at the external surface of 
the epidermis. Contained within the dermis is an extensive vascular network providing for 
skin nutrition, repair and immune responses [15, 30]. 
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Table 1. Characteristics of human skin regions. 
 
Skin region 
 
Thickness 
 
pH 
 
Characteristic cells 
 
Vasculature 
 
Function 
      
SC 10-20 µm 4.2-5.6 Corneocytes None Barrier 
 
Viable epidermis 
 
50-200 µm 
 
≤ 7.4 
 
Keratinocytes 
Melanocytes 
Langerhans cells 
Merkel cells 
 
 
None 
 
Biosynthetic factory 
Metabolic barrier 
 
Dermis 
 
1000-2000 µm 
 
7.4 
 
Fibroblast 
Endothelial cells 
Mast cells 
Macrophages 
Lymphocytes 
Leukocytes 
 
Blood vessels 
Lymphatics 
 
Connective tissue 
Support 
 
 
3.2 Barrier function of the stratum corneum 
 
The barrier function of the skin is strongly attributed to the SC. Removal of SC by tape 
stripping reveals a dramatic increase in the permeability of water and other compounds [31, 
32] (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Sequential removal of SC by tape stripping reveals the location of the skin barrier indicated by 
transepidermal water loss measurements.  
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The water permeability of the SC is 1000 times lower than most other biological membranes. 
This is due to the exceptional structural arrangement of the intercellular lipid matrix and the 
lipid envelope surrounding the corneocytes [33-37]. All the components of the multilamellar 
lipid matrix present in the SC are produced by keratinocytes in the viable epidermis, 
essentially in the stratum granulosum. Vesicular structures called lamellar bodies, rich in 
lipids but also containing various enzymes, fuse with the apical cell membrane of the granular 
keratinocyte, thus delivering their contents to the interface between the stratum granulosum 
and the SC. The hydrolytic enzymes start to process their substrates and finally synthesize 
the SC lipids. The lipids found in the SC are principally ceramides (41%), free fatty acids 
(9%), cholesterol (27%), cholesteryl esters (10%) and cholesteryl sulfate (2%). Unique to any 
other known biological membranes, phospholipids are absent [38, 39] (Figure 4). The 
essential role of the SC lipids inbarrier properties has been demonstrated by removal of lipids 
by solvent extraction, which leads to increased water loss and enhanced skin permeability 
[40-42]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Distribution of lipids in the skin.  
Legend.  During the course of epidermal differentiation, there are distinct alterations in the distribution of lipid type. 
Polar phospholipids which are dominant in the basal layer are virtually absent in the outer layers of the stratum 
corneum. The latter stages of terminal differentiation, the levels of ceramids and neutral lipids increase.  
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3.3 The reservoir of the stratum corneum  
 
In the literature of the last several decades, the term reservoir has been used to describe the 
capacity of the skin or the skin layers to store and subsequently deliver, over a prolonged 
period of time, a xenobiotic to a target site and to other tissues. 
Corticosteroids provide the majority of examples for drug reservoir in the skin. Using dermal 
vasoconstriction as a bioanalytical end point, Vickers [43] showed that corticosteroids 
remained in the skin for about two weeks after a single, occluded application. This was 
demonstrated by vasoconstriction from the steroids 7-10 days after topical drug 
administration (despite washing) by reoccluding the site of application with a plastic.  
Barry [44] suggests that the phenomenon is probably a consequence of the high solubility 
and low diffusivity of the steroids in the SC. Hence, occlusion and penetration enhancers may 
increase the reservoir of the steroids in the SC. Because of its low diffusivity, the steroid 
remains trapped in the SC. On reocclusion, diffusivity is promoted and the steroid is 
absorbed. 
It is currently accepted that a reservoir for drugs exists in the SC and that it can be induced 
by occlusion, increased temperature and humidity [45, 46]. The capacity of a topically applied 
drug remaining in the SC and thus building a reservoir can be influenced by the nature of the 
formulation (see section 6.3.4.3). With vasoconstriction as a biomarker, Vickers [47] 
demonstrated that the vehicle in which the steroid was applied played an important role for 
drug storage in the SC. The maximum longevity of the reservoir was 9.6 days, which was 
obtained with an alcoholic solution. With hydrophilic bases, a greater longevity of the 
reservoir could be achieved than with greasy ointments. In all volunteers, a drug reservoir 
could be demonstrated after application of the alcohol solution. A diminished longevity of the 
reservoir obtained with greasy ointments was often not reproducible (Table 2). 
 
Table 2. Effect of vehicle on the development and duration of the reservoir. 
Vehicles Average longevity of the reservoir (days) 
Greasy ointment 4.6 
Hydrophilic cream 7.4 
95% Alcohol 9.6 
Legend.  Results from 25 volunteers; all were given an adequate dose and the treated skin was occluded; 
 all were previously shown to consistently exhibit drug reservoir. 
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Stoughton [48, 49] investigated the storage capacity of the SC for hexachlorophen and 
hydrocortisone. He described the influence of a vehicle containing dimethylacetamide 
(DMAC) on the deposition of hexachlorophen in the SC. He showed that a vehicle containing 
10% DMAC increased the storage capacity of the SC for the drug hexachlorophen by 5 to 25 
fold over that of a vehicle without 10% DMAC. Furthermore, the presence of DMAC resulted 
in a greatly increased biologic activity of the SC. In constrast to the drug hexachlorphen 
applied in DMAC, the SC reservoir for hexachlorophene was present for 4-5 days whereas 
after application of hexachlorophen alone no drug was measurable within 24 hours. 
In another experiment, Stoughton showed that addition of dimethylsulfoxide to the vehicle 
established a hydrocortisone reservoir in the SC within a few minutes and increased the 
longevity of the reservoir to 16 days. Furthermore, the depot of hydrocortisone was resistant 
to skin cleansing with soap, water and alcohol. 
 
3.4 Lipid organization within the skin barrier 
 
Since lipids form the only continuous region in the SC and substances must diffuse through 
these lipid areas, the lipid organization of the skin is considered very important. Although the 
exact structure and physical state of the SC intercellular lipids have not yet been clearly 
elucidated, studies with mixtures of lipids that mimic SC composition with a diverse range of 
physical techniques such as x-ray, DSC (Differential Scanning Calorimetry), AFM (Atomic 
Force Microscopy), NMR (Nuclear Magnetic Resonance) and FTIR (Fourier Transform 
InfraRed) showed that these lipids are organized in lamellar bilayer structures in which the 
lipid chains are highly organized [50-56]. These studies also showed that the lipid lamellae 
are oriented almost parallel to the corneocyte surface with repetitive distances of 
approximately 6.0-6.4 nm and 13.2-13.4 nm [57-62]. 
 
Ceramides play an important role in the lipid organization. To date, eight subclasses of 
ceramides have been identified in the human SC. Ceramides are sphingolipids that consist of 
a long chain amino alcohol (sphingosine or one of its derivatives) to which a non-hydroxy 
fatty acid or an α-hydroxy fatty acid is linked via an amide bond [63] (Figure 5).  
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Figure 5. Ceramides of the human stratum corneum intercellular space.  
 
The least polar of the ceramides is designated as ceramide 1, or acylceramide. Ceramide 1 
plays an essential role in the formation of the lamellar arrangements. It is thought to function 
as a molecular rivet, stabilizing the intercellular lipid lamella (Figure 6). 
 
 
Figure 6. Interpreation of the lipid orientation and interactions that might produce the unique lamellar patterns 
of the stratum corneum intercellular lamellae.  
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Wide angle x-ray diffraction studies revealed that in the intercellular lipids several lipid 
domains coexist which are identified as crystalline, gel and liquid crystalline lipid phases. In 
the crystalline phase, lipid packing is orthorhombic whereas a hexagonal arrangement is 
found in the gel phase. In the liquid phase, alkyl chains do not pack into specific 
arrangements [64-67]. 
 
Recently, Norlén [68] postulated a new theoretical model for the structure and function of the 
skin barrier- the single gel phase model. He proposed that the intercellular lipid within the SC 
exists as a single and coherent lamellar gel phase. This model differs significantly from 
earlier models in that it clearly states that phase separation is present, either between liquid 
crystalline and gel phases or between different crystalline phases with hexagonal and 
orthorhombic chain packing in the unperturbed barrier structure. 
 
3.5 Desquamation 
 
The barrier function of the skin is facilitated by the continuous desquamation of the horny 
layer thus preventing lipophilic substances such as sunscreen products from being absorbed 
into the skin.  
 
The process of desquamation involves the release of intact keratinocytes, presumably after 
the degradation of the corneodesmosomes, the intercellular adhesive structures between the 
corneocytes.  
The role of the corneodesmosomes was emphasized by Chapman et al. [69] who showed 
that after sequentially tape stripping the same skin site, the strength of cohesion gradually 
decreased from the deeper SC towards the skin surface. The decrease of cohesion can be 
explained by a decrease in the number of corneodesmosomes across the SC.  
Suzuki et al. [70] showed that corneodesmosomes are degraded by proteases to liberate 
corneocytes. Two proteases present in the extracellular spaces of the SC, the SC tryptic 
enzyme (SCTE) and the SC chymotrytpic enzyme (SCCE), are thought to be involved in the 
proteolysis of the corneodesmosal proteins (desmoglein I, desmocollin, corneodesmosin) [25, 
71-74]. In addition, environmental conditions and biochemical factors such as humidity, 
cholesterol sulfate, calcium ion and pH may also play an important role in desquamation 
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although how these factors regulate desquamation still remains unknown [72, 75-77] (Figure 
7). 
 
A normal desquamation is of crucial importance for maintenance of the function of the SC 
and for a normal skin appearance. Assuming an entire body surface of ~1.8 m2 and a 
corneocyte surface of approximately 1000 µm2, the entire surface “film” of corneocytes 
covering the body corresponds roughly to 1.8x109 cells. Since the thickness of a corneocyte 
is ~0.3 µm with a specific weight of 0.75 kg/m3 (=protein), these data can be used to 
calculate a daily loss of about 40 mg of horny cells [78]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Desquamation process.  
Legend.  The keratinocytes divide in the basal membrane, the mitotic skin layer, to produce two identical daughter cells. 
One cell remains in the mitotic layer in order to divide again whereas the other migrates to the upper layers 
where it will undergo numerous morphological and biochemical changes. The keratinocytes reaching the 
horny layer are now called corneocytes which are anucleated flattened cells filled with keratin. The 
corneocytes lose their cohesive properties and thus slough off the surface of the skin upon coming in contact 
with the proteolytic enzymes (SCTE and SCCE). 
 
At equilibrium, the loss of desquamative cells corresponds to the rate of epidermal cell 
production. Failure of the SC cells to be shed in a normal manner leads to increased 
thickening and scaling of the SC (X-linked ichtyosis). Individuals with recessive X-linked 
ichtyosis lack the enzyme cholesterol sulfatase which catalyzes the reaction of the 
transformation of cholesterol sulfate to cholesterol and free sulfate. Cholesterol sulfate has 
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been shown to inhibit pancreatic serin enzyme in vitro and cause scaling on mouse skin in 
vivo [77]. 
3.6 Drug permeation routes 
 
The absorption of drugs through the skin is thought to be passive [31]. The permeation of 
drugs through the skin take place by diffusion through the intact epidermis and through the 
skin appendages i.e. hair follicles and sweat glands which form shunt pathways through the 
intact epidermis. However, these skin appendages occupy only 0.1% of the total human skin 
surface and the contribution of this pathway is usually to be small. As stated above, drug 
permeation through the skin is usually limited by the SC. Two pathways through the intact 
barrier may be identified: the intercellular lipid route between the corneocytes and the 
transcellular route crossing through the corneocytes and the intervening lipids i.e. in both 
cases the permeant must diffuse at some points through the intercellular lipid matrix which is 
now recognized as the major determinant of percutaneous transport rate. 
 
 
4 Solar radiation 
 
Sunlight is composed of radiation with differing wavelengths: Ultraviolet (UV) radiation (5%), 
visible radiation (39%) and infra-red radiation (56%). UV radiation is of particular interest 
because it can interact with human skin cells and cause a variety of damaging effects.  
UV radiation can be further categorized as UVA (320 to 400 nm), UVB (290 to 320 nm) and 
UVC (100 to 290 nm). UVA can further be subdivided in UVA-1 (340 to 400 nm) and UVA-2 
(320 to 340 nm).  
The energetics of the incident radiation is controlled by the fundamental equations: 
E = hν   Equation 1 
ν = c/λ  Equation 2 
E = hc/ λ  Equation 3 
where E = Energy (ergs), h = Planck’s constant (6.62 x 10-27 erg/s), ν = Frequency (Hz),        
c = Speed of light (3.0 x 1010 cm/s), and λ = Wavelength (nm). 
The shorter the wavelength (λ), the higher the energy level (E) of the light and the more 
damage it can do. This means that UVC is the most dangerous radiation, but it is mostly 
absorbed by the ozone layer and does not reach the earth’s surface. The remaining UV 
4 Solar radiation 
T. Fässler Tassopoulos Inauguraldissertation, University of Basel, 2006 Page 28 of 195 
radiation that reaches the ground is about 10% UVB and 90% UVA at midday. In contrast to 
UVB radiation which varies considerably with the time of the day and the seasons, large 
amounts of UVA are constantly present during daylight hours and throughout the year [79, 
80]. Finally, while 90% of UVB radiation is blocked by the SC, over 50% of the UVA radiation 
received is capable of penetrating deep into the cutaneous structures as far as the dermis. 
 
4.1 Acute and chronic damage to the skin due to UV radiation 
 
UV radiation (290 – 400 nm) has been implicated in the induction of various acute and 
chronic harmful reactions in the human skin. As t UV light penetrates of the skin, depending 
on its wavelength, interaction occurs with different cells located in different depths. UV light of 
shorter wavelengths (UVB, 290-320 nm) is more energetic and is mostly absorbed in the 
epidermis and predominantly affects epidermal cells, i.e. keratinocytes. Longer wavelength 
UV light (UVA, 320-400 nm) is of lower energy but penetrates deeper and can interact with 
both epidermal keratinocytes and dermal fibroblasts (Figure 8). 
 
 
Figure 8.  Schematic representation of light penetration into the skin.  
 
The effects of UVB radiation on the skin have become common knowledge and are 
described in a number of publications. The effects of UVA radiation are supplementary to 
those of UVB. Recent studies suggest that UVB and UVA may also work synergistically to 
cause skin damage [81]. In Table 3, the effects caused by UVB and UVA are summarized.  
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Table 3. Effects of UV radiation on the skin. 
 
Mostly attributed to UVB 
 
Mostly attributed to UVA  
 
Acute erythema 
 
Erythema (high doses of UVA required) 
Delayed pigmentation Immediate pigmentation 
Malignant melanoma Cataract 
Basal cell carcinoma (also by UVA) Phototoxic reactions 
Squamous cell carcinoma (also by UVA) Photoallergies 
Potential immunosuppressor Premature aging / wrinkles 
 Potentiate biological effect of UVB 
 
Excessive exposure to UV radiation results in multiple dose- and time-dependent changes in 
the skin. They include inflammation responses such as erythema [82], epidermal 
proliferation, apoptosis and hyperpigmentation.  
DNA is the principle chromophore in the skin, which absorbs UV radiation. This leads to a 
variety of adverse effects such as immunosuppression, sunburn cell formation, mutation and, 
ultimatively, carcinogenesis.  
Within the DNA, UV radiation induces the formation of pyrimidine dimers. Normally this lesion 
is repaired. However, if the enzymes are not functional or if the repair system is overloaded, 
mutations appear in the DNA [83]. Dimer formation is thought to be of crucial importance in 
the initiation of skin cancer because it has been found to be closely linked to the generation 
of mutations in tumor suppressor genes (p53) expressed in UV induced skin cancer [84]. 
In addition, UV radiation is known to generate secondary free radicals and reactive oxygen 
species which result in DNA damage and alteration in keratinocyte metabolism as well as 
chemotaxis and activation of cells involved in the inflammation and immune response 
(Langerhans cells) [85-88]. UV-induced DNA alteration as well as immunosuppression are 
critical for cutaneous carcinogenesis. UV radiation alters antigen-presenting cell function by 
directly affecting the number, the morphology and the functionality of Langerhans cells [89, 
90]. It also induces the release of immunmodulating cytokines [91] and the isomerization of 
urocainic acid from the trans- to the cis-form. The cis isomer of urocainic acid is reported to 
be an important factor in the initiation of photoimmunosuppression [92]. 
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4.2 Protective mechanisms of the skin 
 
The skin adapts to UV radiation exposure by two mechanisms: melanogenesis (tanning) and 
thickening of the SC.  
UVB rays enhance the binding of circulating melanocyte-stimulating hormone to 
melanocytes. In melanosomes, the melanin synthesizing apparatus of the melanocytes, 
melanin is formed. Melanin is a compound that absorbs, reflects and scatters UV radiation 
and acts as a free radical quencher. Melanin is transferred from the dendrites, the 
melanocyte’s cytoplasmic extensions, to the keratinocytes (Figure 9). The keratinocytes’ 
ability to absorb UV radiation is maximal the DNA of basal cells from mutagenic interactions.  
 
Figure 9. Production and storage of melanin.  
Legend. A Melanocytes (1) form dendrites (2), which grow into and through the neighboring keratinocytes (3);  
 B Under influence of UV light, biosynthesis of melanin occurs in the melanosomes. These move toward the 
cell periphery and into the dendrites. Thus, the keratinocytes fill up with melanin and a coloring of the skin 
occurs. Applying a sunscreen product provides additionally protection from damaging UV light. 
 
Melanocyte function is able to influence skin color. Although people of all skin types have 
approximately the same number of melanocytes, there the black race have approximately 
400 melanosomes per basal epidermal cell i.e. four times as many as the typical pale 
Caucasian. This difference reduces UVA and UVB penetration into the dermis by a factor of 
five in Blacks compared with Caucasians [93]. 
A
a 
B 
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In response to prolonged UVB exposure, the SC can hypertrophy to six times its original 
thickness by increased synthesis of keratin by basal keratinocytes. Thickened SC absorbs or 
reflects 90-95% of UVB so that just 5-10% reaches the basal keratinocytes, melanocytes and 
superficial dermal vascular system [94]. 
 
 
5 Sunscreen products  
 
The fashion of suntanning began in the 1940s, promoted by Coco Chanel, the French fashion 
designer [95]. The popularity of suntanning as a symbol of health, wealth and fashion has 
risen almost unabated since the end of World War II. Only recently, spurred by a rapid rise in 
skin cancer and decrease in the ozone layer, there has been an attempt to reverse this 
popularity. The use of sun protection products has increased dramatically and is now 
universally used by the sunbathing population. 
 
The protection provided by modern sunscreen products against UV induced skin cancer was 
proven in animal photocarcinogenicity studies and confirmed by numerous in vitro, animal, 
and human investigations: sunscreening agents protected p53 tumor suppressor gene from 
damage [96, 97] and prevented UV-induced immune suppression [98]. Recent studies 
suggest that sunscreen products protect against precursor lesions of skin cancer such as 
actinic keratoses. Additional benefits of sunscreening agents included prevention of 
photodermatoses such as polymorphic light eruption [99] and possibly photoaging [96, 97]. 
 
The efficacy of a sunscreen product preparation is measured by the amount of harmful solar 
radiation able to be absorbed and/or reflected. The absorption of sunscreening agents is 
influenced by a variety of factors such as the components used to constitute the excipient, 
the pH, the type of emulsion etc.. 
 
5.1 Sun protection factor 
 
To assess the efficacy of a sunscreen product in the UVB range of the spectrum the sun 
protection factor (SPF) is determined.  
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The SPF is defined as the dose of UV radiation required to produce one minimal erythema 
dose (MED) on protected skin after application of 2 mg/cm2 of product divided by the UVR to 
produce one MED on unprotected skin.  
The generally accepted methods to determine the SPF of a sunscreen product have been 
described by the United States Food And Drug Administration (U.S. FDA) [100] and by the 
European Cosmetics and Perfumery Trade Association (COLIPA) [101]. In the COLIPA 
Guidelines a number of criteria were defined such as: (1) the assessment of MED; (2) the 
type of skin and number of test volunteers; (3) the amount of product to be applied; (4) UV 
source to be used and; (5) the statistics for analyzing the data [102, 103]. 
 
5.2 Sunscreening agents 
 
Sunscreening agents have traditionally been divided into chemical (organic) absorbers and 
physical (inorganic) blockers based on their mechanism of action. 
 
Chemical or organic sunscreening agents reduce the amount of UV radiation reaching the 
skin by absorption. They can be subclassified as either UVB or UVA absorbers depending on 
the wavelength of their absorption maxima. Chemical sunscreening agents are generally 
aromatic compounds conjugated with a carbonyl group [104]. These chemicals absorb high 
energy (250-340 nm) UV rays causing an excitation in the molecule to a higher energy state. 
As the excited molecule returns to the ground state, longer lower energy (usually above 380 
nm) wavelengths are emitted. 
 
Physical or inorganic sunscreen products such as titanium dioxide and zinc oxide are very 
efficient attenuators of UV radiation. Microfine titanium dioxide primarily absorbs UVB 
radiation [105] and scatters UVA while zinc oxide absorbs all UV wavelengths. They are used 
either alone in products designed for children and individuals with sensitive skin or in 
combination with organic sunscreen products to achieve high levels of broad-spectrum 
protection. Based on the fact that particles do not penetrate the skin [106], it has been 
alleged that inorganic sunscreening agents may be safer than organic sunscreening agents. 
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Modern sunscreen products provide broad-spectrum UV protection and may contain one or 
several UV filters. A modern sunscreening agent should be heat and photostable, water 
resistant, nontoxic and easy to formulate. 
The effectiveness of sunscreen products depends upon their UV absorption, their 
concentration, formulation and their ability to withstand swimming or sweating (substantivity). 
 
 
6 Topical bioavailability of sunscreening agents 
 
6.1 Definition 
 
The U.S. FDA defines bioavailability as the rate and extent to which the active ingredient or 
active moiety is absorbed from a drug product and becomes available at the site of action. 
For drug products that are not intended to be absorbed into the blood stream, bioavailability 
may be assessed by measurements intended to reflect the rate and extent to which the 
active ingredient or active moiety becomes available at the site of action [107].  
For determination of topical efficacy, systemic measures of drug availability are irrelevant 
because the site of action of the drug is located within the skin. Systemically active drugs and 
their metabolites may, however, raise safety issues.  
 
6.2 Target sites 
 
With a topical product, specific skin sites are targeted. Typical examples are given in Table 4.  
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Table 4.  Skin target sites [108, 109]. 
Target Representative function Examples 
Skin surface Cleaning; protecting; improving skin feel  Soaps, sunscreen products, insect 
repellents, petrolatum 
Stratum corneum  Normalizing SC, treating superficial 
infection 
Moisturizers, antimycotics, sunscreen 
products 
Pilosebaceous unit Treating acne and other conditions of 
follicular origin 
Retinoids, antibiotics 
Sweat duct follicles Preventing sweating Antiperspirant aluminum salts 
Viable epidermis Changing mitosis rate; blocking sensory 
transmission; reducing inflammation 
Steroids, local anaesthetics 
Epidermal basal cells Inhibiting cell proliferation Cytostatic agents (e.g. methotrexate) 
Blood Systemic delivery Transdermal patches (e.g. nitroglycerin) 
Local muscle tissues Relieving pain Nonsteroidal anti-inflammatory drugs 
(NSAID) 
 
For sunscreening agents, localization in the upper layers of the skin is expected to enhance 
photoprotection as these compounds should absorb or scatter the UV radiation before 
reaching the deeper, more vulnerable, viable epidermis and dermis. An ideal sunscreen 
product should contain effective UV absorbers on the skin surface or in the upper SC layers 
with minimal permeation to the systemic circulation. 
 
6.3 Factors affecting the bioavailability of sunscreening agents 
 
As mentioned above (see section 6.2) the target site of sunscreening agents is the skin 
surface and the upper layers of the SC. Ideally, a sunscreen product should impregnate the 
SC and create a barrier against UV radiation but not permeating further into the underlying 
living tissue. Sunscreening agents that penetrate to deeper skin layers are of minor value 
since they would leave the skin unprotected. Thus, a concentration of sunscreening agents 
within the upper layers of the SC are highly desirable, to increase resistance against rubbing 
and sweat and to avoid safety issues. 
 
The rate and extent to which a chemical compound penetrates the skin depends on a variety 
of factors i.e. the physicochemical properties of the compound, the formulation, the 
application, and the type and condition of the skin (Table 5) [110]. 
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Table 5.  Factors influencing percutaneous absorptiona. 
Parameter  
 
Test compound 
 
- molecular weight 
- water / lipid partition coefficient 
- ionization (pKa value) 
 
Formulation - solubility (thermodynamic activity) / polarity 
- volatility / occlusion 
- concentration / thermodynamic activity 
- distribution in stratum corneum  
- ingredients 
- penetration enhancers 
 
Skin - species  
- age, sex, race  
- anatomical site 
- temperature  
- skin condition and hydration of stratum corneum 
- metabolism  
 
Application - skin area dose (film thickness) 
- total skin area in contact with formulation 
- duration of exposure 
 
a
 [110] 
 
6.3.1 Influence of the compound attributes 
The capacity of a molecule to enter the skin depends on its ability to penetrate the alternate 
hydrophobic/hydrophilic barrier layers of the SC. Permeation through the SC depends on 
many physicochemical parameters such as molecular weight, lipophilicity, polarity, capacity 
to form hydrogen bonds, solubility and, for acids or bases, the pKa value. 
 
6.3.1.1 Permeation - Mathematical models for the prediction of skin absorption 
Sunscreen products are repeatedly and often applied to large body areas. Even low fluxes of 
sunscreening agents can cause a considerable amount of penetrant to enter the body. 
Therefore, estimates of percutaneous absorption are required for realistic risk assessment.  
Mathematical modeling from physicochemical data has suggested that permeation of certain 
sunscreening agents through the skin may be significant. Several in vitro and in vivo kinetic 
models for studying percutaneous absorption have been proposed [111-113]. 
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Hagedorn-Leweke and Lippold [112] quantified the transdermal permeabilities and maximum 
fluxes of various sunscreening agents applied as saturated solutions in a propylene glycol-
water mixture applied to human skin in vivo. They found a linear relation between the 
logarithms of SC/vehicle partition coefficient of the penetrants and the corresponding 
logarithms of n-octanol/vehicle partition coefficient values. The correlation revealed that even 
in case of very lipophilic penetrants, no stagnant layers are present in neither the vehicle nor 
the viable skin in vivo. This model allowed the estimation of the amount of sunscreening 
agent absorbed after treating the total skin surface (1.8 m2) with a saturated propylene glycol 
solution for 1 hour (with knowledge of the physicochemical properties of a sunscreening 
agent). The predicted values ranged from 10 mg for octyl dimethyl p-aminobenzoic acid and 
to 89 mg for isoamyl-4-methoxycinnamate, respectively (Table 6). 
 
Table 6. Predicted amount of sunscreening agents absorbed after 1h  
exposure to a saturated propylene glycol solutiona. 
Agent (INCI name) Amount absorbed per hour over 
the 1.8 m2 skin surface (mg) 
 
Octyl dimethyl p-aminobenzoic acid 
 
10 
4-Isopropyl-dibenzoylmethane 15 
4-Methylbenzylidene camphor 38b 
Isoamyl-p-methoxycinnamate 57-89 
Benzophenone-3 76-80 
 
a
 [112] 
b
 Compound used in the experimental part of the thesis. 
 
Another kinetic model was developed by Watkinson and colleagues [111] to calculate the 
extent of percutaneous absorption of sunscreening agents. The model uses first order rate 
constants to describe the processes of transfer and partitioning involved in percutaneous 
penetration. The authors suggested that systemic absorption of sunscreening agents across 
large areas of skin could occur at significant levels after long periods of exposure, even for 
chemicals that are estimated to be absorbed relatively slowly.  
 
In a recent study, Fernandez et al. [113] used two combined non-invasive sampling methods 
to provide information for predicting the absorption and adsorption of benzophenone-3 in vivo 
i.e. the ‘difference’ method and the ‘tape stripping’ method respectively. They found that after 
application of benzophenone-3 in acetone and occlusion for 4 hours according to the method 
of T. Yano [114], the amount of benzophenone-3 crossing the skin was near 35% [113]. With 
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the tape stripping procedure they found that after a 30 minute application the amount of 
topically applied benzophenone-3 in the SC was 4% of the applied dose. In the case of 
benzophenone-3, Hayden and colleagues [115] found that in humans up to 2% of an applied 
benzophenone-3 dose and its metabolites (glucuronides of 2,4-dihydroxybenzophenone and 
2,3,4-trihydroxybenzophenone) were excreted in the urine following topical application of 
commercially available products and in a further study excretion was reported in breast milk 
[116]. 
 
6.3.1.2 Toxicology 
Schlumpf et al. [117] found that five frequently used sunscreening agents increased the 
activity of breast cancer cells (MCF-7) in vitro by proliferation and expression of estrogen-
regulated genes (pS2). Estrogenic in vivo activity of these sunscreening agents was tested 
by an uterotrophic assay on immature Long-Evans rats that received the chemicals for 4 
days in powdered feed. 4-MBC (effective Dose to produce 50% response (ED50) 309 
mg/kg/day), octyl-methoxycinnamate (ED50 935 mg/kg/day), and benzopheneone-3 (ED50 
1525 mg/kg/day) increased uterine weight. 4-Methylbenzylidene camphor was the most 
active compound. The uterine weight also increased after dermal application of 5 % and 
7.5% 4-methylbenzylidene camphor in olive oil to immature hairless rats. The uterotrophic 
assay was repeated by two other investigators [118, 119] that used Sprague-Dawley rats and 
immature Wistar rats. In both studies the uterotrophic response of the sunscreening agents 
observed by Schlumpf et al. [117] could not be confirmed. 
 
Despite the importance of sunscreening agents to protect the human epidermis, the majority 
of the studies are performed in vitro with animal or synthetic membranes and in vivo with 
animal models. Even although human studies are the critically accepted and desired 
standard, data available on humans is limited.  
However, under real life-conditions the actual applied amount of sunscreen product is in the 
order of 0.5 mg/cm2 i.e. far lower than the assumed 2 mg/cm2 [120]. Thus, the actual human 
systemic exposure to sunscreen products is likely to be minimal to negligible. The duration of 
exposure offers an additional safety factor. For most people, the duration of whole-body 
application of sunscreen products is generally limited to 3-4 weeks for the average summer 
holiday period which is far less than the duration of administration or exposure in animal 
toxicity studies. 
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6.3.2 Inlfuence of the skin  
The condition of the skin has a considerable influence on the percutaneous absorption. Not 
only diseased skin conditions but also other factors such as age, race, anatomical location, 
skin temperature and hydration may affect the absorption.  
 
6.3.2.1 Age and race 
Many of the well documented changes that occur in aged skin include: (1) increased SC 
dryness [121, 122]; (2) reduction in sebaceous gland activity resulting in a decrease in the 
amount of skin surface lipids [123]; (3) flattening of the dermal-epidermal junction [124] and; 
(4) atrophy of the skin capillary network resulting in a gradual attenuation of blood supply to 
the viable epidermis [125]. Although several authors report  lower percutaneous absorption of 
different compounds in the elderly (>65 years), the effect of ageing on percutaneous 
absorption has not been evaluated in sufficient detail to permit any generalization to be 
made. The influence of age is thought to be relatively minor compared to all the other 
variables [126] with the exception of premature infants (< 32 weeks) where the skin is 
approximately 2.5 times more permeable than full term or adult skin [15]. 
 
Racial differences in physicochemical properties of the skin have been reported. In Blacks, 
there is increased resistance to tape stripping [127], electrical resistance [128], increased 
lipid content [129], and increased TEWL [130]. Except for one study with nitroglycerin 
percutaneous absorption [131], one may state that if any racial differences exist, they are 
below the limit of detection for currently established methods. 
 
6.3.2.2 Anatomical site 
Depending on the area of the human body, there are considerable differences in the barrier 
function of the skin [132]. Feldmann and Maibach [133] were the first to demonstrate a 
regional influence on percutaneous absorption in humans using hydrocortisone as a model 
compound. Depending upon the anatomical site, a difference by a factor of 100 was found 
with ranking as follows: scrotal skin > jaw angle > forehead > axilla > scalp > back > forearm 
> palm > plantar pedis. A simple correlation between percutaneous absorption and SC 
thickness was not observed. The barrier function of the forehead was 4 times lower than that 
of the upper arm although the SC appeared to be the same [134]. Thus, anatomical site is 
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important and most in vivo human studies on topical application utilize the forearm of human 
volunteers as the primary testing site. The use of the volar forearm offers the advantage of 
accessibility to the anatomical region. Additionally, it was a relatively low density of hair and 
sebaceous glands.  
 
6.3.2.3 Skin temperature and hydration 
Changes in skin temperature are always accompanied by other physiological reactions such 
as increased blood flow or increased moisture content of the SC. These factors can 
contribute to higher percutaneous absorption. Furthermore, increase in temperature 
increases drug solubility in both the vehicle and the SC and increases diffusivity, both of 
which lead to a further increase in percutaneous absorption [135, 136]. For this reason, it is 
important that the skin temperature is controlled in experiments. 
 
Hydration of the skin is an important factor affecting the rate and extent of percutaneous 
absorption. It may reduce the barrier integrity thus increasing the rate of percutaneous 
absorption. The most common method of increasing skin hydration is by occlusion which 
prevents surface evaporation of endogenous water thereby increasing the water content of 
the SC up to 50% [137], the temperature from 32°C to as much as 37°C, and the skin pH 
from 5.6 to 6.7 [138] An assessment of the degree of hydration can be made by monitoring 
the permeability of the SC to water through measurements of the transepidermal water loss 
(TEWL). Occlusion can be achieved by means of plastic films or different types of dermal 
patches. Partial occlusion may be obtained with topical formulations based on petrolatum or 
paraffin, ointments and creams. 
Both hydration and occlusion have increased the percutaneous absorption of different 
topically applied drugs such as hydrocortisone [139], nicotinic acid, salicylic acid [140, 141] 
and parathion [142]. It has been postulated that the SC hydration alters the SC-viable 
epidermis partitioning so that the effective partition coefficient of the penetrant between SC 
and the viable epidermis is reduced. This effect is usually more important for nonpolar than 
for polar molecules [143] and becomes greater as the lipophilicity of the absorbing molecule 
increases. 
6.3.2.4 Diseased and damaged skin 
Skin condition has a major influence on barrier integrity. Skin diseases such as ichtyosis, 
psoriasis and atopic dermatitis, tend to change the skin barrier properties.  
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Exposure to UV radiation provokes changes in the composition and thus in the barrier 
properties of the skin. Acute exposure to UV radiation results in an increased rate of 
epidermal proliferation and desquamation. In addition, acute exposure to damaging levels of 
radiation leads to decreased barrier function [144]. 
 
6.3.2.5 Differences between subjects 
Large differences exist in percutaneous absorption between subjects [145] due to drug-
vehicle-skin interactions. This can result in subject-formulation interactions so that the 
bioavailability of a test product relative to that of a reference product may be consistently 
different between individuals [146]. 
 
6.3.3 Influence of application parameters 
6.3.3.1 Dosing / Application thickness 
Beside the UV filter concentration, the efficacy of a sunscreen product is dependent on 
adequate application; the sunscreen product must be applied evenly and in sufficient 
amounts to achieve adequate protection [147-149]. Several factors affect the thickness of 
sunscreen product applied to the skin such as the texture of the skin, the application 
technique, type of container and the sunscreen formulation product itself.  
The protection offered by a sunscreen product – defined by its SPF – is assessed after it is 
phototested in vivo at an internationally agreed application thickness of 2 mg/cm2 (or             
2 µL/cm2 assuming a specific gravity of 1). To achieve the rated SPF over the whole body, an 
adult with a surface area of 1.73 m2 would therefore need to apply 35 mL of sunscreen 
product. Yet a number of studies have shown that consumers apply much less than this, 
typically 0.39 to 1.5 mg/cm2 [120, 149, 150]. Consequently the SPF varies considerably The 
theoretical relation between the sunscreen product thickness and resulting effective SPF 
when using different SPFs is depicted in Figure 10 and summarized in Table 7 [151]. 
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Figure 10. Relation between applied sunscreen thickness and resulting effective SPF with sunscreens of 
different sun protection factors (SPF) [152]. 
 
Table 7. Theoretical SPF with application of a sunscreen product  
layer thinner than that prescribed by the FDA (2 mg/cm2)a. 
FDA 2.0 mg/cm2 1.5 mg/cm2 1.0 mg/cm2 0.5 mg/cm2 
2 2.0 1.7 1.4 1.2 
4 4.0 2.8 2.0 1.4 
8 8.0 4.8 2.8 1.7 
15 15.0 7.6 3.9 2.0 
30 30.0 12.8 5.5 2.3 
50 50.0 18.8 7.1 2.7 
 
a
 [152] 
 
The layer thickness for sunscreen products with a high versus a low SPF has a greater 
influence on the effective SPF. The protection from a thin layer of sunscreen product cannot 
be increased by using a product with a higher SPF. The effective SPF cannot exceed 3 when 
0.5 mg/cm2 is used and 10 if 1 mg/cm2 is used. These prognoses may not always be 
confirmed in a real life testing situation probably because irregularities of the skin lead to 
uneven sunscreen product thickness which does not exactly fit the ideal mathematical model 
[152]. 
 
Stenberg’s data indicated that the SPF under ad libitum application (1.01 mg/cm2) was 
approximately 50% of that which would be achieved by applying the standard thickness of     
2 mg/cm2 used in testing SPFs. These results are not in agreement with the results of 
Gottlieb et al. [153] who found that applying less than 2 mg/cm2 would not diminish the SPF, 
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at least with the lower SPF sunscreen products. Gottlieb [153] also investigated the influence 
of the consistency of a sunscreen product on the application thickness. With exception of a 
gel, which was applied in slightly greater amount compared with that of other vehicles, they 
found that varying consistencies for different sunscreen products did not appear to play a role 
in application thickness. Diffey and Grice [150] observed that the amount of sunscreen 
product varied depending on the physical characteristics of the formulation - chemical 
(organic) or physical (inorganic) sunscreen product. With the organic sunscreen product 
which is easier to spread, up to 30% more was applied than the inorganic sunscreen product 
(1.48 and 0.94 mg /cm2, respectively). In a recent study Autier et al. [154] showed that the 
median quantity of sunscreen products applied by students from different European countries 
was 0.39 mg/cm2. These investigators also examined factors influencing quantities of 
sunscreen product applied to the skin such as gender, SPF, skin phototype and study place 
(Lyon, Lausanne, Paris, Thionville, Brussels). They found no statistically significant 
differences in quantity of sunscreen product applied according to any of the above mentioned 
factors. An additional factor that influences the amount of formulation applied is the type of 
dispenser [155]. Investigators found that a cream, contained in a jar was more readily applied 
than the same cream from a tube1.7 mg/cm2 vs. 0.71 mg/cm2 respectively.  
 
6.3.3.2 Application technique 
The application technique is an essential factor in the variability of protection over the skin 
surface [156]. By employing an ultraviolet fluorescent photographic technique with sunscreen 
products known to exhibit fluorescent characteristics, Grencis et al. [157] showed that in 
many instances sunscreen products are not applied in an even layer. The SPF for a product 
may therefore not be achieved over the entire area of skin that was intended for protection by 
the user. Lynnfield and Schechter [155] found that the areas skipped most often excluded by 
volunteers were the back, the extremities, the ears and the areas immediately adjacent to the 
bathing suit. Loesch [158] and Azurdia [159] observed that even on the face, coverage by 
sunscreen product was incomplete (Figure 11). 
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Figure 11.  Sunscreen application pattern (from Lit. [158]). 
Legend.  Anatomic regions: (1) hairline, (2) forehead, (3) ears, (4) periorbital, (5) nose, (6) cheeks, (7) nasolabial, and 
(8) perioral. A denser shading indicates better coverage with sunscreen e.g. dark (8) good coverage, light grey 
(1) incomplete coverage.  
 
The consequences of different application techniques were examined [103, 156]. Sayre et al. 
[103] found that rubbing the product into the skin appears also to remove it from the skin and 
thus affects the SPF. When cream was rubbed into the skin, at the standard amount of          
2 mg/cm2, the SPF had a tendency (not always confirmed statistically) to be decreased 
compared to the situation where the cream was not rubbed in.  
The application technique appears to be an important parameter in the determination of the 
actual SPF and thus needs to be rigorously controlled in SPF test protocols. 
 
Reapplication 
A recent Australian study [160] showed that when sunscreen product is applied prior to sun 
exposure and subsequently reapplied after a period of controlled exposure, a 2-3 fold 
increase in protection from sunburn can be expected. 
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Recommendations 
For the application of sunscreen products a variety of recommendations have been 
published. They are helpful to advise the consumer to use the product optimally. 
Nonetheless, some of the recommendations are not scientifically proven.  
• application of sunscreen product 15-20 minutes before sunbathing 
• the rule of nines [161] 
• teaspoon rule [162] (Figure 12) 
 
 
Figure 12.  Variation in the optimal amount of sunscreen needed for different body areas to obtain approximately 
2 mg/cm2.  
 
6.3.3.3 Loss of vehicle from the skin surface 
Loss of product from skin due to rubbing, perspiration, water contact, transfer to clothing and 
absorption can hardly be avoided, particularly in the case of longer exposure.  
 
Using a mathematical model of dermal absorption Auton et al. [163] described removal 
processes on the surface of the skin, including the effects of washing and rubbing off onto 
clothing. In this study, different doses of an aqueous solution of a herbicide (fluazifop-butyl) 
were applied on the backs of human volunteers. Eight hours after application, the skin was 
washed with distilled water and then the volunteers clothed themselves in a cotton T-shirt for 
the next 16 hours. The recovery of the herbicide in T-shirts and water washes were 43-48% 
and 25-34%, respectively. In a further investigation five daily doses of 25 µg/cm2 were 
applied. Contact with a T-shirt as soon as the aqueous formulation had dried on the back of 
the volunteer removed approximately 52% of the applied dose. Only 10% of the dose was 
found in the 8hour wash. These results demonstrate that considerable amounts of the 
chemical were removed by washing or by the clothing. Only a small amount of the dose 
remained on the skin and was absorbed.  
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6.3.4 Influence of the vehicle 
Under conditions of actual exposure, the bioavailability of sunscreening agents will not only 
be determined by their physicochemical properties, but may also be strongly influenced by 
the vehicle in which they are applied. 
 
6.3.4.1 The sunscreen product vehicle 
In one case the vehicle may have a solubilizing effect on the sunscreening agent or 
alternatively the vehicle’s nature may modify properties of the SC (e.g. increased hydration, 
decrease in diffusional resistance), which could influence the penetration profile of 
sunscreening agents [164]. Various authors [6, 165-169] describe oil/water (o/w) or water/oil 
(w/o) emulsions, gels, lotions or hydroalcoholic formulations which were investigated in vitro 
and in vivo. They all found that the vehicle is a factor influencing percutaneous absorption; it 
may enhance or block the movement of the sunscreening agent in the skin. Jiang et al. [170] 
demonstrated that the skin penetration and retention of sunscreening agents of commercial 
products can differ significantly between the formulations used. Therefore, vehicles used for 
sunscreen products should be optimized to maximize the sunscreening agents variability to 
be retained in the SC and to minimize their absorption. 
 
Not only skin penetration and skin retention properties of sunscreening agents are influenced 
by the vehicle but also the SPF can be significantly modulated. It is known that in an o/w 
emulsion the attained SPF is higher than in a w/o emulsion containing an identical 
concentration and combination of sunscreening agents. Treffel and Gabard [6] demonstrated 
that the protection afforded by an emulsion gel formulation was much higher than that of 
petroleum jelly. Even after removal of the excess emulsion gel formulation, an SPF was 
measured that demonstrated the ability of the sunscreening agents to penetrate and react 
within the SC. The authors suggest that the spreadability as well as changes occurring in the 
formulation due to application such as evaporation (vehicle metamorphosis) probably 
concentrated the sunscreening agents in a thin layer in the skin surface, thus improving their 
efficiency to absorb UV light. Rapid evaporation of the volatile vehicle components resulted in 
an appreciable increase in concentration of the sunscreening agents in the vehicle, acting 
directly on their thermodynamic activity and thus increasing their skin penetration. 
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The choice of a vehicle for a sunscreen product is important for several further reasons. A 
solvent may modify the sunscreening agent because of its polarity and thereby dramatically 
shift the absorption spectrum of the agent toward or away from the desired range [171] thus 
profoundly influencing the effectiveness of a sunscreen product formulation.  
The wrong vehicle can act as a skin irritant, induce a phototoxic or photoallergic reaction, or 
may be comedogenic. Finally, especially in recent years, the sunscreen product vehicle has 
an important function, acting as a protective layer on the skin against external potentially 
damaging factors that could come into contact with the body. Recently, there has been an 
increase in various external harmful factors or, at least, a higher awareness about them (e.g. 
air pollution, UV radiation). 
 
6.3.4.2 Substantivity  
To be effective, sunscreening agents must remain on the surface or in the outermost layers 
of the skin [172]. The overall ability of a sunscreen product to remain on the surface or in the 
outermost layers of the skin and thus to resist removal is termed substantivity. Substantivity 
has been defined as the ability of a penetrant to adhere to keratinous substrates in the upper 
skin layers by chemical conjugation with proteins, thereby resisting removal, especially, when 
in contact with water. According to the FDA, a sunscreen product is declared water-resistant 
if it can maintain its original SPF after two 20-min immersions [173]. 
With increasing substantivity the sunscreen product remains in the skin longer resulting in 
higher efficacy and safety due to a reduced need for frequent reapplication and delayed 
percutaneous absorption [174, 175]. Willis and Kligman [176] classified sunscreen products 
into two types: external (residing on the skin surface) and; reservoir (diffusing into and 
remaining within the SC) types, depending on their capacity to diffuse into the SC, therefore 
resisting washing off.  
The location of an absorbed substance within the skin is complex. Goddard [177] reported 
about two main driving forces which may lead to drug accumulation in keratin. First, 
distribution processes, which are strictly governed by the lipophilicity (partition coefficient) of 
the penetrant. Secondly, adsorption can occur. Here, distinction is possible between specific 
adsorption caused by strong physicochemical attraction e.g. ion-ion interactions and, 
additionally, unspecific adsorption on the basis of van der Waals forces or hydrophobic 
interactions. Hagedorn-Leweke and Lippold [178] investigated the affinity of non-ionic 
compounds to animal keratin and to human callus and studied the influence of the skin lipids 
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on their uptake. They found that the keratin affinity was directly related to the lipophilicity of 
the penetrant in terms of the octanol-vehicle partition coefficients and solubility in the vehicle. 
Therefore, they suggested that genuine substantivity, associated with specific adsorption, 
does not seem to occur for these solutes.  
 
6.3.4.3 The vehicle interactions 
The potential for large differences in the extent of absorption between topical formulations is 
due to the complex interactions between the drug, the vehicle and the skin which control 
partitioning into and diffusion through the skin barrier.  
 
6.3.4.3.1 Drug-skin interactions 
Drug-skin interactions include binding of the drug by the skin. In the optimization of 
substantivity, attempts have been made to introduce groups with positive electric charges 
into UV-absorbing molecules [175, 179, 180]. These functional groups are able to interact 
with negative charges of the protein chains of the keratin and consequently a fraction of such 
molecules will be retained by the upper skin layers, at least for a certain period of time. 
However, introduction of ionic groups into the chemical structure of a sunscreening agent 
may reduce its ability to absorb UV radiation and thereby compromise its efficacy [179]. 
 
6.3.4.3.2 Vehicle-drug interactions 
On the other hand, various authors have shown that the choice of the vehicle plays an 
important role in the optimization of a sunscreen products substantivity. Lorenzetti and 
coworkers [181] showed an improved substantivity of para-aminobenzoic acid by using an 
ethanolic protein vehicle. They suggested a retarded penetration due to binding between 
para-aminobenzoic acid molecules and the protein. 
Recently, Felton et al. [182] investigated the influence of HPCD (hydroxypropyl-β-
cyclodextrin) concentration on the transdermal permeation and accumulation of 
benzophenone-3 in the skin. The HPCD-benzophenone complexation significantly 
augmented the aqueous solubility of benzophenone-3, thereby increasing transdermal 
permeation. Maximum flux occurred at 10% HPCD when sufficient HPCD was added to 
solubilize all benzophenone-3. Increasing the HPCD concentration up to 20% shifted the 
theoretical equilibrium of the complexation reaction towards the complexed form and hence 
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reduced the penetration. The authors conclude that at higher HPCD concentrations a 
benzophenone-3 reservoir may be created on the skin surface.  
 
6.3.4.3.3 Vehicle-skin interactions 
Vehicle-skin interactions include the broad field of permeation/penetration enhancers. 
Basically these are vehicle components which interact with the SC to increase drug solubility 
or drug diffusion or both. Penetration enhancers are substances which increase the 
percutaneous penetration of a chemical. It is presumed that they disrupt the organization of 
the SC barrier. Figure 13 is a schematic representation of models to show how an enhancer 
intercalates itself into the closely packed hydrocarbon chains of the SC lipids. 
 
Figure 13.  Schematic representation of the possible mechanisms of action of skin penetration enhancers [183].  
 
Different experiments have indicated that vehicles which enhance penetration also increase 
the quantity and longevity of material retained in the skin [48, 184-189]. Such solvents noted 
are DMSO (dimethylsulfoxide), DMAC (dimethylacetamide), DMFA (dimethylformamide), 
Azone® and Transcutol®CG (diethylen glycol monoethyl ether).  
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Transcutol®CG is a vehicle used as a solvent/cosolvent in cosmetic and topical preparations 
and has been shown to form a cutaneous depot in the skin with corticosteroids [186], 
griseofulvin [190] and ivermectine [188].  
The mechanism behind the increased accumulation of a drug in the skin with the use of 
Transcutol®CG is thought to be a swelling of the SC lipids, thus enabling drugs (especially 
lipophilic compounds) to form a deposit [186]. A recent study [185] investigated the influence 
of the Transcutol®CG concentration on the transdermal permeation and skin accumulation of 
two sunscreening agents, benzophenone-3 and octyl methoxycinnamate. The accumulation 
of both sunscreening agents in the skin was significantly increased by adding 50% 
Transcutol®CG in the formulation. However, transdermal permeation was not increased.  
 
A study performed in vitro revealed that Azone® and Transcutol®CG increased the flux of 
cyanophenol, a model compound, by a factor of 2 [187]. ATR-FTIR (Attenuated Total 
Reflection Fourier Transform InfraRed) spectroscopy revealed that these enhancers act by 
different mechanisms. Azone® reduced diffusional resistance of the SC through direct 
interaction with SC lipids leading to a increased fluidity. Transcutol®CG acted by increasing 
the solubility of the penetrant in the SC. The transport of Transcutol®CG itself through the 
skin also improved the skin skin/vehicle partitioning for the drug. As a result, retention and 
formation of a deposit of the drug was observed [188]. However, evidence for the mechanism 
by which Transcutol®CG enhances is still limited.  
 
Nannipieri and colleagues [191] analyzed vehicle-skin interaction in vitro. They found that the 
vehicle used had an effect on the resistance of the SC or of the viable tissues to the 
permeation of benzophenone-3. The decreasing effect of the SC resistance with several 
tested vehicles was partially or totally concealed by an opposite effect on the viable tissue 
resistance. 
 
With sunscreen products, external factors such as contact with clothing, washing with soap or 
bathing and sweating are more influential and critical for the substantivity, than the sunscreen 
product formulation itself.  
 
6.3.4.3.4 Vehicle-drug–skin interactions 
Formulations in which significant vehicle-drug-skin interactions occur are probably the most 
common. Many pharmaceutical solvents such as propylene glycol are known to have modest 
6 Topical bioavailability of sunscreening agents 
T. Fässler Tassopoulos Inauguraldissertation, University of Basel, 2006 Page 50 of 195 
effect on reducing the skin barrier function (vehicle-drug interaction) as well as influencing the 
solubility of the drug in the delivery vehicle and converting the partitioning of the drug from 
the vehicle into the SC (vehicle-skin interaction). 
 
6.4 Sunscreen product optimization 
 
The recently developed sunscreening agents are generally more lipophilic substrates having 
high affinity for the skin compared to older agents. Different U.S. patents [192-194] describe 
the use of film-forming polymer compositions which, due to their very high molecular weight, 
maintain active agents on and near the skin surface with a minimum of skin penetration. 
Polymers are believed to enhance the water-resistant properties of a sunscreen product by 
maintaining the sunscreening agents on the target sites within the upper layers of the SC. 
Hence, removal of the active agents will only occur by the natural sloughing (desquamation) 
of the upper layers of the SC. 
 
Another approach in the optimization of sunscreen products is the use of a specialized 
delivery system such as liposomes (liquid encapsulation system), and microspheres (solid 
entrapment system e.g. solid lipid nanoparticles (SLN)). A recent study [195] reported on 
incorporation of tocopherol acetate into SLN. The SLN dispersion was at least twice as 
effective as the reference emulsion. The results showed that the incorporation of a 
sunscreening agent in SLN prevents chemical degradation and increases the UV-blocking 
capacity. 
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7 Drug measurement in the stratum corneum  
 
7.1 Skin scraping 
 
The surface topography and the cellular details are not assessed with skin scraping. 
Large amounts of corneocytes can be harvested by curetting the SC from the surface with an 
open dermal steel curette. Usually superficial (-20 µm), and with more vigorous scraping 
midlevel (20-40 µm) SC can be collected [196, 197]. This technique has also been 
successfully employed by Faergemann et al. to determine drug concentration (terbinafine, 
fluconazole) in the SC [198-200]. The degree of superficial sebum and contamination of the 
SC by sweat may influence the amount of drug found in the SC.  
 
7.2 Skin surface biopsy 
 
The SC can also be removed by the so called skin surface biopsy. The skin surface biopsy 
technique using cyanoacrylate contact cement was employed for the diagnosis and study of 
superficial mycoses. The glue is applied to a glass slide and pressed onto the skin surface. 
Then the slide is removed after the glue has polymerized [201, 202]. This technique allows 
the quantification of drug found in the SC after various application durations [196]. Because 
the hair follicle content is also removed with this method, a distinction between the 
transepidermal and the transfollicular routes of absorption is not possible. 
 
7.3 Tape stripping  
 
7.3.1 Tape stripping technique 
Tape stripping is a technique that has been found useful in dermatopharmacological research 
for selectively and, at times, exhaustively removing the skin’s outermost layer, the SC. 
Typically an adhesive tape is pressed onto the skin and is abruptly removed. The application 
and removal procedure may be repeated 10 to more than 100 times [203, 204]. 
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Tape stripping is widely used in various fields of cutaneous biology, namely for the study of 
the barrier function and the reservoir of the skin [205-207], epidermal growth kinetics [208-
211], and various aspects of skin permeability [32, 212, 213]. Differences in the permeability 
of intact and fully stripped skin have provided information about the diffusional resistance of 
the skin [214]. It has been recognized that to reach the point of barrier disruption 30-67 tapes 
are required, depending on the subject’s skin type [215]. Öhman et al. showed that after 100 
tape strippings the entire SC could be removed [204]. However, no permeation data through 
such completely stripped skin exists. 
 
7.3.2 Application of the tape stripping technique 
The stripping technique has been extended as a means of predicting systemic absorption 
following topical application [216]. 
Dupuis, Lotte, Rougier, and coworkers [151, 164, 217] determined the concentration of four 
different chemicals (benzoic acid, benzoic acid sodium salt, caffeine, acetylsalicylic acid) in 
the SC at 30 min after topical application. They found a linear relationship between the SC 
reservoir content and in vivo absorption of the four compounds at various sites in human 
subjects measured by the traditional urinary excretion method [218-220]. They could also 
show for a variety of simple pharmaceutical vehicles that the percutaneous absorption of 
benzoic acid is vehicle dependent and can be predicted from the amount of drug within the 
SC at 30 min after topical application. The tape stripping technique offers the advantages that 
it is essentially non-invasive and that the testing of urine and faecal excretion to determine 
percutaneous absorption can be eliminated. Existing data indicates that there is a good and 
valid correlation between percutaneous absorption and SC reservoir. 
 
7.3.3 Dermatopharmacokinetics 
Tape stripping has been proposed as a method for evaluating bioavailability and 
bioequivalence of topical dermatological dosage forms as an alternative approach in clinical 
trials, analogous to the use of concentration-time curves for systemically administered drugs 
[221]. By sampling different skin sites at progressive application times, it is possible to derive 
kinetic uptake metrics for local bioavailability evaluation thus providing a means for assessing 
the bioequivalence of two dermatological drug products. In the same way, a fixed treatment 
time for all skin sites followed by sequential tape stripping at incremental post-treatment 
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removal allows the clearance of the drug from the SC to be assessed. This in vivo approach 
is also known as “dermatopharmacokinetics” (DPK). DPK studies include validation of both 
analytical methods and tape stripping techniques. The U.S. FDA is seriously considering this 
method for regulatory purposes, and after much discussion [221-225] a draft guidance 
reviewing this procedure has been published [226]. However, further validation is necessary 
in order to assess the feasibility of the approach. 
 
7.3.4 Quantification of stratum corneum removed 
Currently, xenobiotics (e.g. drugs, sunscreening agents) are extracted from a single or 
combined tape strip and the concentration in the extracted solution is determined by an 
appropriate analytical method e.g. HPLC, fluorescence spectroscopy etc. [227-229]. 
Individual analysis of the tape strips allows the SC distribution of the molecule to be 
displayed as a concentration to tape-strip number or concentration to SC depth profile, which 
is an instantaneous and static picture of the drug penetration at a given time. Many studies 
report the mass of penetrating xenobiotic as a function of tape strip number. Although profiles 
of drug levels versus tape strip number give an estimate of the local SC bioavailability, they 
are based upon the assumption that each tape strip removes a constant and reproducible 
amount of SC if the procedure is standardized (e.g. by applying a constant pressure over a 
given time). Van Der Valk and Maibach [230] demonstrated that the amount of SC removed 
can change from approximately < 5-30%. The number of strips does not correlate linearly 
with depth within the SC. The first few corneocyte layers are loosely attached so that 
relatively large quantities of horny tissue patches are removed by the first pieces of tape. 
Each successive strip removes smaller quantities. Thus, the amount of SC removed by each 
tape strip generally decreases with increasing depth [231]. Furthermore, during the tape 
stripping procedure, clusters of corneocytes are removed, rather than perfect layers, and 
furrows are obviously not evenly removed with the superficial tape strips [232]. Additionally, 
the applied vehicle may variably influence both the cohesion of the corneocytes tape as well 
as the adhesive properties of the tape [233 in preparation]. Swelling by skin hydration 
provoked by emollient or occlusive formulations results in the removal of non-reproducible 
amounts of SC [234]. This may be especially true for long application times. It is also 
probable that the particular tape, the pressure applied on the tape and the peeling force 
applied for the removal of the tape will affect SC removal [200]. Determining the amount of 
7 Drug measurement in the stratum corneum 
T. Fässler Tassopoulos Inauguraldissertation, University of Basel, 2006 Page 54 of 195 
SC removed by each single tape strip both intra-individual and inter-individual variability in 
SC thickness is taken into account. 
 
In order to overcome these problems, it is necessary to express the amount of drug 
measured as a function of the amount of SC removed by each individual tape strip.  
Several methods have been proposed to quantify the amount of SC removed by tape 
stripping. These include: (a) gravimetric analysis (weighing); (b) spectroscopic determination 
of the protein absorption of the SC and; (c) measurements of the TEWL. 
 
Weighing is the preferred method [235] but it is a time consuming procedure necessitating a 
micro balance. Artefacts are sometimes observed due to absorption and desorption of 
moisture due to weighing of the tape before and after stripping [8-10]. Furthermore, the 
weight of SC is disturbed by topically applied formulations of sebaceous components of the 
skin [12]. 
Some more rapid and less tedious alternatives include spectroscopic measurements. 
Different spectroscopic methods for measuring the protein absorption of SC have been 
applied. Marttin et al. [10] used the characteristic protein absorption band in the UV range to 
determine the SC amount on each tape. Unfortunately, this method is not very reliable 
because the light scattering by the SC exceeds the light absorption of proteins. Dreher and 
coworkers [8] proposed quantifying SC by a protein assay. This method is limited because 
the tape strips are destroyed and thus are unavailable for subsequent determination of the 
drug concentration on the tape strips. Recently, Weigmann et al. [12] developed a method to 
determine the SC amount directly on tape strips by measuring the skin in the visible spectral 
range. The absorption measured is determined by reflection, scattering and diffraction 
properties of the corneocytes and is taken as a measure of the amount of corneocytes on the 
individual tape. A sum of the absorption which reflects the total SC mass removed during the 
tape stripping procedure is obtained. A correlation of the absorption of each single tape to the 
sum total yields the relative amount of corneocytes in relation to the total amount of SC. 
Therefore, the entire SC has to be removed during the tape stripping procedure.  
 
A further normalization - as relative instead of absolute SC depth - was proposed by Kalia 
and coworkers [236, 237]. They measured transepidermal water loss during sequential tape 
stripping. The theoretical barrier function at the base of the SC can be deduced by this 
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methodology and the total thickness of the layer may be extrapolated thus permitting the 
relative depth to be obtained. 
 
In penetration studies, the first strip is often discarded [238, 239]. The first strip, however, is 
not irrelevant because also a large quantity of SC material is removed. Furthermore, it is the 
strip that removes the greatest quantity of SC material. In order to obtain reliable 
concentration to depth profiles of drugs penetrating into the SC, it is important to determine 
the amount of SC removed by each tape including the first tape strip [10]. 
Most research papers rarely describe the use of a template to assure accurate and 
consistent removal of the SC from the target treatment area. Without such a template, 
consistency in terms of the SC removal area is not assured and thus DPK studies may 
become questionable. 
One unresolved issue of the tape stripping technique is that the skin surface is not flat. The 
topography of the skin presents unique challenges to validate tape stripping. The skin 
possesses innumerable macroscopic furrows [240]. A histological section of the skin that was 
tape-stripped twenty times clearly showed non-stripped skin in the furrows, indicating an 
incomplete tape stripping [232]. Indeed, after removing forty tape strips the furrows were still 
present. On one tape removed from the skin surface, SC cells were obtained and also 
unabsorbed drug from the skin furrows thus distorting the interpretation of the tape stripping 
study (Figure 14). 
 
Figure 14.  A macroscopic furrow of the skin. 
Legend.  A macroscopic furrow of the skin  
  B Schematic drawing of the tape stripping technique. Superficial corneocytes still present in the furrow after 
tape stripping are removed with later tape strips. In this way, tape strips are obtained containing corneocytes 
which originate from different layers of the stratum corneum.  
A B 
7 Drug measurement in the stratum corneum 
T. Fässler Tassopoulos Inauguraldissertation, University of Basel, 2006 Page 56 of 195 
It is obvious that the removal of the drug from the skin surface before stripping is a procedure 
that is important and that has a large influence on the tape stripping study. Residual material 
can be removed by washing the skin with ethanol followed by distilled water and drying with a 
cotton swab [7, 151, 241, 242] or simply gently wiping the skin with dry cotton applicators 
[243]. Wester and [244] demonstrated that the addition of soap reverses the partitioning of 
the compound into the SC. Such cleaning procedures might even damage the skin or 
enhance penetration of the applied compound. The removal procedure should only remove 
excess drug from the SC surface and should not affect drug concentrations in the SC.  
 
Even though tape stripping is considered to be essentially non-invasive, it locally disrupts the 
barrier function and results in skin glistening and erythema. In certain dark-skinned 
individuals the stripped sites may remain pigmented for several months after healing. This 
effect should be communicated to the volunteers before their enrolment in a study.  
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8 Original publications 
 
8.1 Simultaneous spectrophotometric determination of a sunscreen agent and 
relative stratum corneum tissue density in skin tape strips.  I.Validation of 
analytical methodology.1 
 
INTRODUCTION 
 
Tape stripping of the stratum corneum from the skin is a relatively non-invasive and useful 
technique that has been used widely in recent years for bioavailability and 
dermatopharmacokinetic studies of topically-applied drugs [1].  The numerous problems 
associated with the standardization of the tape stripping methodology have been 
documented at length [2, 3].  The general technique used to date involves topical dosing, 
followed by application and subsequent removal of adhesive tape strips from the skin; 
corneocytes adhering to the tape strips are thereby removed from the underlying tissue.  
Each tape used in the stripping process (often 30-50 strips in total from each stripped skin 
site) is usually then solvent extracted to isolate the analyte of interest, prior to high sensitivity 
analysis.  However, the adhesive tape stripping of the stratum corneum is not a linear 
process in terms of the thickness of the layer of corneocytes removed from one strip to the 
next, and is not uniform in thickness across the entire field of each tape area (see electron 
micrographs) [2].  This procedure, therefore, relates the mass of permeant found on each 
strip to the tape strip number analyzed, and not strictly to stratum corneum depth or volume 
[4-7].  A modification of this methodology involves the weighing of the tape strips on a high-
sensitivity balance before and after stripping to obtain a mass of tissue removed with each 
strip [8-11].  Alternatively, tissue mass on the tape strips has been determined in terms of 
protein content using the Lowry method [9].  These tape strip weighing, protein determination 
and extraction procedures are laborious and are susceptible to analytical artefacts (e.g. 
vaporization of volatile components of the tape matrix, static charges on the tape strip, etc.).  
Furthermore, a technique has been researched recently that allows the simultaneous 
analysis of corneocyte density and xenobiotic abundance using ultraviolet and visible 
                                            
1 Text submitted for publication: Tassopoulos T, Figueiredo V, Imanidis G, Smith EW, Surber C 2006. Simultaneous Spectrophotometric 
Determination of a Sunscreen Agent and Relative Stratum Corneum Tissue Density in Skin Tape Strips. I Validation of Analytical 
Methodology. J Pahrm Sci. (Note that the in-text citations are referred to in the bibliography at the end of this section.) 
(UV/VIS) spectroscopy [12-14].  This technique has distinct advantages in terms of facile 
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sample handling procedures when compared with previously described methods.  We have 
used the principle of this technique as a basis for the fully-validated  
studies reported here. 
 
The purpose of this research was: firstly, to develop in our laboratories a standardized 
method for the direct assessment of tapes removed from the skin without the need to conduct 
any preparative procedures (such as extraction or weighing) that may introduce artifacts into 
the analysis. Secondly, to establish in our laboratories a method capable of the simultaneous, 
accurate and simple, UV/VIS spectrophotometric determination of both analyte amount and 
relative corneocyte density on each tape strip.  Thirdly, to fully validate both the new, direct 
UV/VIS analysis of tapes and the conventional sample extraction/HPLC analysis procedure 
as a reference, according to current guidelines, in order to assure that either technique may 
be deemed fit for purpose.  A validated direct spectrophotometric technique would obviate 
the need for an extraction process prior to analysis, but would have to be sensitive enough 
for determination of low analyte concentrations.  The new UV/VIS method must be shown to 
be as good as the HPLC technique if it is to be used for routine analysis. 
 
 
MATERIAL AND METHODS 
 
Materials and Reagents 
The UV filter 3-(4-Methylbenzylidene)-camphor (MBC) (Eusolex® 6300) with a purity of          
> 99.5%; and glacial acetic acid 100%, analysis grade, were obtained from Merck KgaA, 
Darmstadt, Germany.  Methanol, gradient HPLC grade, was obtained from Scharlau Chemie 
S.A., Barcelona, Spain.  Water for HPLC analysis was purified by reverse osmosis (Osmostil 
LN 4/2 PH - Septron 500 PH, Christ Aqua ecolife AG, Aesch, Switzerland).  Tesa Multi-Film 
Kristall-Klar 57315 tape was obtained from Tesa, Beiersdorf, Hamburg, Germany.  Working 
solutions of MBC were freshly prepared from a methanolic stock solution of concentration     
1 mg/mL.  Methanolic extraction solutions were filtered through a 0.45 µm membrane (Nylon 
GyroDisc, Orange Scientific, Braine l’Alleud, Belgium). 
 
UV/VIS Spectrophotometric Procedure 
The analytical technique monitors the absorbance/transmission behavior of UV and visible 
wavelength light as this radiation passes through the tape/corneocyte sample.  The proteins 
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and lipids of the stratum corneum are relatively weak chromophores and do not absorb UV 
light to any appreciable extent [10].  This is not the case for certain xenobiotics (e.g. UV 
filters) that penetrate the skin after topical administration: the presence of these chemicals in 
the layers of the skin present relatively strong absorbing chromophores to the incident UV 
light, and result in appreciable absorbance measurements.  On the other hand, the physical 
structures of the corneocytes and other stratal components of the skin present formidable 
barriers to the passage of visible-wavelength light, resulting in appreciable reflectance and 
scattering of the incident radiation.  In practical terms, this scattering of the visible light is 
measured as a decrease in the transmission through the sample or is monitored as an 
“absorbance” in the non-classical sense.  The analytical usefulness of this phenomenon is 
that the degree of visible light scatter is proportional to the density of the corneocytes in the 
path of the light.  Therefore, it is possible to obtain a percentage abundance of corneocytes 
on each tape strip, as a function of the total abundance on all strips, by monitoring the degree 
of absorbance taking place in the visible wavelength region.  A single absorbance spectrum 
measurement between 220 and 500 nm of each tape strip removed from the skin is, 
therefore able to yield analytical data of both the sunscreen concentration in the stratal layers 
removed, and the relative amount of skin tissue adhering to the strip. 
 
Spectrophotometric measurements of MBC on the tape matrix were made using an UV-
Spectrophotometer (Lambda 35, Perkin Elmer, Ueberlingen, Germany); which was controlled 
by UV WinLab Software (v 2.85).  The optics of the spectrophotometer were modified by the 
manufacturer to enable monitoring of a square incident light beam of 1 cm2 area, instead of a 
narrow slit (Measurements to assess sunscreen efficacy in industrial research, EU-project; 
contract no. SMT-CT 97-2152, 01.12.1997 – 30.11.2000).  Continuous spectra of each tape 
were recorded between 220 and 500 nm as shown in Figure 1.  The baseline “absorbance” 
value of the spectrum depends on the relative amount of corneocytes adhering to the tape 
strips.  The relative abundance of corneocytes is, therefore, represented by the plateau 
absorbance value in the visible range when compared with the spectra of reference tapes 
without adhering corneocytes (approximating λ2).  The absorbance spectrum of MBC on the 
corneocyte tape strips showed a λMAX at 297 nm, however the absorbance was always 
recorded at three different wavelengths (peak start (λ3), λMAX (λ1)and peak end (λ2) as shown 
in Figure 1), in order to calculate the total absorbance due to MBC alone by using Equation 1. 
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Axenobiotic = A(λ1) −
A(λ2) − A(λ3)[ ] λ1− λ3( )
λ2 − λ3( ) − A(λ3)  
Equation 1.  Calculation of MBC absorbance by three-wavelength analysis. 
Legend.  A = Absorbance units; for wavelength λ 1, λ 2 and λ 3 see legend Figure 1.  
 
 
HPLC Procedure 
MBC concentrations were assayed by HPLC using an Alliance HPLC System (2690 
Separations Module, 996 Photodiode Array Detector, Millenium32 Software), and a Symmetry 
Shield RP18 (2.1x 100 mm, 3.5 µm particle size) column (all Waters Corporation, Millford, 
Massachusetts, USA).  The mobile phase consisted of 75% (v/v) methanol and 25% (v/v) 
water with pH adjustment to 4.8 using glacial acetic acid (approximately 0.01% v/v); the flow 
rate was set at 0.4 mL/min.  The analytical column temperature was set at 35°C, sample 
aliquots of 10 µL were injected into the chromatograph and the principal detection 
wavelength was set at 305 nm (the maximum absorbance wavelength of MBC). 
 
 
VALIDATION PROCEDURES AND RESULTS 
 
Method validation is a process of proving that a quantitative research method (or set of 
methods) is acceptable for its intended purpose.  Usually validation is conducted in parallel 
with the method development.  Each analytical procedure to be used in this research (the 
UV/VIS spectrophotometric and HPLC methods) had to be validated as a stand-alone 
analytical tool.  The guidelines of the International Conference on the Harmonization of 
Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) were 
applied for this purpose [15].  These guidelines recommend a set of tests and procedures to 
be followed (e.g. specificity, linearity, detection limit, quantitation limit, repeatability, accuracy 
and other evaluations) for validating quantitative analytical procedures. 
Furthermore, the validation of the entire set of methods, when used together in this 
investigation, includes the verification of the following correlations: 
• Relative mass of corneocyte tissue adhering to each tape strip as assessed by 
weighing on a balance or by protein analysis, and as determined by the UV/VIS 
spectroscopy method.  This has previously be validated by Lademann and coworkers 
[12-14]. 
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• Abundance of the analyte of interest on each tape strip as determined by the UV/VIS 
spectroscopy method and as assessed by solvent tape extraction/HPLC analysis. 
In this manner the technique would be documented to be at least as good as previously-used 
HPLC methods in determining analyte concentrations in the skin strata, but with the major 
advantage of simplicity in sample handling and analysis. 
 
Statistical analysis of validation data was carried out using Method Validation in Analytics 
(MVA) software (Novia GmbH, Saarbrücken, Germany), which is based on the ICH 
guidelines.  Regression analysis and test result evaluations were carried out using the 
appropriate methods in Statgraphics PLUS 5 software (Manugistic, Inc., Rockville, Maryland, 
USA). 
 
UV/VIS Spectroscopy Method 
Specificity 
To assure that there is no interference of matrix components of the tape (e.g. the polymer 
film or adhesive) with MBC, tapes were spiked with 25 µL of pure methanol and with 25 µL 
aliquots of standard methanolic MBC solutions to yield loading doses of 1.0 and 35.0 µg/cm2 
on the tapes.  In addition, to demonstrate that the specificity of the analytical methods is 
unaffected by the presence of corneocytes, tapes stripped from human forearm skin were 
similarly spiked.  In each case the methanol was allowed to evaporate completely under 
ambient conditions after spiking, the tapes were mounted on the spectrophotometer 
recording frame and an absorbance spectrum was recorded between 220 and 500 nm.  In 
this manner absorbance spectra of: a) untreated tapes, b) untreated tapes stripped from the 
skin, c) methanol-spiked tapes, d) methanol-spiked tapes stripped from the skin,                   
e) MBC/methanol-spiked tapes, and f) MBC/methanol-spiked tapes stripped from the skin 
were compared.  Analyte specificity would require that none of these handling procedures 
influence the quantitative dose of MBC found on the tape strips by UV/VIS assessment.  Full 
spectral analysis (as in Figure 1) indicated that there is no interference between MBC and 
either the tape matrix components, or the tape matrix components/corneocytes, thereby 
validating the specificity of the technique. 
 
Linearity and Range 
A linear relationship between analyte concentration and measured signal (analytical 
response) exists for many methods used in pharmaceutical analysis.  Linear regression 
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models of absorbance versus concentration are simple to implement, when compared with 
quadratic or polynominal regression models, and the former are preferred over the latter 
models if equivalent results can be achieved.  However particular caution should be taken in 
order to demonstrate the linearity of the analytical response when the analyte of interest may 
interact with a matrix (e.g. tape or corneocytes).  Usually, UV/VIS spectroscopy is used for 
the determination of xenobiotics in solution.  In most cases the solute concentration can be 
adjusted to the validated, linear range (low concentration) of analytical quantification by 
dilution of the working solutions.  In contrast, in this methodology the solute is determined on 
tape strips where the xenobiotic concentration cannot be adjusted to an ideal concentration 
range.  It was anticipated that a few samples of high concentration and many samples of low 
concentration would be expected in the present investigation, based on preliminary studies 
and literature data [12].  Therefore, linearity of the assay would, ideally, have to be shown 
over a wide range of analyte abundance.  Theory would suggest that two calibration curves 
be established for the analysis in this situation; one curve for the high-abundance samples, 
and one curve for the multiple, low-abundance tape samples.  This would allow greater 
accuracy in determining the (more important) lower concentrations, by not introducing linear 
skew artifacts from the (less important) high-abundance points that may occur if all 
concentrations were used in establishing a single curve. 
 
Therefore, to assess the linearity and range of detection for the UV/VIS method, two 
methanolic solutions of 1.2 and 2.4 mg/mL MBC were freshly prepared.  Appropriate dilutions 
of these solutions gave concentrations of 0.024 mg/mL to 4.7 mg/mL (0.024, 0.12, 0.24, 0.36, 
0.48, 0.60, 1.20, 1.80, 2.40, 3.00, 3.60, 4.20 and 4.68 mg/mL).  Aliquots of 25 µL of these 
solutions were dosed onto an area of 3 cm2 (delineated by a template) on the tapes, in 
triplicate, yielding loading doses of 0.2, 1.0, 2.0, 3.0, 4.0, 5.0, 10.0, 15.0, 20.0, 25.0, 30.0, 
35.0 and 39.0 µg/cm2.  Two calibration curves (curve 1 and 2) were established ranging from 
24 to 600 mg/mL and 0.6 to 4.68 mg/mL, to be used with tape doses of 0.2–5.0 µg/cm2 and 
5.0–39.0 µg/cm2, respectively.  Spectral analysis was carried out and MBC absorbance was 
calculated for each prepared tape in order to assess the linearity of the detector response in 
both concentration ranges. 
 
The two concentration/absorbance plots were analyzed with different linear regression 
models (unweighted, 1/x weighted and 1/x2 weighted) to test for optimal linearity parameters.  
These linearity parameters were compared by means of the Mandel fitting test (DIN 38402 
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1986), which compares the three linear regression models to a quadratic model in order to 
determine which models are closest to the quadratic descriptor.  All linear regression models 
(i.e. the unweighted, 1/x and 1/x2 weighted) can be accepted at a 95% confidence level for 
calibration curve 1.  However, only the 1/x2 weighted linear model can be accepted at a 95% 
confidence level for calibration curve 2.  Therefore, to standardize the methodology, only the 
1/x2 weighted linear models for curves 1 and 2 were selected for further validation. 
 
Accuracy 
Accuracy of the UV/VIS method was determined by analyzing tapes spiked with methanolic 
solutions of MBC, using the linear calibration curve established above.  Three concentrations 
were used for accuracy determination (0.2, 5.0 and 39.0 µg/cm2).  Five independent solutions 
were made up at each concentration, and 2 tapes were spiked with each solution. The 
accuracy values were expressed as relative percentage error (Er %) and were found as 
follows: at 0.2 µg/cm2 Er = 97.2%, at 5.0 µg/cm2 Er = 99.1% and at 39.0 µg/cm2 Er = 96.4% 
(overall Er = 97.6%).  These parameters demonstrate sufficient accuracy in the UV/VIS 
methodology for quantitative measurements. 
 
Exclusion of Matrix Effects in the Low Concentration Range 
Theoretically, a calibration curve for low analyte concentrations must pass through the origin 
(zero).  In cases of matrix effects that cannot be corrected by a reference sample, a 
calibration curve may not pass through zero, indicating systematic errors in the methodology.  
If systematic errors are negligibly small, then the confidence interval range for the y-intercept 
of the calibration curve must include zero and the intercept should statistically not be 
distinguishable from zero at the defined level of confidence.  This requirement is met for 
calibration curve 1 (lower range) at a 95% confidence interval with an intercept range from     
-1.97E-03 to 1.27E-03 (including zero).  It can therefore be assumed that there are no 
systematic errors in the methodology at low MBC concentrations. 
 
Reference Calibration Curve 
In contrast to HPLC procedures where there is a need to establish daily calibration curves, 
UV/VIS spectrophotometry is negligibly susceptible to instrument based interferences.  It is 
therefore feasible to establish a single, representative calibration curve for the instrument to 
determine MBC concentrations on tape strips for use over the entire experimental period.  
Five calibration curves were constructed over a 4 week period (low and high abundance 
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range), each having six standards for calibration curve 1, eight standards for calibration curve 
2, n=3 for each level.  The average regression parameters for all five curves were determined 
using the MVA software package (Table 1). 
 
To investigate the homogeneity of the variance of all data points across the entire range of 
the mean, 1/x2-weighted calibration curves 1 and 2, the Cochran’s C test was applied to the 
merged data from the five calibration constructions.  The null hypothesis assumes that the 
variances are equal (homoscedasic) at each concentration value across the entire data 
range.  The Cochran’s C test confirmed homogeneity of variances for calibration curves 1 
and 2 over the entire concentration range (P-value curve 1 = 0.09, P-value curve 2 = 1.0 
where P-values > 0.05 indicate that variances are not significantly different).  Therefore, the 
mean reference calibration curves 1 and 2 were used for all further analytical measurements. 
 
Detection Limit (DL) and Quantitation Limit (QL) 
According to the ICH recommendations, several methods could be used for determining the 
DL and QL, these include: 
1. calculation from noise (DL=3.3*xnoise, QL=10*xnoise), 
2. calculation from standard deviation (SD) of the blank (DL=3.3*SDblank/slope, 
QL=10*SDblank/slope), 
3. calculation from standard deviation of the y-intercept (DL=3.3* SDintercept /slope, 
QL=10* SDintercept /slope), 
4. calculation from the standard error of the estimate (Sr) of the calibration line 
(DL=3.3*Sr/slope, QL=10*Sr/slope). 
 
As outlined in Table 2, DL and QL results for the reference calibration curve 1 and QL for 
reference calibration curve 2 were dependent on the calculation method applied. 
 
Method 4 (worst case scenario) was chosen to define the detection and quantification limits 
for the assay when used for quantitative investigations.  This offers the highest confidence 
when applying the UV/VIS method for evaluating MBC concentration in the tapes. 
 
Precision 
The data from the five calibration curves constructed over the period of four weeks were used 
for the estimation of repeatability (intra-day variation) and intermediate precision (inter-day 
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variation) of the UV/VIS method.  In the construction of each calibration curve, three samples 
were analyzed at each concentration level (6 concentration levels for calibration curve 1 and 
for 8 concentration levels for calibration curve 2).  Therefore, the precision parameters were 
estimated at each concentration by 15 data points collected on five occasions over a four-
week period.  The precision parameters were calculated for the ratio of absorbance and 
concentration (sensitivity, response factor), by analysis of variance considering the 
contributions of intra-series and of inter-series effects.  There was no significant difference of 
the means at a 95% confidence level for the two calibration curves.  Calibration curve 1: the 
coefficients of variation for the different series were lower or equal to 6.2%, the repeatability 
and the intermediate precision were 4.3% and 4.4%, respectively.  Calibration curve 2: the 
coefficients of variation for the different series were lower or equal to 5.9%, the repeatability 
and the intermediate precision were 5.3% and 5.3%, respectively. 
 
Therefore, the parameters described above fully validate the UV/VIS methodology and give 
credence for the use of the technique in tape strip analysis. 
 
HPLC Methodology 
In the previous section (see UV/VIS Spectroscopy Method) the validation procedures and 
results for the UV/VIS spectroscopy method has been described at length.  The HPLC 
methodology has been validated.  In a similar way, however, since HPLC validation is a 
routine laboratory procedure, the technical descriptions have been abbreviated here. 
 
Specificity 
To determine HPLC specificity, tapes spiked by the same procedure as described in section 
UV/VIS Spectroscopy Method, Specificity were extracted for 16 h with 2.0 ml methanol in 
stoppered 50 ml-volumetric flasks, and aliquots of this extraction solution were injected into 
the HPLC system without further dilution.  The eluent peak diode array spectra obtained from 
these injections were compared with spectra from an authenticated MBC sample.  The 
retention time of MBC was recorded at 4.33 ± 0.01min (Figure 2).  The chromatograms of the 
extracts indicated that there is no interference between MBC and the tape matrix 
components or the tape matrix components/corneocytes. 
 
Linearity and Range 
A stock solution was prepared in triplicate by dissolving 100 mg of MBC in 100 mL methanol.  
8 Original publications 
T. Fässler Tassopoulos Inauguraldissertation, University of Basel, 2006 Page 66 of 195 
Appropriate dilutions of the stock solution gave standard solutions with concentrations of 0.5, 
1.0, 2.5, 5.0, 7.5 and 10.0 µg/mL.  These standard solutions were injected in triplicate into the 
HPLC system to evaluate linearity.  Data were analyzed as described in section UV/VIS 
Spectroscopy Method, Linearity and Range, which yielded a linear relationship between the 
peak area and the concentration.  The results of the Mandel’s fitting test showed that the 1/x 
weighted and 1/x2 weighted linear regression model can be accepted at a 95% confidence 
level.  Theoretically, the calibration curve must pass through the origin; this requirement is 
met at a 95% confidence interval with a range of values from -2.06E03 to 3.16E03, including 
zero.  The Cochran’s C test was used to asses the homogeneity of the variance over the 
range of the 1/x-weighted calibration curve.  The P-value was found to be higher than 0.05 
(P-value = 0.12) indicating that there are no statistically significant differences among the 
variances over the concentration range at the 95% confidence level.  Therefore, the 1/x-
weighted regression model was used for further validation of the calibration curve and for 
analytical HPLC determination of MBC from tape extracts. 
 
Accuracy 
Accuracy of the HPLC system was determined by analyzing independent, known methanolic 
solutions of MBC, using the linear calibration curve established above.  Three concentrations 
were used for accuracy determination (0.5, 5.0 and 10.0 µg/mL).  Five independent solutions 
were made up at each concentration, three replicates were injected for each solution.  The 
accuracy values were expressed as relative percentage error (Er %) and were found as 
follows: at 0.5 µg/mL Er = 101.2%, at 5.0 µg/mL Er = 97.6% and at 10.0 µg/mL Er = 103.4% 
(overall Er = 100.7%). Therefore, according to the ICH guidelines the accuracy of the HPLC 
techniques was found to be acceptable for analytical determinations. 
 
Detection Limit (DL) and Quantitation Limit (QL) 
The four methods described in section UV/VIS Spectroscopy Method, Detection Limit and 
Quantitation Limit were used to determine the DL and QL of the HPLC system.  The noise of 
the HPLC method was measured between the highest and the lowest signal of a blank 
(methanol) injection.  The DL and QL calculated from the standard error of the estimate of the 
calibration line (method 4: DL=3.3*Sr/slope, QL=10*Sr/slope) gave the greatest values and 
was therefore used for quantitative analysis (DL = 1.64E-01 µg/mL, QL = 4.98E-01 µg/mL).  
As previously, the worst case scenario was chosen to define the detection and quantification 
limits as this offers the highest confidence when applying the HPLC methodology to the 
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evaluation of MBC concentrations in the tapes. 
Precision 
The data from three calibration curves constructed on three different days were used for the 
estimation of repeatability (intraday variation), and intermediate precision (interday variation).  
Three replicates of each concentration of the calibration curve were injected into the HPLC.  
There was no significant difference of the means at a 95% confidence level for the calibration 
curves.  The coefficients of variation for the different series were lower or equal to 4.8%.  The 
repeatability and the intermediate precision were 3.4% and 3.4%, respectively.  Therefore, 
the precision of the HPLC methodology is shown to be acceptable for analytical purposes. 
 
Determination of Extraction Recovery 
The extraction recovery was determined by spiking skin-stripped tapes with methanolic 
solutions at three different MBC doses (1, 5 and 35 µg/cm2).  After solvent evaporation, MBC 
was extracted by methanol as described in section HPLC Methodology, Specificity and, after 
appropriate dilution, the solute concentrations in the extracts were determined by the HPLC 
procedure described above.  The analyte recovery was calculated from the MBC 
concentration determined with the calibration curve and compared with the dose spiked on 
the tapes with corneocytes.  The mean recovery for MBC was 91.9% at a concentration of 1 
µg/cm2, 96.1% at a concentration of 5 µg/cm2 and 90.9% at a concentration of 35 µg/cm2.  
Therefore, the average recovery over the entire analytical range is 93.0%.  A recovery value 
may not be a 100% of the nominal MBC concentration.  If the average recovery is known 
(93%), the analytically-measured concentration in routine sample analysis can be corrected 
to obtain the theoretical 100% nominal concentration.  Sample extracts measured by HPLC 
may therefore be corrected by a factor of 1.075 to yield true concentrations. 
 
 
Comparison of HPLC and UV/VIS Data 
To compare the MBC concentration measured by UV/VIS with the MBC concentration 
measured by HPLC, tapes were spiked by the same procedure as described in section 
UV/VIS Spectroscopy Method, Specificity, at loading doses of approximately 1, 5 and 35 
µg/cm2.  After evaporation of the methanol, an absorbance spectrum was recorded between 
220 and 500 nm and the MBC concentration was determined by the mean regression 
equation (see Table 1).  The same tapes were methanol extracted as described in section 
HPLC Methodology, Specificity, and the extracted solutions were assayed by the HPLC 
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system described above.  The results found by HPLC were corrected by the factor of 1.075 
(see section Determination of Extraction Recovery).  The MBC concentrations found by 
UV/VIS and HPLC were compared to each other in terms of recovery (Table 3). 
 
A t-test was performed to compare the HPLC data with the UV/VIS data.  The computed p 
value was 0.51, indicating that there was no statistically significant difference in the amount 
of MBC found by both methods at a 95% confidence interval.  This clearly demonstrates that 
analytical data from both methods are equivalent in quality. 
 
 
DISCUSSION AND CONCLUSIONS 
 
In an attempt to accurately and reproducibly quantify the mass of a sunscreen agent that 
penetrates into the stratum corneum after topical application, we have independently 
validated a direct UV/VIS analysis and a solvent extraction/HPLC analytical method for skin 
tape strips.  Each procedure has independently been shown fit for purpose according to the 
currently-accepted laboratory guidelines.  In addition, we have compared the data from the 
two analytical methods and found them to be equally accurate and precise in determining 
sunscreen abundance in the corneocyte layers removed by tape stripping.  However, the 
direct spectrophotometric technique obviates the need for any tape extraction process prior 
to analysis, and is sensitive enough for the accurate determination of low analyte 
concentrations on the tape strips since there is no loss of analyte in the sample handling 
protocol.  The simplicity of the direct spectrophotometric method, combined with its accuracy 
and precision, make this an ideal analytical tool for rapidly processing the large data sets 
involved in dermatopharmacokinetic testing of sunscreen agents, contained in a variety of 
delivery systems. 
 
The essential scientific prerequisites for a critical comparison of the quantitative data 
obtained from the two methods have therefore been established; the application of these 
validated analytical techniques to in vivo human studies will be described in the second paper 
in this series. 
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Figure 1: UV spectrum of a tape strip removed from the skin after treatment with a MBC 
formulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend.  λ 1 = wavelength at maximum absorbance 
 λ 2 = wavelength at end of peak 
 λ 3 = wavelength at start of peak 
 
 
λ2 λ3 λ1 
Ab
so
rb
a
n
ce
 
u
n
its
 
Wavelength (nm) 
Sunscreen agent 
8 Original publications 
T. Fässler Tassopoulos Inauguraldissertation, University of Basel, 2006 Page 72 of 195 
Figure 2: A Chromatogram; B Spectrum index plot and; C 3D plot of MBC. 
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Table 1:  Mean Reference Calibration Curve for UV/VIS Method 
S.D.c 
 
Mean Regression Equationa rb 
Slope Intercept 
Srd 
Calibration Curve 1 y=0.0796 x – 7.205E-4 0.999 7.561E-4 3.600E-4 1.609E-3 
Calibration Curve 2 y=0.0728 x + 0.0510 0.998 7.010E-4 8.020E-2 3.185E-2 
 
a Calculated absorbance y versus appropriate abundance x, in µg/cm2; 90 data points for calibration curve 1, 
120 data points for calibration curve 2. 
b  Correlation coefficient 
c  Standard deviation of slope / intercept 
d  Standard error of estimate 
 
 
 
Table 2:  Detection and quantitation limit of MBC by the UV/VIS method according to the ICH 
guidelines. 
 Reference Calibration Curve 1 Reference Calibration Curve 2 
Calculation Method DL a QL b QL b 
1 1.76E-03 5.33E-03 5.33E-03 
2 1.73E-03 5.23E-03 5.23E-03 
3 2.43E-02 7.37E-02 2.94 
4 4.86E-02 1.47E-01 5.22 
 
a
 Detection limit in µg/cm2, b Quantitation limit in µg/cm2 
 
 
 
Table 3:  Method comparison in terms of recovery at 3 different levels of MBC concentration 
% Recovery ± SD Approx. Concentration Level 
(n=5) UV/VIS method HPLC method  
1 (1.17) µg/cm2 100.18 ± 2.84 98.98 ± 1.13 
5 (4.66) µg/cm2 98.88 ± 2.23 103.93 ± 1.41 
35 (34.97) µg/cm2 100.11 ± 0.75 98.24 ± 2.20 
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8.2 Simultaneous spectrophotometric determination of a sunscreen agent and 
relative stratum corneum tissue density in skin tape strips.  II. Application of 
the method in Humans2 
 
INTRODUCTION 
 
One of many self-evident prerequisites for investigations in man are well developed analytical 
methodologies that have been proven fit for purpose. In a previous publication [1] we have 
detailed the independent validation of: a) the direct UV/VIS spectrophotometric determination 
of a sunscreen agent on tapes stripped from the skin; and b) an HPLC method for analysis of 
the sunscreen when solvent extracted from the skin tape strips.  These two analytical 
methods were fully validated as stand-alone procedures according to current guidelines of 
the International Conference on the Harmonization of Technical Requirements for the 
Registration of Pharmaceuticals for Human Use (ICH) [2].  In the current paper we report on 
the comparison of analytical data from the two methods when evaluated in vivo using human 
volunteers.  A standardized tape skin stripping procedure has been developed for this 
purpose. It has been optimized in terms of methodological shortcomings previously reported 
for the technique [3-6].  The aim of the research presented here is to minimize the variability 
of the tape stripping data by optimization and standardization of the methodology, and to 
complete the validation of the direct spectrophotometric procedure by comparing the quality 
of the data from UV/VIS and solvent-extracted HPLC analyses, when applied to an in vivo 
situation where there is an added parameter of a complex topical delivery vehicle.  
 
 
MATERIAL AND METHODS 
 
Emulsion Formulation 
The emulsion formulation used as the delivery vehicle for the sunscreen in these experiments 
was a modified P3 standard formulation from the European Cosmetic, Toiletry, and 
Perfumery Association (COLIPA) guidelines [7].  The ingredients of the emulsion were: 
                                            
2 Text submitted for publication: Tassopoulos T, Figueiredo V, Imanidis G, Smith EW, Surber C 2006. Simultaneous Spectrophotometric 
Determination of a Sunscreen Agent and Relative Stratum Corneum Tissue Density in Skin Tape Strips. II Application of the Method in 
Humans. J Pahrm Sci. (Note that the in-text citations are referred to in the bibliography at the end of this section.) 
Tegosoft TN (C12-15 Alkyl benzoate) 15 g, Emulgade F (cetearyl alcohol, PEG-40, castor oil 
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and sodium cetearyl sulfate) 3.15 g, Carbopol 934 (carbomer) 0.3 g, ethanol 8.0 g, KOH 
solution 10% 1.5 g, Eusolex 6300 3-(4-Methylbenzylidene)-camphor (MBC) 2.0 g or 4.0 g, 
and water q.s. 100g.  The MBC and potassium hydroxide were obtained from Merck KgaA, 
Darmstadt, Germany.  Tegosoft TN was obtained from Goldschmidt AG, Essen, Germany.  
Emulgade F was obtained from Cognis Deutschland GmbH, Düsseldorf, Germany.  Carbopol 
934 was obtained from Noveon Inc., Cleveland, Ohio, USA.  Absolute ethanol was obtained 
from Fluka, Buchs, Switzerland. 
 
All the components of the oil phase (MBC, Emulgade F and Tegosoft TN) were melted 
together at 90°C over a water bath.  The carbopol was dispersed in water for approximately 
30 seconds with an Ultra Turrax agitator (IKA Ultra Turrax T25 Basic with IKA disperser 
S25N25F) set at 16 000 rpm and was also warmed to 90°C using a water bath.  The aqueous 
solution was then slowly added to the oil phase with continuous stirring (200 rpm) using a 
stirring motor (type IKA Eurostardigital / IKA RW 28 Basic).  The ethanol was added when the 
emulsion had cooled to a temperature of 40°C.  The emulsion was then homogenized with 
the Ultra Turrax (16 000 rpm) for one minute and finally stirred (50 rpm) for 30 minutes until 
room temperature was reached.  The mass of the final formulation was checked and adjusted 
to the datum with water during the final stirring phases.  All production steps were carried out 
under GMP conditions.  The emulsion phase stability was verified through stress-testing by 
means of centrifugation (15 min at 5’000rpm). The microscopic aspect and pH of the 
formulations were tested.  The emulsions for both dosing strength were stable (droplet size, 
pH) throughout this investigation.  
 
Subjects 
A standardized clinical protocol was developed for volunteer processing, according to 
international GCP guidelines and was approved for implementation by the Internal Review 
Board of the institution [8].  Five volunteers (2 female, 3 male), aged from 24 to 29 years, 
participated in the study.  All subjects were in good general health and had no history of 
dermatological diseases.  Informed consent was obtained from all the participants.  The 
volunteers were asked not to apply detergents or emollients to the forearm on the day of the 
experiment.  The subjects rested 30 min before the experiment at constant environmental 
conditions of 24°C room temperature and 40% relative humidity. 
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Tape Stripping Procedure 
A rectangular formulation application area was delineated on the volar surface of each arm 
by dermatological pen to yield a site of 45 cm2.  The compounded emulsions containing MBC 
were randomly applied to the demarcated application sites, one arm of each subject was 
treated with 2% formulation and the other arm with 4% formulation.  In each case, 90 mg of 
the product was applied to the skin by the portion with a 1 ml syringe and the formulation 
spread evenly over the demarcated area with a gloved finger, to yield a topical application 
dose of 2 mg/cm2.  This application modality ensures a homogenous and accurate 
distribution and dosing of the formulation. 
 
The dosed skin sites were stripped one hour after formulation application.  The central area 
of the application site to be tape stripped was demarcated by fixing a flexible, grease-proof 
paper template to the skin with adhesive tape.  The template had a rectangular aperture of 
1.3 cm x 3.3 cm, thereby exposing a constant skin area (4.29 cm2) for each sequential tape 
stripping, and ensuring consistent removal of stratum corneum from exactly the same 
formulation application site.  The long axis of the template was fixed along the midline of the 
forearm to ensure intimate contact with the skin and to simplify the subsequent stripping 
procedure. 
 
Tape stripping was carried out with Tesa tape (Multi-Film Kristall-Klar 57315 tape, Tesa, 
Beiersdorf, Hamburg, Germany) of width 1.5 cm.  A strip of adhesive tape (longer than the 
aperture of the template) was placed over the skin area exposed through the template 
aperture.  Pressure was then applied perpendicularly to the adhering tape in a uniform 
manner using a hand roller that supplied a gravitational weight of 140 g/cm2 to the skin.  The 
roller was uniformly passed over the tape 10 times at each stripping, thereby addressing the 
inconsistency issues of pressure application as described in previous papers [5, 6].  The tape 
(with adhering corneocytes) was then manually removed from the skin by pulling, using firm, 
rapid and uniform tension.  The direction of tape removal (elbow-to-wrist or wrist-to-elbow) 
was alternated with each tape in order to strip the stratum corneum in a consistent manner 
(Figure 1). 
 
This standardized procedure was developed and optimized from previous experience [9], 
with the intention of addressing as many of the adverse issues as possible that had 
previously been reported with the tape stripping methodology.  These issues centered mainly 
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on the adhesivity of the tape used, the pressure of tape application, the reproducibility of 
locating each sequential tape strip on exactly the same skin site, and the uniformity of the 
process of tape removal from the skin.  The permanent template fixed to the skin in the 
procedure described here ensures exact placement of every tape and the weighted roller 
provides uniformity of pressure application on the tapes.  There may certainly still be some 
variability in the manual removal of the tapes after adhesion, however, with experience and 
repetition of this process, variability is presumed to be acceptably low when assessed in 
relation to the overall experimental protocol. 
 
Tape Strip Assessment 
Once removed from the skin, each tape was fixed across a photographic slide frame, 
exposing the tape and adhering corneocytes through the frame aperture (Figure 1D).  This 
frame could easily be accommodated in the solid-sample holder of the spectrophotometer 
(Lambda 35, Perkin Elmer, Ueberlingen, Germany) with custom modification to monitor an 
incident light path area of 1 cm2 [1]. Each frame was stored under controlled conditions 
pending analysis. 
 
Stripping with sequential tapes was carried out in this manner at each skin test site to remove 
the entire stratum corneum layer.  The absorbance of every tenth tape/corneocyte sample 
was measured at 430 nm immediately after removal from the application site, to determine 
the transmission through the specimen in relation to blank tape.  The absorbance 
(transmission) measured at 430 nm was taken as the relative abundance of stratum corneum 
material on the sample.  Typically the absorbance value recorded at 430 nm is large initially, 
representing the large percentage of stratum corneum adhering to the first and initial series of 
strips.  Thereafter the absorbance at 430 nm declines as fewer corneocytes adhere to each 
subsequent tape.  Stripping of the skin was stopped when transmission at 430 nm 
approached 97% (representing almost complete removal of the stratum corneum).  In this 
evaluation the average number of tapes required to remove the entire SC was 62 ± 12 tapes.  
 
Each tape was scanned for absorbance potential between 220 and 500 nm (in order to 
quantify the sunscreen and relative abundance of corneocytes).  Additionally, a blank tape 
reference was sampled sequentially from the stock roll of Tesa tape after every five skin strip 
tapes and included in the sample series for analysis.  These reference blank tapes served as 
a baseline control for comparison of the corneocyte/tape data, and sequential inclusion of 
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multiple blanks allowed continuous correction for any irregularities in the optical properties of 
the tape from the start to the end of the roll.  A typical UV/VIS scan from a tape manipulated 
in this manner has been presented earlier which shows the strong absorbance at 297 nm, 
due to the presence of MBC in the sample, and the plateau absorbance value in the visible 
range due to the presence of corneocytes adhering to the tape [1]. 
 
In addition, after being spectrophotometer-analyzed in this manner, each tape was solvent 
extracted for HPLC analysis as described previously [1].  In this manner the quantitative data 
from the direct spectrophotometric method and from the conventional solvent 
extraction/analysis method could be compared. 
 
Statistical Analysis 
Validation assessments were conducted using MVA software (Method Validation in 
Analytics, Novia GmbH, Saarbrücken, Germany), which is based on the guidelines of the 
ICH.  Regression analysis and test result evaluations were made using the appropriate 
statistical methods within Statgraphics PLUS 5 software (Manugistic, Inc., Rockville, 
Maryland, USA). 
 
 
RESULTS 
 
Direct Spectrophotometric Analysis 
The MBC and the corneocytes adhering to the tapes were assessed by scanning the tapes 
spectrophotometrically after stripping from the skin.  The absorbance value at 297 nm 
(Equation 1) [1] was used to determine the abundance of MBC in µg/cm2 by interpolation of 
either calibration curve 1 (0.2–5.0 µg/cm2) or calibration curve 2 (5.0–39.0 µg/cm2).  The 
plateau absorbance value at 430 nm, when compared with the next blank tape in the series, 
gave an indication of the relative amount of corneocyte material adhering to each strip. 
Each tape strip analyzed in this manner therefore yields information about the abundance of 
the sunscreen analyte within the skin tape strip, and the relative amount of stratum corneum 
adhering to each tape (see section Tape Strip Assessment).  As exemplified in Figure 2 data 
can thus be presented in terms of sunscreen abundance versus either the tape strip number 
or the relative fraction of stratum corneum removed from the epidermis [10]. 
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To determine the total amount of MBC that has entered the SC, the MBC abundance 
determined per tape and area of tape strip was summated yielding information of the total 
mass of compound delivered from a specific formulation. The largest abundance of MBC was 
always found in the initial tape strips, which also removed the largest amount of corneocyte 
matrix.  The first tape removes not only SC with penetrated MBC, but also un-penetrated 
MBC remaining on the skin surface with residual vehicle.  Therefore, data from the first tape 
was always ignored when the total mass of compound delivered from a vehicle was 
calculated. The individual and average data for all the subjects tested are depicted in Figure 
3.  In each subject, delivery is greater from the 4% than from the 2% formulation. Differences 
between the mass penetrated from the two formulations were analyzed with ANOVA at a 
95% confidence level.  The results show that the dosing strength of the formulations has a 
statistically significant (p<0.05) influence on the penetration of MBC (no statistically 
significant influence of the volunteers on the data). 
 
Comparison of UV/VIS and HPLC Analysis 
After the direct determination of MBC on the tapes by UV/VIS spectroscopy, the MBC was 
extracted from each tape by methanol and, after appropriate dilution, the concentration in the 
extracts of each tape was assayed by HPLC as described previously [1].  In this manner the 
analytical data from the UV/VIS and HPLC methods could be compared directly.  To this end, 
all the concentrations obtained by direct spectrophotometric quantification were plotted 
against the MBC concentrations measured by HPLC (Figure 4) [1].  The data of 2 outliers 
were included (subject 3, tape 2, formulation MBC 4% and subject 2, tape 1, formulation 
MBC 4%). The linear correlation factor was 0.974.  The value of the slope of the curve is 
0.978 with a 95% confidence interval of 0.953 – 1.002.  This confirms statistically that the 
MBC concentration found by UV/VIS method correlates directly with the MBC concentration 
measured by HPLC after extraction. A paired-sample hypothesis test confirmed that there is 
no significant difference (p>0.05) between the two analytical procedures. 
 
 
DISCUSSION AND CONCLUSIONS 
 
In the present research the validation of a direct spectrophotometric procedure was 
completed by comparing in vivo data from a UV/VIS assessment and from HPLC analysis 
following solvent extraction of MBC from tapes strips harvested from skin treated with a 
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complex topical delivery vehicle.  A highly standardized tape skin stripping procedure has 
been developed for this purpose to overcome methodological shortcomings previously 
reported for the technique [9].  A direct correlation has been found for the data from the two 
methods.  Therefore, the validations presented here verify that the direct spectrophotometric 
analysis of MBC on skin tape strips is equally valid to the more laborious solvent 
extraction/HPLC analysis. 
 
The results show furthermore that the dosing strength (2% vs 4%) of the formulations has a 
statistically significant (p<0.05) influence on the penetration of MBC (no statistically 
significant influence of the volunteers on the data) into stratum corneum.  This is clear 
evidence that the tape-stripping technique is sensitive and reliable enough to be used for 
developing new or improving old formulations including topical sun protection products. 
 
This experimental evaluation completes the full validation of the optimized and standardized 
tape stripping methodology and gives credence to the use of this technique for the in vivo 
determination of sunscreen delivery to the skin from topical delivery vehicles.  The delivery of 
sunscreen from a representative sample of vehicles, using the direct spectrophotometric 
determination method, is compared in paper three of this series [11]. 
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Figure 1: Tape stripping procedure. A strip of adhesive tape was placed over the skin area 
exposed through the template aperture (B, C).  Pressure was then applied perpendicularly to the 
adhering tape in a uniform manner using a hand roller that supplied a gravitational weight of           
140 g/cm2 to the skin (A).  The roller was uniformly passed over the tape 10 times at each stripping.  
The tape (with adhering corneocytes) was then manually removed from the skin by pulling, using firm, 
rapid and uniform tension (C).  The direction of tape removal (elbow-to-wrist or wrist-to-elbow) was 
alternated with each tape in order to strip the stratum corneum in a consistent manner. Once removed 
from the skin, each tape was fixed across a photographic slide frame, exposing the tape and adhering 
corneocytes through the frame aperture (D). Each frame was stored under controlled conditions 
pending analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(C) (D) 
(B) 
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Figure 2: Typical stratum corneum profile of MBC from the (A) 2% formulation and the (B) 4% 
formulation from an individual. Data is presented in terms of sunscreen abundance versus either tape 
strip number (left axis) or relative fraction of stratum corneum removed from the epidermis (right axis). 
 
0 55 1010 1515 2020 2525
0
10
20
30
40
50
60
70
80
90
100
H
o
rn
y 
la
ye
r 
th
ic
kn
es
s 
in
 
%
T
ap
e
 n
u
m
b
e
r
 MBC Abundance in µg/cm²
1
5
10
15
20
25
30
35
40
55
 
 
0 55 1010 1515 2020 2525
0
10
20
30
40
50
60
70
80
90
100
H
o
rn
y 
la
ye
r 
th
ic
kn
es
s 
in
 
%
T
ap
e
 n
u
m
b
e
r
 MBC Abundance in µg/cm²
1
5
10
15
20
25
30
35
40
55
 
(A))) 2% MBC formulation 
(B) 4% MBC formulation 
8 Original publications 
T. Fässler Tassopoulos Inauguraldissertation, University of Basel, 2006 Page 84 of 195 
0
20
40
60
80
100
120
0
20
40
60
80
100
120
Nr 1 Nr 2 Nr 3 Nr 4 Nr 5
2% MBC 4% MBC
Volunteer 
To
ta
l M
a
ss
 
in
 
µg
 
Figure 3: Total mass (µg) of MBC determined by direct spectrophotometric analysis 
delivered from the 2% and 4% formulations: individual subjects (A), and average data for all 
subjects (B). Dosing strength of the formulations has a statistically significant (p<0.05) 
influence on the penetration of MBC. 
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Figure 4:  Correlation of the MBC concentrations measured by UV/VIS spectroscopy and the 
concentrations measured by HPLC.  Regression equation: y = 0.978x + 0.193, R2 = 0.974. 
Information on outliers see section Comparison of UV/VIS and HPLC Analysis. 
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8.3 Simulataneous spectrophotometric determination of a sunscreen agent and 
relative stratum corneum tissue density in skin tape strips.  III. Comparison 
of vehicle effects in Humans3 
 
INTRODUCTION 
 
It is a well established phenomenon in topical and transdermal formulation development that 
the vehicle into which the active is incorporated has a marked influence on the rate and 
extent of drug delivery [1-3].  Moreover, we have already shown the importance in the drug 
delivery process of not only the chemical composition of the delivery formulation, but also the 
three-dimensional structural matrix that is formed on manufacture [4].  This concept is 
currently being investigated at length for physical matrices such as microemulsions and solid 
lipid nanoparticles [5].  The influence of the delivery vehicle is therefore an important 
parameter that must be evaluated and validated in the development of a new analytical 
procedure.  Any analytical process that is adopted for routine use in the pharmaceutical 
industry must be shown to be sensitive and accurate in the presence of diverse delivery 
matrices.  Moreover, if the analytical procedure is quantifying bioavailability parameters, then 
the protocol must be able to show significant difference in the rate and extent of topical drug 
delivery if these differences exist. 
A previous publication [6] has described the quantitative comparison and analytical validation 
of 3-(4-Methylbenzylidene)-camphor (MBC) data from an optimized human skin tape 
stripping procedure.  This data has been obtained from the tape matrix by both conventional 
solvent extraction/HPLC means, and directly assessed by our fully-validated UV/VIS 
methodology.  This data was found to equally accurate and precise, regardless of the means 
of analysis.  The convenience and facilitated sample handling of the UV/VIS methodology 
make this the method of choice for further study.  Therefore, in this paper we describe the 
application of the direct UV/VIS technique to the in vivo determination of sunscreen delivery 
to the skin from different topical delivery vehicles, in an attempt to validate the usefulness of 
the direct UV technique in assessing complex  vehicle effects in topical drug delivery. 
                                            
3 Text submitted for publication: Tassopoulos T, Figueiredo V, Imanidis G, Smith EW, Surber C 2006. Simultaneous Spectrophotometric 
Determination of a Sunscreen Agent and Relative Stratum Corneum Tissue Density in Skin Tape Strips. III. Comparison of Vehicle Effect 
in Humans. J Pahrm Sci. (Note that the in-text citations are referred to in the bibliography at the end of this section.) 
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MATERIAL AND METHODS 
 
Chemicals 
The UV filter 3-(4-Methylbenzylidene)-camphor (MBC) was obtained from Merck KgaA, 
Darmstadt, Germany.  Propylene glycol and polyethylene glycol 400 (Macrogol 400) were 
purchased from Hänseler AG, Herisau, Switzerland.  Mineral oil (paraffinum liquidum) was 
purchased from Siegrfried Ltd., Zofingen, Switzerland.  Transcutol®GC (diethylene glycol 
monoethyl ether) was obtained from Gattefossé S.A., Saint Priest, France.  Tesa Multi-Film 
Kristall-Klar 57315 tape was obtained from Tesa, Beiersdorf, Hamburg, Germany.  
Methanol, HPLC grade, was obtained from Scharlau Chemie S.A., Barcelona, Spain. 
 
Instrumentation, Equipment and Statistical Analysis 
Leopold glass application chambers (Figure 1) [7] were used to apply and contain the liquid 
delivery vehicles on the skin.  Spectrophotometric measurements of MBC on the tapes 
stripped from the skin were made using a custom-modified UV-Spectrophotometer (Lambda 
35, Perkin Elmer, Ueberlingen, Germany); which was controlled by UV WinLab Software      
(v 2.85) [6, 8].  Skin strips collected from the vehicle-treated sites were analyzed for MBC 
content and corneocyte abundance according to a fully validated UV/VIS method described 
in detail previously [6, 8].  Data were evaluated for statistically significant differences (p<0.05) 
using analysis of variance (ANOVA) procedure in Statgraphics® PLUS 5 software 
(Manugistic, Inc., Rockville, Maryland, USA).   
 
Subjects 
A standardized clinical protocol was developed for volunteer processing, according to 
international GCP guidelines [9] and was approved for implementation by the Internal Review 
Board of the institution.  Fifteen volunteers (7 female, 8 male), aged from 25 to 35 years, 
participated in the studies.  All subjects were in good general health and had no history of 
dermatological diseases.  Informed consent was obtained from all the participants.  The 
volunteers were asked not to apply detergents or emollients to the forearm on the day of the 
experiment.  The subjects rested for 30 min before the experiment at constant environmental 
conditions of 24°C room temperature and 40% relative humidity. 
 
8 Original publications 
T. Fässler Tassopoulos Inauguraldissertation, University of Basel, 2006 Page 88 of 195 
Vehicle Formulations 
The delivery vehicles were prepared according to cGMP Guidelines.  The following five 
vehicles were used: propylene glycol, mineral oil, PEG 400, PEG 400 containing 10% 
Transcutol®GC, and PEG 400 containing 50% Transcutol®GC.  To ensure comparable 
thermodynamic activity of MBC in the different vehicles, all formulations were saturated with 
MBC.  Saturation solubility of MBC was achieved by adding an excess amount of the 
sunscreen to each vehicle in a 50 mL flask, and the solution was equilibrated for 24 hours in 
a water bath at 33 ± 1°C with continuous stirring.  After centrifugation of the mixture 
(Labofuge I, Haereus Christ, Laborgeräte AG, Zürich, Switzerland, 10 min., 4000 rpm) the 
solution was maintained at 33°C until used for subject application.  The MBC saturation 
solubility in the different formulations was determined by simple UV/VIS spectroscopy and 
these values are shown in Table 1. 
 
Vehicle Application 
Two or three sites on the ventral surface of each forearm of each volunteer were treated (four 
or six total sites per subject dependent on the protocol).  The glass chamber was fixed to the 
application site with straps and an aliquot of the delivery vehicle was introduced through the 
side-port. At the end of the vehicle-skin contact time, the residual formulation was removed at 
each site with four, sequential, dry cotton swabs before tape stripping the treated skin area. 
 
Tape stripping procedure 
Treated skin sites were tape-stripped with Tesa® tape using a standardized method 
previously described in detail [6, 8].  After removal of the delivery formulations, a flexible 
template of 5 cm x 7 cm with a rectangular aperture of 1.3 cm x 3.3 cm was fixed onto the 
treated skin surface with adhesive tape.  A strip of Tesa® tape was placed on the skin surface 
exposed through the aperture, and pressure was applied perpendicularly to the adhering tape 
in a uniform manner using a hand roller.  The tape was then manually removed, alternating 
the direction of stripping (elbow-to-wrist or wrist-to-elbow). 
 
Experimental Design 
Two sets of experiments were conducted to evaluate the influence of vehicle and application 
time on MBC penetration into the SC and the influence of vehicle to create a reservoir of 
MBC in the skin (substantivity). 
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Influence of Vehicle and Application Time on MBC Penetration 
The influence of propylene glycol (F1) and mineral oil (F2) as vehicle, and the influence of the 
skin-contact time, on MBC penetration were investigated in five subjects (2 males/3 females).  
Three sites were dosed on each forearm such that each formulation was randomly applied 
three times to each subject.  Each formulation was allowed to remain on the skin for three 
durations (t=1h, t=3h, and t=6h) before removal of residual formulation. 
 
Influence of Vehicle on the Substantivity of MBC 
Three formulations, PEG 400 (F3) [control], PEG 400 containing 10% Transcutol®GC (F4) 
and PEG 400 containing 50% Transcutol®GC (F5), were evaluated in ten subjects (5 males/5 
females) for their ability to create a reservoir of MBC in the skin (substantivity).  Each subject 
was treated with control (F3) and one other formulation: either F3/F4 (five subjects) or F3/F5 
(five subjects). At time zero, each of the two formulations was applied to a single site on each 
forearm of every subject, randomized with respect to the location on the arm and left versus 
right arm.  All formulations remained on the skin for one hour, and residual vehicle was then 
removed by dry swabbing.  One treated site for each vehicle was stripped immediately after 
removal of the formulation (at one hour post application); the other site was stripped at seven 
hours after initial application, six hours after vehicle removal. 
 
 
RESULTS 
 
Influence of Vehicle and Application Time on MBC Penetration 
The total mass of MBC penetrating into the SC on all the tape strips was summated from the 
data of each individual strip analysis as described in detail previously [6].  The first tape 
collected from each site of all the subjects was discarded due to potential drug/vehicle 
remaining on the skin surface.  The data from this evaluation are depicted in Figure 2. 
At all contact times investigated there was greater penetration of MBC into the SC from the 
propylene glycol than from the mineral oil vehicle.  An ANOVA evaluation was conducted 
with the log-transformed results based on the analysis factors of “formulation”, “time” and 
“volunteer”.  In addition, the combined effects of a) formulation – time, b) formulation – 
volunteer and c) time – volunteer were evaluated.  The only statistical parameter that 
showed a significant effect (p<0.05) on MBC penetration was “formulation”.  All other factors 
evaluated (time, volunteer, and combined effects) showed no significant effect. 
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The number of tape strips used to completely remove the stratum corneum was compared for 
the propylene glycol and mineral oil vehicles in the five subjects (Figure 3).  A paired sample 
t-test was conducted to compare the means of the total number of tapes required for 
complete SC removal for all application durations.  There is a statistically significant 
difference (p=0.05) between the number of tape strips required for complete SC removal in 
the presence of the propylene glycol and mineral oil vehicles, at each application duration. 
 
Influence of Vehicle on the Substantivity of MBC 
The total mass of MBC penetrating the SC after one hour of vehicle contact, and the mass 
remaining in the SC six hours after swabbing of residual formulation (seven hours after initial 
application), was analyzed as previously described.  An ANOVA evaluation was conducted 
with the log-transformed results based on the analysis factors of “formulation”, “time” and 
“volunteer”.  In addition, the combined effects of a) formulation – time, b) formulation – 
volunteer and c) time – volunteer were evaluated. 
 
PEG 400 (F3) versus PEG 400 + 10% Transcutol®GC (F4) 
There was no significant difference (p<0.05, all factors) in the mass of MBC found in the 
stratum corneum delivered from the PEG 400 formulation or from that containing 10% 
Transcutol®CG, either at 1- nor 7-hours after initial application (Figure 4). 
 
PEG 400 (F3) versus PEG 400 + 50% Transcutol®GC (F5) 
The comparison of the formulations containing 50% Transcutol®CG and the formulation 
without Transcutol®CG by means of the variance analysis was statistically significant for the 
factors “formulation”, “time interval” and “volunteer” (p<0.05). No significant effect was 
detected for the combined effects.  Thus, there is a significant difference in MBC penetration 
in the presence or absence of 50% Transcutol®CG, both at 1-hour and at 7-hours post 
application (Figure 5).  In addition, this comparison of formulations indicated a significant 
difference between individual test subjects (inter-individual distribution).  This methodology 
is, therefore, capable of detecting differences in the extent of reservoir formation of the 
sunscreen when applied to the skin in different delivery vehicles. 
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CONCLUSIONS 
 
The evaluations reported in this series of papers [6, 8, 10] provide a comprehensive 
evaluation of the optimized tape-stripping technique, the analysis of permeant and 
corneocyte abundance on tape strips, and the comparison of HPLC-extract and direct 
UV/VIS analysis of the strip samples.  In addition, it has been shown that the fully validated 
UV/VIS method of analysis for skin tape strips collected from the optimized in vivo 
methodology is applicable to accurately monitoring the delivery of MBC from different topical 
vehicles.  Importantly, the optimized methodology is capable of showing significantly-different 
extents of active delivery from the different vehicles where these exist, underscoring the 
potential use of the stripping protocol in topical bioequivalence evaluations.  It must be 
stressed that the credence of this data obtained is based on a full analytical validation and 
verification of all aspects of the methodology – both analytical procedures and sample 
procurement methods – based on pharmaceutical industry standards.  The facilitated 
handling of the tape strips, and the rapid means of analysis make this a very attractive 
method for sunscreen product development and formulation performance evaluation.  
Moreover, the analytical procedures, with appropriate modifications, should have equal 
applicability to other classes of topical drugs (e.g. topical antifungals or retinoids), and to 
other chemicals that may be important for agricultural or military monitoring (e.g. insecticides 
or chemical warfare agents). 
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Figure 1: Leopold glass application chamber.  
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Figure 2: Total mass (µg) of MBC determined delivered from propylene glycol and mineral oil after 
1h, 3h, and 6h of vehicle application ( x  ± SD ; n=5 ). 
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Figure 3. Number of tapes required to remove the stratum corneum after treatment with propylene 
glycol (F1) and mineral oil (F2), at different application durations. 
 
Legend.  n=5 (volunteers) for both formulations. 
F1, 1h: x = 43; SD = ± 9. 
F1, 3h: x = 42; SD = ± 6. 
F1, 6h: x = 45; SD = ± 5. 
 F2, 1h: x = 70; SD = ± 6. 
 F2, 3h: x = 59; SD = ± 9. 
F2, 6h: x = 66; SD = ± 11. 
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Figure 4: Total mass (µg) of MBC determined delivered from the formulations containing 0% and 
10% Transcutol at 1 hour and 7 hours post application ( x  ± SD ; n=5 except for PEG 400, 0h and 
PEG 400, 6h (n=10)). 
 
 
 
 
Figure 5: Total mass (µg) of MBC determined delivered from the formulations containing 0% and 
50% Transcutol at 1 hour and 7 hours post application ( x  ± SD ; n=5 except for PEG 400, 0h and 
PEG 400, 6h (n=10)). 
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Table 1: Saturation solubility of MBC in different delivery vehicles 
VEHICLE ABBREVIATION SATURATION SOLUBILITY 
Propylene glycol F1 2.4 ± 0.1% (m/m) 24.4 ± 1.2 mg/mL 
Mineral oil F2 8.8 ± 0.7% (m/m) 76.3 ± 6.9 mg/mL 
PEG 400 F3 7.6 ± 0.2% (m/m) 85.2 ± 3.6 mg/mL 
PEG 400 + 10% Transcutol®GC F4 9.4 ± 0.4% (m/m) 103.0 ± 4.3 mg/mL 
PEG 400 + 50% Transcutol®GC F5 19.6 ± 0.6% (m/m) 203.3 ± 5.8 mg/mL 
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9 Overall conclusion and future perspectives 
 
Chemical sunscreening agents are the active ingredients in sunscreens and they reduce the 
amount of UV radiation reaching the skin by absorption. The concentration and combination 
of sunscreening agents in a formulation determine the efficacy of sunscreens as measured 
by the sun protection factor. To be effective the sunscreening agents should ideally remain 
on the skin surface or penetrate in the upper most layers of the stratum corneum (SC) after 
application. The vehicle influences both the sun protection factor and the extent of 
sunscreening agent penetration. In the present work, the SC penetration capacity of the 
model compound 3-(4-Methylbenzylidene)camphor (4-MBC), a commonly used sunscreening 
agent, from different delivery vehicles was investigated by tape skin stripping. The data of the 
stripping experiment were analyzed by an analytical method developed and validated for the 
simultaneous determination of the analyte and SC directly on tapes.  
 
Validation of Analytical Methodology. 
A commonly used method for analyte determination on tapes consists of sample extraction 
followed by HPLC analysis. However, this quantification method is time consuming and may 
involve loss of analyte. In order to relate the mass of permeant found on each strip to SC 
depth or volume, the mass of SC removed has to be determined. For SC determination 
several methods are described in the literature (e.g. weighing of tapes or determination of the 
protein content) that are laborious and susceptible to artefacts. The present 
spectrophotometric method comprises the advantage of a simultaneous determination of SC 
and analyte directly on the tape using simple sample handling procedures. With a modified 
UV/VIS spectrophotometer, the simultaneous determination of SC and at least one analyte 
on a tape with only one absorbance spectrum can be performed presuming different 
absorbance maxima of the analytes and no interferences with the tape matrix. The purpose 
of the first part of the present work was to develop and validate a simple and accurate 
spectrophotometric method for the simultaneous quantification of both 4-MBC and SC on 
tape strips. The validation parameters of the proposed spectrophotometric method were 
evaluated according to guidelines of the International Conference on Harmonization of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and 
compared to a conventional solvent extraction/HPLC method.  
The following validation parameters were absolutely comparable to those of the HPLC 
method: linearity range, intermediate precision and repeatability, accuracy, detection limit 
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(DL) and quantitation limit (QL). In particular, DL und QL of the UV/VIS method were lower by 
approximately a factor 2 than DL and QL of the HPLC method. Statistical analysis of recovery 
data showed no difference in the amount of 4-MBC found by both methods. The direct 
spectrophotometric technique was demonstrated to be precise and sensitive enough for the 
accurate determination of low analyte concentrations on the tape strips as there was no loss 
of analyte in the sample handling protocol. 
 
Application of the method in Humans. 
The second part of the work consisted in a tape stripping experiment with the purpose of 
investigating 4-MBC delivery into the SC after application of a 2% and 4% emulsion for one 
hour in vivo. Both methods, UV/VIS spectroscopy and solvent extraction/HPLC, were applied 
for analysis of the tapes. The data obtained from the analytical methods were set in 
comparison to each other. The 4-MBC delivery from both formulations was evaluated. 
The variability of the tape stripping data was minimized by optimization and standardization 
of the sample procurement. These issues centered mainly on the adhesivity of the tape used, 
the pressure of tape application by using a hand roller, the reproducibility of locating each 
sequential tape strip on exactly the same skin site by using a template, and the uniformity of 
the process of tape removal from the skin.  
In order to compare the total amount of 4-MBC that had entered the SC, the data were 
evaluated as SC profiles and the 4-MBC abundance determined per tape and area of tape 
strip was summated  in order to yield information of the total mass of compound delivered. In 
the profiles, the penetrated 4-MBC amount is presented versus either the tape strip number 
or the relative fraction of stratum corneum removed from the epidermis. The vehicle effect 
can be visualized by the thickness of the bars representing the relative amount of stratum 
corneum adhering to the tape. However, the interpretation of the amount of sunscreening 
agent in the SC depicted as a funnel does not represent the real distribution of the compound 
and can thus be misleading. In order to compare the 4-MBC delivery from the 2% and 4%    
4-MBC formulation, the data were calculated as total mass. The results show that the dosing 
strength of the formulations has a statistically significant influence on the penetration of        
4-MBC. The higher 4-MBC delivery from the 4% 4-MBC formulation can be explained by the 
higher drug concentration and saturation degree in the vehicle. The 4-MBC abundance 
measured by UV/VIS spectroscopy showed an excellent correlation (R2 = 0.974) with the 
solvent extraction/HPLC. This investigation confirmed that the accuracy and precision of the 
direct spectrophotometric method, combined with its ease of use, make this an ideal 
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analytical tool for rapidly processing the large data sets involved in dermatopharmacokinetic 
studies of sunscreening agents, contained in a variety of delivery systems.  
 
Comparison of vehicle effects in Humans 
The third part of the present work addresses the evaluation of the influence of delivery 
vehicle and application time on the penetratio and substantivity of 4-MBC into the SC in vivo 
using the direct spectrophotometric method. The vehicle effect describes not only the 
influence of a delivery vehicle on the penetration due to its composition, but also the 
influence of a delivery vehicle due to the changes occurring in the formulation due to 
application (vehicle metamorphosis). These changes include: evaporation of volatile 
components, penetration of ingredients into the skin, or water uptake from the skin into the 
vehicle. All of these effects also depend on the individual and on the environmental 
conditions.  
In this part, the influence of the following vehicles on 4-MBC penetration was investigated:  
(1) propylene glycol (PG) versus mineral oil (MO); (2) Polyethylene glycol 400 (PEG 400) 
vehicles containing 0%, 10% and 50% Transcutol®CG. In order to compare the influence of 
different vehicles on 4-MBC penetration into the SC, all vehicles investigated in the 
experiments were saturated 4-MBC-solutions thus obtaining constant thermodynamic activity 
of 4-MBC in all vehicles. 
The vehicle effect of PG and MO on 4-MBC penetration could clearly be demonstrated. The 
experiment showed that the sunscreening agent delivery was significantly higher from the PG 
formulation than from the MO formulation, although the solubility of 4-MBC was 
approximately 3.5 times lower in the PG formulation than in the MO formulation. These 
observations point to the penetration enhancing effect of PG. A plausible hypothesis is that 
PG loosens the corneocytes and thereby alters the skin barrier function. This phenomenon 
was clearly demonstated by the low number of tapes required to strip off the entire SC. The 
different application times (1hr, 3hrs and 6hrs) had no significant influence on the penetration 
of 4-MBC neither from the PG nor from the MO formulation.  
Adding 10% Transcutol®CG to PEG 400 did not increase the total mass of 4-MBC penetrated 
compared to pure PEG 400 at one hour post application. Seven hours post vehicle 
application the total mass of 4-MBC in SC was the same as at one hour post application for 
both vehicles. An addition of 50% Transcutol®CG increased the 4-MBC solubility and 
consequently the total mass of penetrated 4-MBC almost proportionally to the solubility. 
Seven hours post application the total mass of 4-MBC was reduced compared to one hour 
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post application. The experiment confirmed that rate and extent of compound penetration, 
measured one hour post application, correlate with its solubility in the vehicle. PEG 400 is 
known to increase the solubility of a compound in the SC and thus retain it in the SC. Adding 
Transcutol®CG in a concentration of 10% did not result in changes in substantivity seven 
hours post application. For 50% Transcutol®CG, however, a difference in 4-MBC measured 
in the SC between one hour and seven hours post application could be confirmed by 
ANVOVA. 
The findings of this experiment cannot readily be applied to commercial sunscreens because 
of the special conditions throughout this experiment such as vehicle application through the 
Leopold chamber, which affects the environmental conditions and thus the vehicle 
metamorphosis. They provide, however, useful insights into the influence of these studies 
parameters on the effectiveness of sunscreen formulations.  
 
 
Future Perspectives 
While conceptually simple, sunscreen formulations are quite complex, requiring careful 
selection and evaluation of UV filter and vehicle components. The facilitated handling of the 
tape strips and the rapid means of analysis render the spectrophotometric method a very 
attractive tool for sunscreen product development and formulation performance evaluation.  
Future perspectives in the development of sunscreens include DNA repair enzymes or 
factors, which can induce the endogenous cellular DNA repair system such as topically 
applied pTT (thymidine dinucleotide). Thereby, the risk to develop UV-induced skin 
malignancies is markedly reduced. Forthcoming research also has the potential to develop 
sunscreens that can prevent UV-induced immune suppression and that can greatly enhance 
the ability to deflect the UV rays. In the research and development of new sunscreening 
agents it is of great importance not to investigate only the effects of individual potential 
compounds, but to take into consideration the impact of the vehicle they will be embedded in. 
Recently, for the first time a clinical study was able to show the potential of a commercial 
sunscreen product to block UV-induced immunosuppression in healthy volunteers [245]. 
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10 Appendix 
 
10.1 Physical and Chemical Data for 4-Methylbenzylidene camphor 
 
IUPAC name 1,7,7-trimethyl-3-[(4-methylphenyl)methylidene]norbornan-2-one 
Other names  3-(4-Methylbenzylidene)-camphor; 3-(4-methylbenzylidene)-DL-camphor; 
3-(4-Methylbenzylidene)bornan-2-one; Eusolex 6300; Neo Heliopan 
MBC; Parsol 5000; Uvinul MBC 95 
 C18H22O 
Chemical structure 
Molecular weight  254.37g/mol 
 
Appearance    white powder 
Solubility    isopropanol  25 g in 100 mL  
ethanol  25 g in 100 mL  
glycerol  12 g in 100 mL  
propylene glycol   4 g in 100 mL  
water   0.00013 g in 100 mL  
vegetable oils freely soluble  
 
Specific absorbance 930-990 at 299 nm (1%, MeOH, 1 cm) 
λmax    ca. 300 nm  
4-Methylbenzylidene camphor is a UVB filter with high absorptivity that is approved in the EU 
and is suitable for use in all major types of sunscreen products (o/w and w/o emulsions, gels 
and aerosols). Concentration up to 4% is recommended. 
O
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Table 8. Approval status of 4-MBC. 
 EU USA Japan 
4-MBC + (4%) - - 
 
+ = provisionally or finally approved as a sunscreen agent (with max. concentration) 
- = not approved 
 
 
10.2 UV/VIS spectrophotometer specification 
 
In order to guarantee the success of this project a special spectral device was necessary that 
measures the components fixed on the tape strips and integrates an area of about 1 cm2 in 
the strips. Perkin Elmer produced this instrument with the following technical specifications: 
• Double beam spectrometer  
• Wavelength range 190-1100 nm 
• Wavelength resolution 2 nm 
• Measuring area ≥ 1cm2 
 
10.2.1 Introduction 
The measurements of the horny layer particles require a specific measurement set up. This 
set up has been realized on the basis of a Perkin-Elmer Lambda 35 UV/VIS 
spectrophotometer. The aim of this set-up is to provide a uniform measurement area of 
approximately 10 mm x 10 mm while keeping the operating functions and options of a 
standard UV/VIS spectrophotometer. In Berlin and Athens two instruments have been 
modified according to the instrument optics. 
 
Lambda 35 is a high quality routine UV/VIS spectrometer with a wavelength range of 190-
1100 nm and a standard resolution of 2 nm spectral bandwidth. The instrument is equipped 
with a serial RS-232C communications interface that allows full control of the instrument by 
PC software. The UV/VIS spectroscopy applications software package UVWinLab version 
2.7 is part of the package.  
10 Appendix 
T. Fässler Tassopoulos Inauguraldissertation, University of Basel, 2006 Page 104 of 195 
10.2.2 Adaptations of Perkin-Elmer Lambda 35 UV/VIS-Spectrometer 
The instrument has been adapted by Perkin Elmer (Ascanis OHG, D-88662 Überlingen, Mr. 
Liekmeier). A number of different approaches were tested by optical calculations and 
experimental set ups.  
The spherical mirror within the common beam was replaced by a toroidical mirror of radius 
vertical Rv=215.3 mm and radius horizontal Rh=275.6 mm. Size and thickness of the mirror 
were approximately 25 mm x 25 mm and 14 mm, respectively. The modified optics increase 
the beam size at the sample position to a quadratic area of 14 mm x 14 mm without 
requirements for mechanical modifications on the instruments base or in the sample 
compartment. The main area of 10 mm x 10 mm covers 72% of the original energy. This 
range is selected for sample illumination by a quadratic beam mask of 10 mm x 10 mm 
aperture in front of the sample holder. The lens in front of the detectors was replaced by 
larger lenses with the same optical data. 
 
Figure 15.  Optical diagram of sample beam using a lambda 35 spectrophotometer.  
Legend.  M = mirror 
 M4 = torroidal mirror  
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The standard cell sample holders were replaced by specifically designed sample holders. 
These holders carry the metal rings used for the experimental tapes. The holder encloses the 
aperture mask and is adjustable to the beam in height and position. 
Specification measurements showed that the loss of energy was 30% but that the typical 
specifications of the instruments are, nevertheless, valid. These specifications comprised 
noise, baseline stability and stray light data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Pattern of light distribution produced by beam sample.  
Legend.  Modified parameters used to obtain the designated pattern of light distribution: 80% radius [mm] = 5.987; 
image dist. [mm] = 164.229; wavelength [nm] = 750.000 ; (r100-r80)/r80 = 44.4% ; centre vert. [mm] = 0.023 ; 
centre hor. [mm] = 0.192 ; y-range [mm] = 12.679 ; z-range [mm] = 12.969.  
 
 
The standard applications software UVWinLab version 2.7 controls the spectrophotometer. 
This application software package supplies all general functions necessary for the project 
applications. The two UV/VIS spectroscopic measuring systems were developed and 
manufactured by Perkin Elmer. 
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10.3 Selection of adhesive tape 
 
10.3.1 Physicochemical properties of adhesive tapes 
Selection of adhesive tape with appropriate properties is a necessary prerequisite for 
accurate dermatopharmacological studies based on stratum corneum stripping for 
determination of a drug concentration profile. If the tape is too aggressive removing large 
parts of the SC in only few strippings a profile of minor value would result. A tape that 
removes the stratum corneum in forty strips will then give a better profile. One relevant 
parameter for determination of a drug concentration profile is the relative depth of penetration 
which can be visualized after a large series of strippings.  
Recently, Bashir et al. [3] analyzed the influence of the adhesive properties of tapes and their 
barrier as a possible source of variation in by measuring SC amount removal and TEWL. 
They concluded that the choice of tape influences the degree of barrier disruption as does 
the number of tape strips. Some tapes failed to increase TEWL after repeated stripping [3, 9]. 
The failure of these tapes to increase TEWL provides some evidence that the SC remains 
intact and that the water barrier is not significantly disrupted. The adhesivness of the tape for 
particular components of the SC may serve as an explanation. Moreover, the tapes are not 
stripping components of the SC which are responsible for barrier maintenance e.g. ceramids, 
lipids and free fatty acids. 
 
As already outlined (see section 7.3.4), the UV/VIS spectroscopy allows quantification of the 
SC removed and, at the same time to quantification of the sunscreening agent.  
The individual tape properties are responsible for the amount of SC removed.  
The prerequisites of the tape used in the present experimental part were: 
a) non-absorbance in the ultraviolet wavelength range thus preventing interference with 
absorbance measured of the UV-filter, 4-MBC (λmax 299 nm) and  
b) sufficient removal of SC by each tape. 
A first selection was performed based on the absorbance characteristics of different 
commercially available tapes.  
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Table 9. Physicochemical properties of selected adhesive tapes. 
Tape trademark Backing Thickness Adhesive Absorbance a 
 
Sellotape, Sellux PP b 47µm Acrylate 0.0707 
D-Squame Skin Sampling Discs Polyester 100 µm Polyacrylate ester 3.4127 
Scotch crystall clear 600  Acetate 62 µm Synthetic acrylics 0.1791 
Scotch Book Tape 845 PP 85 µm Synthetic acrylics 0.8977 
Tesa Pack 4024, Beiersdorf PP 50 µm Acrylate 0.0596 
Tesa Multifilm transparent 
57315, Beiersdorf 
PP 58 µm Acrylate 0.0611 
Tesa Pack 4124, Beiersdorf PVC c 60 µm Natural rubber  1.1475 
 
a
 λ = 299 nm 
b
 polypropylene 
c
 polyvinylchloride 
    
 
The absorbance spectra are displayed in Figure 17. 
The absorbance characteristics of the tapes revealed three candidates which were suitable 
for evaluation and comparison of further properties i.e. Sellux, Tesa Pack 4024, and Tesa 
Multifilm transparent 57315. 
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Figure 17. Absorbance spectra for different tape brands. 
 
To ensure the completeness of SC removal, the transmission of SC material on the tape had to be 
above 97% at 430 nm. Two tape types which gave a transmission > 97% turned out to be painful and 
irritating (Sellotape and Tesa Multifilm transparent 57315; Table 10). With Tesa Multifilm 
transparent 57315, 40 tapes were necessary to remove sufficient SC material to reach a transmission 
> 97%. However, the sensations during and after tape stripping were acceptable for the volunteers. 
 
Table 10. Adhesive power criteria for selection of optimal tape. 
Tape trademark  Number of tapesa Transmission (%) 
of last tape 
Sensation  
Sellotape, Sellux 45 97.10 painful, irritating 
Tesa Pack 4024, Beiersdorf 80 98.90 painful 
Tesa Multifilm transparent 57315, Beiersdorf 40 97.80 acceptable 
a number of tapes required to remove sufficient SC to reach a transmission of >97%. 
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10.4 Validation 
 
Method validation is the process of proving that an analytical method is acceptable for its 
intended purpose. Various approaches to perform validation are known. The International 
Conference of Harmonization of the Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) guidelines [246] provide a framework for performing 
such validations. However, they provide only a basis for the validation parameters, their 
calculation and for their interpretation. Based on these parameters and requirements of the 
different guidelines, the design of these validation studies and the evaluation of their results 
can be adjusted to the individual analytical procedure in order to achieve an understanding of 
their real performance. 
 
The UV/VIS spectrophotometric and the HPLC methods were validated in terms of 
performance characteristics such as specificity, linearity and range, detection limit, 
quantitation limit, precision (repeatability, intermediate precision) and accuracy. Statistical 
analysis of the data was used to demonstrate validity and justify the adequacy of the 
analytical procedures. 
 
10.4.1 UV/VIS Method 
10.4.1.1 UV/VIS spectrophotometric procedure 
Spectrophotometric measurements of 4-MBC on the tape matrix were made using an UV-
Spectrophotometer (Perkin Elmer Lambda 35); which was controlled by UV WinLab software 
(v 2.85), (Perkin Elmer, Überlingen, Germany). The optical chamber of the 
spectrophotometer was modified by the manufacturer to house a specialized sample holder 
that enabled monitoring of a rectangular incident light beam of 1 cm2 area on each tape. 
Spectra of each tape were recorded between 220 and 500 nm. 
 
10.4.1.2 The template 
The validation of the UV/VIS method was performed directly on the tape by spiking it with 
standard solutions of different 4-MBC concentrations using a template (Figure 18). In order to 
define the spiking area a template (B) was stacked on every tape (A) yielding a spiking area 
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of 2.3 cm x 1.3 cm. The complex of tape and template (C) was fixed across a photographic 
slide frame (D), exposing the tape through the aperture. 
 
 
Figure 18. Composition of template. 
Legend.  A Tape 
 B Template 
 C Tape stacked on template 
 D Tape and template fixed on photographic slide frame. 
 
A colored, methanol solution was spiked on the tape area (Figure 19 A) in order to verify the 
distribution of the 4-MBC containing methanol solution on the tape. The homogeneously 
colored tape confirmed that the methanol solution was evenly distributed and that the solution 
was not running out of the area delimited by the template (Figure 19 B). 
A B 
C D 
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Figure 19. Standardization of spiking procedure.  
Legend.  A Spiking of template-tape with a colored, methanol 4-MBC solution. 
 B Visualization of distribution after spiking.  
 
10.4.1.3 Specificity 
To ensure that there was no interference of 4-MBC with the tape stripping matrix components 
(e.g. polymer film or adhesive) in the direct spectrophotometric monitoring method, tapes 
were spiked with a 25 µL standard methanol solution containing 0.0, 1.0 and 35.0 µg/cm2 of     
4-MBC. In addition, to demonstrate that the specificity of the analytical method was 
unaffected by the presence of corneocytes, tapes stripped from human forearm skin were 
similarly spiked. The methanol and 4-MBC solutions were allowed to evaporate completely 
under ambient conditions after spiking. 
 
The specificity of the spectrophotometric methodology was assessed by recording and 
comparing absorbance spectra of untreated tapes, methanol-spiked tapes, 4-MBC/methanol-
spiked tapes and 4-MBC/methanol-spiked tapes all of which were stripped from the skin. In 
each case, the tapes were mounted on a spectrophotometer recording frame and an 
absorbance spectrum for each tape was recorded between 220 and 500 nm. 
A 
B 
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10.4.1.3.1 The absorbance spectrum  
The absorbance spectrum of 4-MBC reached a maximum at 297 nm. There was no 
interference between 4-MBC and the tape matrix or corneocytes. Due to SC adhering on the 
tape, the absorbance of 4-MBC was always calculated by three-wavelength analysis (Figure 
20, Equation 4). Absorbance values are taken at three different wavelengths in order to 
evaluate the actual absorbance of the compound of interest. 
Figure 20. UV spectrum of a tape strip removed from the skin after treatment with a 4-MBC formulation. 
Legend.  λ 1 = wavelength at maximum peak absorbance 
 λ 2 = wavelength at end of peak absorbance 
 λ 3 = wavelength at beginning of peak absorbance. 
 
 
  
Axenobiotic = A(λ1) −
A(λ2) − A(λ3)[ ] λ1− λ3( )
λ2 − λ3( ) − A(λ3)  
 
Equation 4.  Calculation of 4-MBC absorbance by three wavelength analysis. 
Legend.  A = Absorbance units; for wavelength λ 1, λ 2 and λ 3 see legend Figure 20.  
λ2 λ3 λ1 
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10.4.1.3.2 Influence of skin and time on the 4-MBC absorbance 
The purpose of the following experiment was to investigate of the influence of SC adhering to 
the tape and the time on the absorbance of 4-MBC obtained from tape measurements.  
Stripped tapes (with corneocytes) and blank tapes were spiked with 25 µL of 4-MBC standard 
solutions. The experiment was performed at three different concentration levels: 1, 5 or       
35 µg/cm2. Directly after evaporation of methanol, the absorbance of 4-MBC was measured 
at a wavelength of 299 nm. The measurement was repeated 24h and 48h later. For each 
concentrations 5 stripped and 5 blank tapes were spiked.  
 
Results 
The absorbance values and absorbance ratios are presented in Table 11. The absorbance 
ratios of are depicted in Figure 21. 
 
Table 11. Absorbance values and absorbance ratios based on various concentrations of 4-MBC measured on 
tapes at various time points. 
 4-MBC-concentrations (µg/cm2) a 
 Stripped tapes (n=5)  Blank tapes (n=5) 
 1 5 35  1 5 35 
Absorbance values       
0h 0.1213 0.5362 2.9159  0.0981 0.4910 2.9306 
24h 0.1199 0.5331 2.9839  0.0977 0.4900 2.9299 
48h 0.1195 0.5313 2.9789  0.0975 0.4882 2.9286 
        
Absorbance ratios       
24:0  0.989 0.994 1.024  0.995 0.998 1.000 
48:0  0.985 0.991 1.022  0.993 0.994 0.999 
48:24 0.997 0.997 0.998  0.998 0.996 1.000 
a
 measured at 299 nm 
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Figure 21. Absorbance ratios based on various concentrations of 4-MBC measured on tapes at various time 
points. 
 
A paired sample t-test for the ratio 24:0 with stripped tapes and blank tapes at a 
concentration of 5 µg/cm2 confirmed that there was no statistically significant difference in the 
4-MBC absorbance in the presence of skin. The t-test for the ratios 24:0 and 48:24 also 
revealed that time had no statistically significant influence on 4-MBC absorbance.  
 
10.4.1.4 Linearity and Range 
For the UV/VIS method two methanol solutions of 1.2 and 2.4 mg/mL 4-MBC were freshly 
prepared. Appropriate dilutions of these solutions gave concentrations of 0.024 mg/mL to   
4.7 mg/mL (0.024, 0.12, 0.24, 0.36, 0.48, 0.60, 1.20, 1.80, 2.40, 3.00, 3.60, 4.20 and        
4.68 mg/mL). Aliquots of 25 µL of these solutions were dosed onto tapes, yielding loading 
doses of 0.2, 1.0, 2.0, 3.0, 4.0, 5.0, 10.0, 15.0, 20.0, 25.0, 30.0, 35.0 and 39.0 µg/cm2. A 
template was stacked on every tape that was used to define spiking area (2.3 cm x 1.3 cm) 
(see section 10.4.1.2). Two calibration curves (curve 1 and curve 2) were established ranging 
from 24 to 600 µg/mL and 0.6 to 4.68 mg/mL corresponding to tape doses of 0.2-5.0 µg/cm2 
and 5.0–39.0 µg/cm2, respectively. Three replicates were performed at each concentration 
level and linearity was evaluated for each curve. Spectral analysis was carried out and 4-
MBC absorbance was calculated for each prepared tape (Equation 4) in order to assess the 
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linearity of the detector response in both concentration ranges.  
Linear relationship was obtained between the absorbance and the concentration of 4-MBC.  
Both calibration curves were tested for linearity by means of the Mandel fitting test. 
Therefore, unweighted and weighted (weighting factors 1/x and 1/x2) linear regression 
models were compared with the quadratic regression model. Mandel’s fitting test is 
commonly used to ascertain whether the chosen regression model adequately fits the data. 
The Mandel test value (Fcrit, 95%) follows F-distribution and the significance of the test values 
can be calculated. If the Test-value is higher than F (95%) the quadratic regression model will 
be more significant. 
The results in Table 12 show that the unweighted linear regression model can be accepted 
for calibration curve 1 at a 95% confidence level. For calibration curve 2, the linear and the 
linear 1/x weighted model must be rejected at the 95% confidence level. The best-fit equation 
for calibration curve 2 is the 1/x2 weighted linear regression. 
 
Table 12. Mandel’s fitting test for calibrations curves with the UV/VIS method  
 Calibration curve 1 Calibration curve 2 
 s2y  
a
 F (95%) Test value s2y F (95%) Test value 
Linear 4.963E-05 10.13 0.03 1.669E-03 6.61 8.59 
Linear weighted 1/x  1.290E-05  -2.21 1.912E-03  10.56 
Linear weighted 1/x2 1.375E-06  -2.92 1.392E-03  6.33 
Quadratic 6.543E-05   7.371E-04   
 
a
 Residual variance  
 
10.4.1.5 Agreement between nominal and measured 4-MBC concentrations 
To assure the quality of the 4-MBC detection in the tape by UV/VIS spectroscopy the 
agreement between the nominal 4-MBC concentrations on spiked tapes and the actually 
measured 4-MBC concentrations was determined applying the linear regression model (1/x2 
weighted). Deviation between nominal and measured 4-MBC concentration was calculated 
according to Equation 5. Results are presented in Table 13. 
 
Deviation from nominal conc. = (nominal conc.- determined conc.) x100 
      nominal conc. 
Equation 5. Calculation of deviation between nominal 4-MBC spiked on tapes and measured 4-MBC by UV/VIS 
spectroscopy.  
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Table 13.  Deviation (%) between nominal and measured 4-MBC concentration (n=3, nominal samples at each 
concentration). 
 Nominal conc. (µg/cm2) Deviation from nominal conc. (%) 
  
1/x2 weighted linear  
Calibration curve 1 0.2 -0.62 
 1.0 3.28 
 2.0 2.07 
 3.0 -0.30 
 4.0 -4.76 
 5.0 0.31 
 x  (%) 0.00 
 SD 2.77 
Calibration curve 2 5.0 4.04 
 10.0 -8.91 
 15.0 0.00 
 20.0 -1.57 
 25.0 -1.64 
 30.0 1.83 
 35.0 2.30 
 39.0 3.95 
 x  (%) 0.00 
 SD 4.23 
 
Based on theses results, the linear 1/x2 weighted regression model was used for interpolation 
of the absorbance data for all samples measured (calibration curve 1 and calibration curve 2) 
in these studies. 
 
10.4.1.6 Exclusion of Matrix Effects in the Low Concentration Range 
Theoretically, a calibration curve must pass through the origin (zero). In cases of matrix 
effects, a calibration curve may not pass through zero, indicating systematic errors in the 
methodology. To exclude a systematic error the confidence interval range of the y-intercept 
must include zero end the intercept should statistically not be distinguishable from zero at a 
defined level of confidence. This requirement is met at a 95% confidence interval ranging 
from -1.97E-03 to +1.27E-03 including zero (Table 14). It can therefore be assumed that 
there are no systematic errors at low 4-MBC concentration measurements.  
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Table 14 Regression parameters of calibration curve 1. 
Regression equationa rb SDc  Srd 
  Slope Intercept  
y=0.0796 x – 3.566E-4 1.000 1.232E-3 5.867E-4 1.173E-3 
 
a
 Peak area y vs appropriate concentration x in µg/cm2; six standards  
b
 Correlation coefficient 
c
 Standard deviation of slope and of intercept  
d
 Standard error of estimate 
 
10.4.1.7 Reference Calibration Curve 
In contrast to HPLC procedures where a need of establishing daily calibration curves exist 
UV/VIS spectroscopy is little susceptible to instrument based interferences. It is therefore 
feasible to establish a representative calibration curve for the instrument for determining      
4-MBC concentrations on the tape strips for the entire experimental period (6 weeks). 
Nonetheless, the "stability" of the determination of 4-MBC concentration was tested over a 4 
week period and average regression parameters were determined from five curves using the 
Method Validation in Analytics - MVA software (Novia, Frankfurt am Main, Germany) (Table 
15). 
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Table 15. Calibration equation for 4-MBC determination by UV/VIS spectroscopy. 
Sample (µg/cm2) Regression equationa rb SDc  Srd 
4-MBC   Slope Intercept  
0.2-5.0 (I) y=0.0796 x – 3.566E-4 1.000 1.232E-3 5.867E-4 1.173E-3 
0.2-5.0 (II) y=0.0790 x + 2.918E-4 0.999 1.291E-3 6.146E-4 1.229E-3 
0.2-5.0 (III) y=0.0808 x – 1.036E-4 0.999 1.930E-3 9.189E-4 1.837E-3 
0.2-5.0 (IV) y=0.0772 x + 2.226E-3 0.999 1.501E-3 7.149E-4 1.429E-3 
0.2-5.0 (V) y=0.0814 x + 1.545E-3 1.000 1.083E-3 5.159E-4 1.031E-3 
Reference 
calibration curve 1 
y=0.0796 x – 7.205E-4 0.999 7.561E-4 3.600E-4 1.609E-3 
      
5.0-39.0 (I) y=0.0714 x + 0.0562 0.998 1.836E-3 2.101E-2 3.731E-2 
5.0-39.0 (II) y=0.0728 x + 0.0515 0.999 1.394E-3 1.594E-2 2.832E-2 
5.0-39.0 (III) y=0.0740 x + 0.0450 0.998 1.997E-3 2.285E-2 4.059E-2 
5.0-39.0 (IV) y=0.0752 x + 0.0358 0.998 1.847E-3 2.113E-2 3.753E-2 
5.0-39.0 (V) y=0.0707 x + 0.0668 1.000 4.977E-4 5.693E-3 1.011E-2 
Reference 
calibration curve 2 
y=0.0728 x + 0.0510 0.998 7.010E-4 8.020E-2 3.185E-2 
 
a
 Peak area y vs appropriate concentration x in µg/cm2; six standards for calibration curve 1; eight standards for 
calibration curve 2 
b
 Correlation coefficient 
c
 Standard deviation of slope and of intercept 
d
 Standard error of estimate 
 
The reference calibration curve 1 and 2 were used for all further measurements.  
 
10.4.1.8 Lack-of-Fit Test 
The lack-of-fit test is designed to determine the adequacy of the regression model for the 
description of the data. Significant lack-of-fit shows that the specified model does not 
adequately fit the response. Analysis of variance (ANOVA) with lack-of-fit test for the overall 
analysis of calibration curves 1 and 2 are shown in Table 16 and Table 17. Since the p value 
in the ANOVA table corresponding to F test for significance of regression is 0.0000, a 
statistically significant relationship appears between absorbance and concentration of          
4-MBC. The p value for the lack-of-fit test is higher than 0.10. Therefore, the model appears 
to be adequate. 
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Table 16. ANOVA with lack-of-fit for overall analysis calibration curve 1. 
Source Sum of squares Df Mean squares F-ratio p value 
Model 0.3798 1 0.3798 21803.98 0.0000 
Residual  0.0015 88 0.0000   
Lack-of-fit -0.0053 4 -0.0013 -16.28 1.0000 
Pure error 0.0068 84 0.0001   
Total  0.3814 89    
 
Table 17. ANOVA with lack-of-fit for overall analysis calibration curve 2. 
Source Sum of squares Df Mean squares F-ratio p value 
Model 0.2510 1 0.2510 22996.72 0.0000 
Residual  0.0013 118 0.0000   
Lack-of-fit -0.3925 6 -0.0654 -18.61 1.0000 
Pure error 0.3938 112 0.0035   
Total  0.2523 119    
 
 
10.4.1.9 Detection Limit and Quantitation Limit 
According to the ICH recommendations several methods were used for determining detection 
limit (DL) and quantitation limit (QL). These included:  
1. calculation from noise (DL=3.3*xnoise, QL=10*xnoise) 
2. calculation from standard deviation of the blank (DL=3.3*SDblank/slope, 
QL=10*SDblank/slope) 
3. calculation from standard deviation of the y intercept (DL=3.3*SDintercept/slope, 
QL=10*SDintercept/slope) 
4. calculation from residual standard deviation of the calibration line (DL=3.3*sy/slope, 
QL=10*sy/slope) 
 
For determining the noise of the UV/VIS method blank tapes were spiked with methanol and 
the spectrum was recorded. The noise corresponds to the amplitude between the highest 
and the lowest signal. 
Using the blank procedure, the corresponding calculation value was multiplied by the factors 
3.3 and 10 for the DL and the QL, respectively. The calculations from the standard deviation 
of the blank, from the residual standard deviation and from the intercept were performed 
using the (1/x2) weighted linear regression parameters.  
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Results of the DL and QL of the UV/VIS method are summarized in Table 18. The DL and QL 
were quite different according to the respective calculation method. The DL and QL obtained 
from the calculation of the SD of the blank yielded the lowest values. The DL and QL for      
4-MBC determined showed the highest value when using the residual standard deviation 
calculation. However, in order to be as objective as possible the residual standard deviation 
method was chosen for calculation of DL and QL of 4-MBC, yielding for calibration curve 1 
values of 0.049 µg/cm2 and 0.147 µg/cm2 respectively. For calibration curve 2, QL was     
5.22 µg/cm2 using the residual standard deviation method. 
 
Table 18. Detection and quantitation limit of the UV/VIS method. 
 Calibration curve 1  Calibration curve 2 
Calculation method DL (µg/cm2) QL (µg/cm2)  QL (µg/cm2) 
1. Signal-to-noise 1.76E-03 5.33E-03  5.33E-03 
2. SD of the blank 1.73E-03 5.23E-03  5.23E-03 
3. SD of the intercept 0.024 0.074  2.94 
4. Residual SD 0.047 0.147  5.22 
 
Figure 22. Discrepancies based on different recommendations of the ICH Guidelines for calculation of detection 
limit and quantitation limit for the UV/VIS method. 
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10.4.1.10 Repeatability and intermediate precision 
For the estimation of the repeatability (intra-day variation) and intermediate precision (inter-
day variation) of the UV/VIS method, the standard solutions of both calibration curves were 
used. Three replicates were performed at each concentration level to ensure the 
repeatability. The entire procedure was repeated on five different days to determine 
intermediate precision. 
 
Both calibration curves 1 and 2 were studied separately to evaluate repeatability and 
intermediate precision of the UV/VIS method.  
The precision parameters were calculated using the ratio of absorbance to concentration. All 
parameters of calibration curve 1 are listed in Table 19. The various levels of precision were 
calculated by means of ANOVA where the overall variation is divided into the contributions of 
intra-serial and inter-serial variance. There was no significant difference between the means 
at the 95% confidence level. The repeatability and the intermediate precision were 4.3% and 
4.4% respectively. The coefficients of variation for the different series were lower or equal to 
6.21%. 
 
Table 19.  Repeatability and intermediate precision with UV/VIS method for curve 1. 
Series number a 1 2 3 4 5 
CV 2.90% 3.00% 4.28% 6.21% 4.18% 
x   7.92E-02 7.93E-02 8.07E-02 7.99E-02 8.32E-02 
Intra serial variance 1.19E-05     
Inter serial variance 8.13E-07     
Overall variance 1.27E-05     
Overall x   8.05E-02     
Repeatability 4.29%     
Intermediate precision  4.43%     
a
 for each series number, n=6 
 
The precision parameters of calibration curve 2 are listed in Table 20. The coefficients of 
variation for the different series were lower or equal to 5.9%. The repeatability and the 
intermediate precision were 5.3% and 5.3%, respectively. 
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Table 20. Repeatability and intermediate precision with UV/VIS method for curve 2. 
Seriesnumber a 1 2 3 4 5 
CV 5.93% 4.98% 5.47% 4.76% 5.32% 
x  7.53E-02 7.63E-02 7.70E-02 7.77E-02 7.53E-02 
Intra serial variance 1.63E-05     
Inter serial variance -9.21E-07     
Overall variance 1.64E-05     
Overall x   7.63E-02     
Repeatability 5.30%     
Intermediate precision  5.30%     
a
 for each series number, n=8 
 
Finally, Cochran’s C test was performed to compare variances over the entire concentration 
range of each calibration curve. Since the p values for both curves were higher than 0.05     
(p value curve 1 = 0.09, p value curve 2 = 1.0), there was no statistically significant difference 
for variances at the 95% confidence level.  
 
10.4.1.11 Accuracy by comparison 
As there was no extraction step accuracy can be obtained after precision, linearity and 
specificity have been established (ICH). Therefore, accuracy of the UV/VIS method was 
obtained by comparing the 4-MBC amounts measured directly on the tapes by UV/VIS 
spectroscopy with those measured by the HPLC method after extraction of 4-MBC from the 
tapes. The t-test allows the comparison of two analytical procedures (see section 10.5.5.1). 
 
10.4.2 HPLC Method 
10.4.2.1 Chromatographic conditions 
4-MBC concentrations were assayed by HPLC using a Waters Alliance HPLC System (2690 
Separations Module, 996 Photodiode Array Detector, Millenium32 software and a Symmetry 
Shield RP18 (2.1x 100 mm, 3.5 µm particle size) column (all Waters Corporation, Millford, 
Massachusetts). The mobile phase consisted of 75% (v/v) methanol and 25% (v/v) water 
adjusted to the pH 4.8 with glacial acetic acid (approximately 0.01% v/v); the flow rate was 
set at 0.4 mL/min. The analytical column temperature was set at 35°C. Sample aliquots of 
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10µL were injected into the chromatograph and the principal wavelength for detection was 
set at 305 nm.  
 
10.4.2.2 Specificity 
To determine HPLC specificity, the tapes prepared as described in section 10.4.2.1 were 
extracted for 16 hours with 2.0 mL methanol in a stoppered, 50 mL-volumetric flask. Then, a 
filtered aliquot of this extraction solution was injected onto the HPLC column without further 
dilution. The spectra obtained from these injections were compared to the MBC spectrum 
from injection of a standard solution.  
For the HPLC method, the retention time of 4-MBC was recorded at 4.33 ± 0.01 min. In the 
chromatograms of the tape extracts, skin components and tape material did not interfere with 
the peak of interest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. A Chromatogram; B Spectrum index plot and; C 3D plot. 
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10.4.2.3 Linearity and Range 
The linearity of the HPLC method was evaluated by injecting six standard solutions with 
concentrations ranging from 0.5 - 10.0 µg/mL. Therefore, a stock solution was prepared by 
dissolving 100 mg of 4-MBC in 100 mL methanol. Appropriate dilutions of the stock solution 
gave standard solutions with concentrations of 0.5, 1.0, 2.5, 5.0, 7.5 and 10.0 µg/mL. Linear 
relationship was obtained between the peak area and the concentration. 
 
 
Figure 24. Chromatogram standards. 
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Table 21. Peak Summary with Statistics. 
 
Sample Name Sample Type Name 
Retention 
Time (min) Area Concentration Units 
1 A 0.5 µg/mL Standard 4-MBC 4.347 19’971 0.5 µg/mL 
2 B 1.0 µg/mL Standard 4-MBC 4.344 41’382 1.0 µg/mL 
3 C 2.5 µg/mL Standard 4-MBC 4.326 97’109 2.5 µg/mL 
4 D 5.0 µg/mL Standard 4-MBC 4.310 195’937 5.0 µg/mL 
5 E 7.5 µg/mL Standard 4-MBC 4.307 298’211 7.5 µg/mL 
6 F 10.0 µg/mL Standard 4-MBC 4.312 406’998 10.0 µg/mL 
 
The Mandel fitting test tested the calibration curve for linearity. Therefore, the data was fitted 
to unweighted and weighted linear regression models with the weighting factors 1/x and 1/x2 
and compared to the quadratic regression model. 
With respect to the HPLC method, the results in Table 22 showed that the quadratic 
regression model can be rejected at the 95% confidence level, if a 1/x weighted linear 
regression model is used. 
 
Table 22. Mandel’s fitting test HPLC method. 
 s2y  
a
 F (95%) Test value 
Linear 1.039E+07 10.13 32.72 
Linear weighted 1/x  3.427E+06  8.80 
Linear weighted 1/x2 6.643E+05  -0.71 
Quadratic 1.162E+06   
 
a
 Residual variance    
 
The equation of the 1/x weighted linear regression, the correlation coefficient (r) and the 
standard error of the estimates (Sr) of the calibration line are given in Table 23, along with the 
standard deviations of the slope and the intercept.  
 
The y intercept of the calibration curve was statistically equal to zero since the p value was 
0.28. 
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Table 23.  Calibration equation for 4-MBC determination by HPLC. 
Sample (µg/mL) Regression equation a r b SD c  Sr d 
4-MBC   Slope Intercept  
0.5-10.0 y=3954 x + 549 1.000 358 940 1851 
 
a
 Peak area y vs appropriate concentration x in µg/mL; six standards 
b
 Correlation coefficient 
c
 Standard deviation of slope and of intercept 
d
 Standard error of estimates 
 
10.4.2.4 Detection Limit and Quantitation Limit 
The DL and QL were evaluated according to the different methods described in section 
10.4.1.9. 
The noise of the HPLC method was measured between the highest and the lowest signal of a 
blank (methanol) injection. 
 
Results of the DL and QL of the HPLC method are summarized in Table 24. The DL and QL 
were quite different according to the calculation method used. The DL and QL obtained from 
the calculation of the SD of the blank yielded the lowest values. The DL and QL for 4-MBC 
determined using the residual standard deviation calculation showed the highest values. 
Using the residual standard deviation method, DL and QL were calculated at a concentration 
of 0.164 and 0.498 µg/mL, respectively. 
 
Table 24.  Detection limit and quantitation limit of the HPLC method. 
Calculation method DL (µg/mL) QL (µg/mL) 
1. Signal-to-noise 1.32E-04 3.98E-04 
2. SD of the blank 8.13E-10 2.46E-09 
3. SD of the intercept 0.835 0.253 
4. Residual SD 0.164 0.498 
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Figure 25. Discrepancies based on different recommendations of the ICH Guidelines for calculation of detection 
limit and quantitation limit for the HPLC method.  
 
10.4.2.5 Repeatability and Intermediate Precision 
In order to evaluate the repeatability of the HPLC method, three replicates of each 
concentration level of the calibration curve were injected onto the HPLC system. The entire 
procedure was repeated on different days to test intermediate precision. 
 
The precision parameters were calculated based on the ratio of area and concentration. 
Precision parameters are listed in Table 25. The coefficients of variation for the different 
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series were found to be 4.79%, 2.40% and 2.15% respectively. There was no significant 
difference between the means at a 95% confidence level. The repeatability and the 
intermediate precision were both 3.35%. These results were acceptable for the quantification 
of 4-MBC by HPLC. 
 
Table 25. Repeatability and intermediate precision of the HPLC method. 
Series number a 1 2 3 
CV 4.79% 2.40% 2.15% 
x   4.02E+04 3.99E+04 3.94E+04 
Intra serial variance 1.78E+06    
Inter serial variance -1.53E+05    
Overall variance 1.78E+06   
Overall x   3.98E+04   
Repeatability 3.35%   
Intermediate precision  3.35%   
a
 for each series number, n=6 
 
Cochran’s C test was performed in order to compare variances over the entire concentration range. 
Since the p value was higher than 0.05 (p value = 0.12), there was no statistically significant 
difference among the variances at the 95% confidence level. 
 
10.4.2.6 Accuracy by recovery 
The accuracy of the HPLC method was calculated from the recovery yield between the value 
found with a calibration curve and the true value of 4-MBC spiked on a tape. The accuracy 
was determined by spiking skin-stripped tapes with known amounts of 4-MBC at 
concentrations of 1.17, 4.66 and 34.97 µg/cm2. 4-MBC was extracted for 16 hours with       
2.0 mL methanol in a stoppered, 50 mL-volumetric flask. After appropriate dilution, the 4-
MBC concentration in the extracts were assayed by the HPLC procedure described in section 
10.4.2.1. The accuracy was calculated from the recovery yield between the value found with 
a calibration curve and the true value spiked on the skin-stripped tape. 
 
Recoveries were determined at three concentration levels. The recovery for 4-MBC was 
91.9% at a concentration of 1.17µg/cm2. Recoveries were found to be 96.1% and 90.9%, for 
concentrations of 4.66 and 34.97 µg/cm2 respectively. The recovery data are summarized in 
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Table 26. The mean recovery ( x recovery) of 4-MBC from spiked tapes was 93% (95% 
confidence interval = 86.1% to 99.8%). From the recovery rates, it can be concluded that this 
extraction procedure provides a reliable quantitative determination of the UV filter in tape 
extracts. 
 
Table 26 Recoveries of 4-MBC on spiked tapes. 
Amount added 
(µg/cm2) 
Amount found (µg/cm2) 
x  ± SD (n = 6) 
Recovery (%) x recovery (%) CI a (95%) 
1.17  1.08 ± 0.01  91.9   
4.66  4.49 ± 0.07  96.1   
34.97  31.79 ± 0.65  90.9  
92.7 
 
86.1 - 99.8 
a
 CI = confidence interval 
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10.5 Experiment 1 
 
In Experiment 1, the penetration of 4-MBC from a 2% and 4% standard formulation was 
investigated by tape stripping. Preparation of the test area (volar aspect of the forearm), 
vehicle application and the tape stripping procedure as well as environmental conditions were 
standardized. The amount of 4-MBC and the thickness of SC in each single tape were 
simultaneously determined by the previously validated UV/VIS spectroscopic method. In 
addition, the amount of 4-MBC in each single tape was verified by the validated HPLC assay.  
 
 
Figure 26.  Scheme illustrating distribution of 4-MBC in SC obtained by a new, direct one-step spectroscopic 
method vs an established, multistep method.  
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10.5.1 4-MBC Sunscreen formulation 
The sunscreen used was a formulation based on the proposed Standard P3 formulation of 
the COLIPA Guidelines [101] for sun protection factor measurement. The sunscreen was an 
o/w emulsion. As 4-MBC solubility in water is low, the major part of the UV filter will be diluted 
in the oil phase.  
 
10.5.1.1 Ingredients 
Solubility of 4-MBC in Tegosoft TN was investigated prior to producing 4-MBC formulations. 
At room temperature and under constant stirring, 40% (w/w) 4-MBC could still be solved in 
Tegosoft TN. 50% (w/w) 4-MBC was no longer soluble in Tegosoft TN. 
 
The emulsion formulation used as the delivery vehicle for the sunscreen in these experiments 
was a modified P3 standard formulation from the COLIPA guidelines [101]. The ingredients of 
the emulsion are listed in Table 27. 
 
Table 27. Composition of 4-MBC sunscreen formulations tested. 
Component  Percent (%) 
4-MBC 2.00 or 4.00 
Tegosoft TN 15.00 
Emulgade F 3.15 
KOH (10% sol) 1.50 
Carbopol 934 0.30 
Ethanol absolutum 8.00 
Water 70.05 or 68.05 
  
Total  100.00 
 
The 4-MBC and potassium hydroxide were obtained from Merck KgaA, D-64271 Darmstadt, 
Germany; Tegosoft TN (C12-15 Alkyl benzoate) from Goldschmidt AG, D-45127 Essen, 
Germany; Emulgade F (Cetearyl alcohol & PEG-40 castor oil & sodium cetearyl sulfate) from 
Cognis Deutschland GmbH, D-40551, Düsseldorf, Germany; Carbopol 934 (Carbomer) from 
Noveon Inc., Cleveland-OH 44141, USA; Ethanol absolutum from Fluka, Buchs, Switzerland.  
All the components of the oil phase (4-MBC, Emulgade F and Tegosoft TN) were melted 
together at 90°C over a water bath. Carbopol was dispersed in water at 16’000 rpm during 
approximately 30 seconds with an Ultra Turrax agitator (IKA Ultra Turrax T25 Basic with IKA 
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Dispergierer S25N25F) and was also heated to 90°C using a water bath. The aqueous 
solution was then slowly added to the oil phase with continuous stirring (200 rpm) using a 
stirring motor (type IKA Eurostardigital / IKA RW 28 Basic). The ethanol was added when the 
emulsion had cooled to a temperature of 40°C. The emulsion was then homogenized with the 
Ultra Turrax (16 000 rpm) during one minute and finally stirred (50 rpm) during 30 minutes 
until room temperature was reached. The mass of the final formulation was checked and 
brought up to the final volume with water during the final stirring phases. The emulsion phase 
stability was checked by centrifuging (15 min at 5000rpm). In addition, the microscopic 
aspect and pH of the formulations were tested. The emulsions were homogeneous and 
stable after centrifuging. The microscopic examination confirmed a monodisperse 
appearance for both emulsion concentrations without the presence of any crystals. The pH 
was measured at 6.6 for the 4% 4-MBC formulation and 7.0 for the 2% 4-MBC formulation. 
 
 
 
  
10.5.1.2 Stability testing  
Table 28. Stability tests of 2% and 4% 4-MBC formulations. 
19.4.2001 Start 2 Weeks 6 Weeks 3 Months 6 Months 
 
 5°C RT 43°C 5°C RT 43°C 5°C RT 43°C RT 
2% 4-MBC            
Phase stability 
 1  1 1  1 1  1  
Color 
 white *  white * white *  white * white *  white *  
Microscopy 
 1a  1a 1a  1a 1a  1a  
Skin feel / Stickiness 
 1a  1a 1a  1a 1a  1a  
Odor 
 1  1 1  1 1  1  
pH value 25°C 0.00 6.61  6.53 6.54  6.533 6.59  6.59  
Viscosity (Brookfield RVT) 
Value at 25°C in Cps, after 30s            
 
           
19.4.2001 Start 2 Weeks 6 Weeks 3 Months 6 Months 
 
 5°C RT 43°C 5°C RT 43°C 5°C RT 43°C RT 
4% 4-MBC            
Phase stability 
 1  1 1  1 1  1  
Color 
 white *  white * white *  white * white *  white *  
Microscopy 
 1a  1a 1a  1a 1a  1a  
Skin feel / Stickiness 
 1a  1a 1a  1a 1a  1a  
Odor 
 1  1 1  1 1  1  
pH value 25°C 0.00 6.6  6.56 657  6.6 6.41  6.57  
Viscosity (Brookfield RVT) 
value at 25°C in Cps, after 30s            
 
           
Phase Stability    Microscopy    Odor  Skin Feel and Stickiness 
1: Stable 4: clearly separating  1: monodisperse a) No Crystals 1:good  1:not oily a: non sticky 
2: slightly inhomogenous 5: separated  2: polydisperse b) Crystals  2: acceptable  2:slightly oily b: slightly sticky 
3:begins to separate        3: bad  3:oily c: sticky 
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10.5.2 Determination of 4-MBC concentration in formulation 
10.5.2.1 Material  
 
Chromatograph Waters Alliance HPLC System (2690 Separations Module, 996 
Photodiode Array Detector, Millenium32 Software (all Waters 
Corporation, Millford, Massachusetts) 
Column  Symmetry Shield RP18 (2.1x 100 mm, 3.5 µm particle size) 
Mobile phase 75% (v/v) methanol, 25% (v/v) water and glacial acetic acid 
(approximately 0.01% v/v) at 0.4 mL/min 
Volume of injection 10 µL 
Detection 
wavelength 
Absorbance at 305 nm  
 
10.5.2.2 Method  
4-MBC was extracted from the formulation with methanol. This included the weighing of an 
appropriate amount (1 g) of formulation in a 100 mL volumetric flask and adding methanol 
(ca. 90 mL). The volumetric flask was then placed in an ultrasonic bath during 5 minutes. As 
soon as the solution had cooled down to room temperature (24°C) methanol was added to 
the mark. The solution was filtered through a 0.45 µm membrane (Nylon GyroDisc, Orange 
Scientific, Braine l’ Alleud, Belgium). Then, 0.5 mL of the filtered solution was diluted to 50 
mL (volumetric flask) with methanol. 4-MBC concentrations were assayed by HPLC. 
The extraction procedure was performed in a triplicate with both formulations (4% and 2%   
4-MBC). 
 
10.5.2.3 Results 
The concentrations were determined with the validated HPLC method. The 4-MBC 
concentration in the 4% and 2% formulation was 3.89% and 1.97% respectively.  
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10.5.3 Study Design for Experiment 1 
Five human volunteers, three males and two females aged 24-29 participated in the study. 
The volunteers were all naive to topical drug therapy.  
 
The compounded emulsions containing 4-MBC were randomly applied to the volar surfaces 
of the forearms. One arm of each subject was treated with a 2% formulation (F1) and the 
other arm with a 4% formulation (F2). In each case, 90 mg of the product was applied to the 
skin with a 1 mL syringe and spread over an area of 45 cm2 with a gloved finger, to give a 
topical application dose of 2 mg/cm2. One hour after formulation application, an area of    
4.03 cm2 of the dosed skin sites were stripped. 
 
Figure 27. Treatment scheme for test person for Experiment 1. 
Legend. F1=2% 4-MBC formulation; 
 F2=4% 4-MBC formulation. 
 
10.5.4 Tape stripping procedure 
The formulation application area on each arm was delineated by taping a flexible template on 
the skin. The template had a rectangular aperture of 1.3 cm x 3.1 cm, thereby exposing a 
constant skin area for each sequential tape stripping and ensuring consistent removal of 
stratum corneum from exactly the same formulation application site. The long axis of the 
F1 
F2 
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template was fixed along the midline of the forearm to ensure intimate contact with the skin 
and to simplify the subsequent stripping procedure. Tape stripping was carried out with Tesa 
tape (Multi-Film Kristall-Klar 57315 tape, Tesa, Beiersdorf, Hamburg, Germany) of 1.5 cm 
width. A strip of adhesive tape (larger than the aperture of the template) was placed on the 
skin area exposed through the template aperture. Pressure was then applied perpendicularly 
to the adhering tape in a uniform manner using a hand roller that supplied a gravitational 
weight of 140 g/cm2 to the skin. The roller was uniformly passed over the tape 10 times at 
each stripping, thus compensating for any inconsistency issues of pressure application as 
described in previous papers [247, 248]. The tape (with adhering corneocytes) was then 
manually removed from the skin by pulling, using firm, rapid and uniform tension. The 
direction of tape removal (elbow-to-wrist or wrist-to-elbow) was alternated with each tape in 
order to strip the stratum corneum in a consistent manner (Figure 28). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Demonstration of tape stripping.  
Legend. Tapes are pressed by a roll (A) on the skin defined by a template with a pressure of 140 g/cm2 (B); they are 
then stripped (C) to be finally fixed onto a photographic slide frame (D). 
 
Once removed from the skin, each tape was fixed across a photographic slide frame, 
exposing the tape and adhering corneocytes through the aperture. This frame size could 
easily be accommodated in the solid-sample holder of the spectrophotometer (Lambda 35 
A 
C D 
B 
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with custom modification to monitor an incident light path area of 1 cm2, Perkin Elmer 
Instruments, Überlingen, Germany). 
Stripping with sequential tapes was carried out in this manner at each skin test site to remove 
the entire stratum corneum layer. The absorbance of every tenth tape/corneocyte sample 
was measured at 430 nm to determine the transmission through the specimen in relation to 
blank tape. Stripping of the skin stopped when transmission at 430 nm approached 97% 
(representing almost complete removal of the stratum corneum). 
Once all the tape strips had been collected from each test site, samples were allowed to 
equilibrate for 24 hours before being scanned for absorbance potential between 220 and 500 
nm and were then extracted for HPLC analysis as described above. 
 
10.5.5 Results 
10.5.5.1 Correlation of UV/VIS spectroscopy with HPLC (Accuracy by comparison) 
All 4-MBC concentrations measured directly on the tapes by the UV/VIS method were 
compared to results obtained from HPLC. As the first tape strip always contains the largest  
4-MBC quantity, which is much higher than in the following tape strips, its influence on the 
regression curve is too large. Therefore, the first tape was not used for calculating the 
regression equation. Table 29 lists the number of tape strips used for the correlation of the   
4-MBC concentrations which were measured by the UV/VIS method and the one found by 
the HPLC method.  
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Table 29.  Correlation of the 4-MBC concentration found by UV/VIS spectroscopy and HPLC without including 
the first tape. 
Volunteer Age (Sexa) Formulationb Number of tapes 
for correlation 
Regression equationc r2 d 
F1 12 y = 1.0068x + 0.0573 0.976 1 24 (f) 
F2 23 y = 1.0493x + 0.0620 0.976 
F1 10 y = 0.9654x + 0.0055 0.997 2 26 (m) 
F2 12 y = 1.0866x + 0.0418 0.997 
F1 16 y = 0.9001x + 0.0673 0.995 3 29 (m) 
F2 13 y = 1.6846x + 0.5995 0.910 
F1 13 y = 0.8207x + 0.1327 0.999 4 25 (f) 
F2 24 y = 1.0282x + 0.0239 0.994 
F1 10 y = 0.8768x + 0.1005 0.982 5 25 (m) 
F2 19 y = 1.1583x + 0.0143 0.974 
 
a
 (f) female, (m) male 
b
 F1   2% 4-MBC formulation, F2    4% 4-MBC formulation  
c
 4-MBC concentration measured by UV/VIS spectroscopy vs concentration measured after 4-MBC extraction by 
HPLC  
d
 correlation coefficient 
 
In order to determine if there was no difference between the two analytical methods, the data 
were subjected to null hypothesis using the paired sample t-test. However, this hypothesis 
gave a p value > 0.05 (p value 0.167), proving that there was no significant difference 
between the UV/VIS and the HPLC method.  
 
Statistical data analysis of the correlation was performed by using a paired-sample t-test 
where data collected in pairs is compared. In the paired-sample t-test the data was analyzed 
by calculating the difference between each value in each pair of observations. The null 
hypothesis is rejected if the mean for the paired differences is not equal to 0 for a given 
alpha. Since the p value was higher than 0.05 (p value 0.167) the null hypothesis cannot be 
rejected at the 95% confidence level.  
 
Table 30 shows a frequency tabulation dividing the range of the paired differences into equal 
width intervals. The number of data values were counted in each interval. The frequencies 
show the number of data values in each interval while the relative frequencies show the 
proportions in each interval. Both Table 30 and the histogram in Figure 29 showed that 
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97.55% of the data fell within one interval, again indicating that there were no significant 
differences between the two analytical methods.  
 
Table 30. Frequency tabulation. 
Class Lower 
Limit 
Upper 
Limit 
Midpoint Frequency Relative 
Frequency 
Cumulative 
Frequency 
Cum. Rel. 
Frequency 
At   or   below -9.0  0 0.0000 0 0.0000 
1 -9.0 -7.3 -8.2 1 0.0061 1 0.0061 
2 -7.3 -5.7 -6.5 0 0.0000 1 0.0061 
3 -5.7 -4.0 -4.8 0 0.0000 1 0.0061 
4 -4.0 -2.3 -3.2 0 0.0000 1 0.0061 
5 -2.3 -0.7 -1.5 2 0.0123 3 0.0184 
6 -0.7 1.0 0.2 159 0.9755 162 0.9939 
7 1.0 2.7 1.8 0 0.0000 162 0.9939 
8 2.7 4.3 3.5 1 0.0061 163 1.0000 
9 4.3 6.0 5.2 0 0.0000 163 1.0000 
Above                  6.0   0 0.0000 163 1.0000 
 
x  = -0.079 , SD = 0.723 
 
 
Figure 29. Histogram showing distribution of paired differences for data from UV/VIS vs HPLC. 
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10.5.5.2 Stratum Corneum Profiles  
 
Volunteer 1 
2% 4-MBC formulation, AUCconc-sc = 33.21 (without first tape) 
 
4% 4-MBC formulation, AUCconc-sc = 76.32 (without first tape) 
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Volunteer 2 
2% 4-MBC formulation, AUCconc-sc = 63.61 (without first tape) 
 
4% 4-MBC formulation, AUCconc-sc = 101.95 (without first tape) 
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Volunteer 3 
2% 4-MBC formulation, AUCconc-sc = 62.54 (without first tape) 
 
4% 4-MBC formulation, AUCconc-sc = 104.46 (without first tape) 
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Volunteer 4 
2% 4-MBC formulation, AUCconc-sc = 43.97 (without first tape) 
 
4% 4-MBC formulation, AUCconc-sc = 56.41 (without first tape) 
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Volunteer 5 
2% 4-MBC formulation,  AUCconc-sc = 55.02 (without first tape) 
 
4% 4-MBC formulation, AUCconc-sc = 74.15 (without first tape) 
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10.5.5.3 Amount of 4-MBC penetrating the SC (results calculated by the UV/VIS 
method) 
The amount of 4-MBC amount penetrating into the SC was calculated as area under the 
curve of the concentration in the SC (AUCconc-sc). The 4-MBC concentration (µg/cm2) found in 
one tape was multiplied by the stripped skin area (cm2) to obtain the total mass (µg) of 
compound in one tape. Adding up the total mass of 4-MBC of each tape strip gave the 
AUCconc-sc corresponding to total compound delivered to the skin. 
 
In Figure 30 - Figure 32 the volunteers’ AUCconc-sc are presented calculated with all the tapes, 
discarding the first tape and discarding tape 1-4.  
Statistical analysis of the data were performed with StatgraphicsPLUS 5 software 
(Manugistic, Inc., Rockville, Maryland, USA). Differences in the AUCconc-sc between the two 
formulations were statistically analyzed at 95% confidence with multifactor ANOVA. 
 
 
Figure 30. AUCconc-sc for tape strips from individual (A) and from all volunteers (B). 
Legend.  B  x  ± SD (n=5) expressed as AUCconc-sc in µg/tape; * p < 0.05. A significant difference in the AUCconc-sc 
between the 2% and 4% formulations were found. 
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Figure 31. AUCconc-sc without including the first tape strip from individual (A) and from all volunteers (B). 
Legend.  B  x  ± SD (n=5) expressed as AUCconc-sc in µg/tape; * p < 0.05. A significant difference in the AUCconc-sc 
between the 2% and 4% formulations were found. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. AUCconc-sc without including tape strips 1-4 from individual (A) and from all volunteers (B). 
Legend.  B  x  ± SD (n=5) expressed as AUCconc-sc in µg/tape, p > 0.05. If tapes 1-4 were discarded, no statistically 
significant difference in the AUCconc-sc between the 2% and 4% formulations were found. 
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10.6 Experiment 2 
 
The purpose of Experiment 2 was to determine how the penetration of 4-MBC into SC was 
affected by the vehicle and duration of application. Therefore, saturated solutions 
(thermodynamic activity = 1) of 4-MBC in different vehicles (mineral oil and propylene glycol) 
were applied on the volar forearm of 5 volunteers for a time period of 1, 3 and 6 hours. SC 
samples were collected by standardized tape stripping. Absorption of 4-MBC and 
corneocytes on the tapes were determined simultaneously using two different wavelength 
(297 nm and 430 nm respectively) by the validated UV/VIS spectroscopic method. 
Distribution profiles of 4-MBC in SC were then assessed and an ANOVA was conducted with 
the logarithmic AUCconc-sc.  
 
10.6.1 Vehicles 
10.6.1.1 Propylene glycol 
 
IUPAC Name 1,2-Propanediol  
Molecular weight 74.13 
 
Chemical structure  C3H8O2 
 
Properties 
Propylene glycol (PG) belongs to the class of dialcohols some of which are widely used in 
cosmetics and in dermatological formulations. Of the two PGs, 1,2-propanediol is used far 
more often than 1,3-propanediol. PG and 1,2-propanediol are synonyms. PG is characterized 
as an odorless, viscous liquid; it is readily miscible with water, acetone, chloroform and 
essential oils; in addition, it is soluble in ether. The isotonic concentration is 2% in water. It is 
very hygroscopic in higher concentrations.  
 
PG is an important part of the vehicle for most transdermal formulations. In fact, the 
penetration of corticosteroids is often greatly enhanced by PG. PG also potentiates the 
penetration of other drugs e.g. minoxidil, methotrexate, diclofenac, norfloxacin etc. In 
cosmetic vehicles, PG has been shown to increase the penetration of allantoin [249]. 
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PG is believed to act by increasing drug solubility in the skin.  
 
PG’s importance as a cosolvent for lipophilic drugs and potential enhancers such as Azone 
and fatty acids has been acknowledged but the literature provides conflicting results as to 
whether this molecule is able to increase skin permeability.  
The alteration of the barrier function includes affecting the bilayer structure of the intercellular 
lipids and/or the keratinocytes, especially a-keratin structure. It is questionable whether the 
increased drug uptake, based on higher partitioning into the SC as a consequence of solvent 
penetration, could be considered to be an enhancing action since the intact skin structure is 
not changed. This effect, directed at the increase of the solution capacity within the SC, is 
supposed to be the main effect of PG.  
Based on numerous experiments, the action of solvents such as PG was attributed to a pure 
cosolvent effect. Maximizing the thermodynamic activity of a drug on the vehicle PG 
contributes to increased drug uptake in the skin. The permeation of many drugs, especially of 
very lipophilic molecules, was shown to be unaffected when they were applied in PG as 
compared to a standard vehicle. Therefore, the effects of PG were explained by differences 
in drug solubility on the donor site etc. [250]. 
 
10.6.1.2 Mineral oil 
 
IUPAC name Hydrocarbon oils 
Formula Unspecified 
Molecular weight - 
 
Properties 
Following application of mineral oil (MO) to the skin, the intercellular space is relatively 
uniformly filled with a smooth-appearing amorphous material, presumably the MO. 
Intercellular spaces were occasionally focally dilated. The MO appeared to have little effect 
other than a “spacer” separating corneocytes [251]. 
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10.6.2 Determination of solubility of 4-MBC in vehicles 
The formulations were prepared freshly for every volunteer. 
10.6.2.1 Material  
• UV/VIS-spectrophotometer, Lambda Bio 20, Perkin Elmer, Norwalk, CT, 06859 USA, 
serial # 101N7062724; UVWinLab Software V2.85. 04 
• Magnetic stirrer, N.ZIVY & CIE SA, 4104 Oberwil, Switzerland 
• Pharmacopoeial thermometer (from -2 to +50°C), Ph. Helv., 1994, SCS3120.  
• Water-bath WTE var 3185 
• Labofuge I, Haereus Christ, Laborgeräte AG, Zürich, Switzerland, serial # 00100581. 
 
10.6.2.2 Method 
The saturation solubility of 4-MBC in MO and PG was determined at 33°C i.e. skin 
temperature. An excess amount of 4-MBC was added to each vehicle. The suspensions were 
kept in sealed glass flasks, stirred magnetically and allowed to equilibrate in a thermostat 
water bath maintaining the sample temperature at 33 ± 1°C for 24h. The saturated solutions 
were centrifuged at 4000rpm for 10 min. The supernatant solution was diluted with methanol 
and analyzed by UV spectroscopy at 299 nm. 
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10.6.2.3 Results 
The solubility of 4-MBC in MO and PG is presented in Figure 33. The small standard 
deviations ensure the reproducibility of the preparation of the formulation. 
Figure 33. Saturation solubility of 4-MBC in mineral oil and in propylene glycol. 
Legend.  Saturation solubility was measured at 33°C; n=5 for both solvents. 
Mineral oil: x = 8.7; SD = ± 0.7. 
Propylene glycol: x = 2.6; SD = ± 0.1. 
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10.6.3 Study Design for Experiment 2 
All suitable test persons for this series of studies were selected according to inclusive and 
exclusive criteria (see section 10.6.4). 
Due to their liquid form, the formulations were applied to the skin of the test persons’ 
forearms by means of an application chamber (Figure 34). Each test person was treated with 
both formulations. 
 
Figure 34. Application chamber. 
 
The penetration of 4-MBC was measured for each formulation on three different patches of 
application at three different times (Figure 36, Table 31). At t =1, 3 and 6 h the application 
chambres were removed. The extra amount of formulation was removed with a dry cotton 
swab and the penetration of 4-MBC was measured by means of the tape stripping method. 
Based on the data thus gained, the AUCconc-sc of 4-MBC was calculated. 
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F1, 3h 
F1, 6h 
F1, 1h 
F2, 3h 
F2, 1h 
F2, 6h 
 
Figure 35. Treatment scheme for test person with different formulations (F) for Experiment 2.  
Legend. F1, 1h = mineral oil saturated with 4-MBC applied to skin for 1 hour. 
F1, 3h = mineral oil saturated with 4-MBC applied to skin for 3 hours. 
F1, 6h = mineral oil saturated with 4-MBC applied to skin for 6 hours. 
F2, 1h = propylene glycol saturated with 4-MBC applied to skin for 1 hour. 
F2, 3h = propylene glycol saturated with 4-MBC applied to skin for 3 hours. 
F2, 6h = propylene glycol saturated with 4-MBC applied to skin for 6 hours. 
 
Table 31. Scheme for a test person for Experiment 2. 
 F 1 F 2 
t = 1 h F1, 1h F2, 1h 
t = 3 h F1, 3h  F2, 3h  
t = 6 h F1, 6h F2, 6h 
 
F= formulation 
t= duration of application of formulation 
 
In summary, each test person undergoes 6 measurements, the two formulations at three 
different application durations each. The application duration of the treatment varies with 
regard to the three patches on each arm (arm A: t = 1, 3 and 6 h, arm B: t = 1, 3 and 6 h), 
where the duration on the arm was chosen at random. One duration of application per 
person was tested simultaneously with respect to both formulations. 
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10.6.4 Inclusion Exclusion Criteria 
Before entering the study, the skin of the volunteer had to first be examined by a 
Dermatologist who then had to confirm the eligibility of the volunteer for entrance into the 
study providing the Inclusion and Exclusion Criteria below were met.  
 
10.6.4.1 Inclusion Criteria 
Volunteers who 
⋅ are between 18 and 35 years old 
⋅ have Caucasian skin type 
⋅ are willing to participate into the study. 
 
10.6.4.2 Exclusion Criteria 
Volunteers who  
⋅ do not want to participate or who are unable to understand and/or sign the consent 
form 
⋅ have acute inflammations of the skin 
⋅ have other diseases or allergies 
⋅ are pregnant or lactating 
⋅ have limited abilities to register and/or judge their circumstances 
⋅ are participating in other ongoing studies 
⋅ have a positive HIV-Test. 
 
  
10.6.5 Results 
10.6.5.1 Stratum Corneum Profiles 
Volunteer 1 
Mineral oil 1h, AUCconc-sc = 41.12 Mineral oil 3h, AUCconc-sc = 43.67 Mineral oil 6h, AUCconc-sc = 180.75 
   
Propylene glycol 1h, AUCconc-sc = 75.48 Propylene glycol 3h, AUCconc-sc = 45.39 Propylene glycol 6h, AUCconc-sc = 85.58 
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Volunteer 2 
Mineral oil 1h, AUCconc-sc = 36.41 Mineral oil 3h, AUCconc-sc = 27.79 Mineral oil 6h, AUCconc-sc = 36.32 
   
Propylene glycol 1h, AUCconc-sc = 22.04 Propylene glycol 3h, AUCconc-sc = 47.21 Propylene glycol 6h, AUCconc-sc = 57.45 
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Volunteer 3 
Mineral oil 1h, AUCconc-sc = 17.12 Mineral oil 3h, AUCconc-sc = 41.62 Mineral oil 6h, AUCconc-sc = 34.36 
   
Propylene glycol 1h, AUCconc-sc = 36.65 Propylene glycol 3h, AUCconc-sc = 68.09 Propylene glycol 6h, AUCconc-sc = 97.93 
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Volunteer 4 
Mineral oil 1h, AUCconc-sc = 25.12 Mineral oil 3h, AUCconc-sc = 18.84 Mineral oil 6h, AUCconc-sc = 26.50 
   
Propylene glycol 1h, AUCconc-sc = 20.89 Propylene glycol 3h, AUCconc-sc = 35.57 Propylene glycol 6h, AUCconc-sc = 86.16 
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Volunteer 5  
Mineral oil 1h, AUCconc-sc = 61.11 Mineral oil 3h, AUCconc-sc = 50.98 Mineral oil 6h, AUCconc-sc = 26.59 
   
Propylene glycol 1h, AUCconc-sc = 42.91 Propylene glycol 3h, AUCconc-sc = 30.24 Propylene glycol 6h, AUCconc-sc = 43.17 
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10.6.5.2 Results for Experiment 2: AUCconc-sc 
For the calculation of the AUCconc-sc, the first tape collected was discarded due to potential 
drug remaining on the skin surface. 
 
Table 32. AUCconc-sc-values for Experiment 2. 
Volunteer Mineral oil (F1) Propylene glycol (F2) 
No. Age (Sexa) 1h 3h 6h 1h 3h 6h 
1 26 (m) 41.12 43.67 180.75 75.48 45.39 85.58 
2 22 (m) 36.41 27.79 36.32 22.04 47.21 57.45 
3 30 (f) 17.12 41.62 34.36 36.65 68.09 97.93 
4 25 (f) 25.12 18.84 26.50 20.89 35.57 86.16 
5 27 (f) 61.11 50.98 26.59 42.91 30.24 43.17 
x   36.17 36.58 60.90 39.59 45.30 74.06 
SD 16.82 12.99 67.14 22.17 14.53 22.80 
       
a
 (f) female, (m) male 
 
 
10.6.5.3 Statistical analysis of results for Experiment 2 
An ANOVA was conducted with the results of both experiments, based on the main factors of 
formulation, time and volunteer. In addition, the analysis included the impact of interaction, 
consisting of formulation x time, formulation x volunteer and time x volunteer.  
The variance analysis presumes an equal distribution on the different factor levels. In 
general, the relative standard deviation tends to be more independent (variance coefficients) 
from the factor levels than the absolute standard deviations with regard to concentration 
measurement. In this case, the equality of the absolute dispersion can be calculated when 
taking the logarithm of the data. This transformation was applied to these data. 
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Table 33. Logarithmic AUCconc-sc values for Experiment 2. 
Volunteer Mineral oil (F1) Propylene glycol (F2) 
No. 1h 3h 6h 1h 3h 6h 
1 1.61 1.64 2.26 1.88 1.66 1.93 
2 1.56 1.44 1.56 1.34 1.67 1.76 
3 1.23 1.62 1.54 1.56 1.83 1.99 
4 1.40 1.28 1.42 1.32 1.55 1.94 
5 1.79 1.71 1.42 1.63 1.48 1.64 
 
The variance analysis excluded the extreme value (volunteer 1, F1, 6h). 
The factor formulation showed a significant impact (p<0.05) on the amount of 4-MBC which 
penetrated the stratum corneum. The factors of time and volunteer as well as interaction 
showed no significant impact. 
This experiment leads to the conclusion that more 4-MBC penetrated the skin from PG than 
from MO. 
 
Table 34. ANOVA for 4-MBC amount in SC from F1 and F2 in Experiment 2 – Type III Sum of Squares. 
Source Sum of Squares Df Mean square F-ratio p value 
main effects 
A: formulation 
B: time 
C: volunteer 
 
0.1821 
0.0780 
0.1298 
 
1 
2 
4 
 
0.1821 
0.0390 
0.0324 
 
11.25 
2.41 
2.00 
 
0.0122 
0.1598 
0.1983 
interactions 
AB 
AC 
BC 
 
0.1295 
0.1416 
0.2665 
 
2 
4 
8 
 
0.0647 
0.0354 
0.0333 
 
4.00 
2.19 
2.06 
 
0.0694 
0.1724 
0.1786 
residual  0.1133 7 0.0162   
total 1.1358 28    
All F-ratios are based on the residual mean square error 
 
10.6.5.4 Number of tapes stripped 
The number of tape strips used to remove the stratum corneum was compared for MO and 
PG. A paired sample t-test was used to compare the mean (n=5) total number of tapes 
stripped for every site of application. There is a statistically significant (p=0.05) difference 
between MO and PG vehicles required for complete SC removal at every duration of 
application. More tapes (67 tapes (mean value over all durations of application)) were 
necessary to strip the whole stratum corneum of test sites that had previously been treated 
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with MO. Skin that had been treated with PG was completely stripped using fewer tapes (45 
tapes (mean value over all experiments)) (Figure 36). 
 
 
Figure 36. Number of tapes removed from skin treated with mineral oil (F1) and propylene glycol (F2) after 
different durations of application. 
Legend.  n=5 (volunteers) for both formulations. 
 F1, 1h: x = 70; SD = ± 7. 
 F1, 3h: x = 62; SD = ± 10. 
F1, 6h: x = 68; SD = ± 13. 
F2, 1h: x = 45; SD = ± 10. 
F2, 3h: x = 44; SD = ± 7. 
F2, 6h: x = 47; SD = ± 6. 
F1 ,1h F1, 3h  F1, 6h F2, 1h F2, 3h F2, 6h 
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CH2 CH2 OHOH
n
10.7 Experiment 3 
 
The effect of the penetration enhancer Transcutol®CG on the substantitvity of 4-MBC in the 
SC was investigated on the volar forearm of 10 volunteers. After one hour of skin contact with 
saturated 4-MBC (thermodynamic activity = 1) in Polyethylene glycol 400 containing 0%, 10% 
and 50% Transcutol®CG, tape stripping immediately and after 6 hours. SC samples were 
collected by standardized tape stripping. Absorption of 4-MBC and corneocytes on the tapes 
was determined simultaneously at 297 nm and 430 nm, respectively, by the validated UV/VIS 
spectroscopic method. Distribution profiles of 4-MBC in SC were assessed and an ANOVA 
was conducted with the logarithmic AUCconc-sc.  
 
10.7.1 Vehicles 
10.7.1.1 Polyethylene glycol 400 
IUPAC name  Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-. 
Molecular weight 380-420 
 
Chemical structure (C2H4O)n H2O 
 
Properties 
Polyethylene glycol (PEG) polymers are available in a variety of molecular weights. These 
materials are water-soluble and neither hydrolyze nor support mold growth. Thus, PEGs are 
ideal bases for washable ointments and can be formulated to provide either soft or hard 
consistencies. PEGs dissolve in water to form clear solutions. They are also soluble in 
organic solvents such as mineral oil and produce formulations that are more substantive to 
the skin [252]. 
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CH2
CH2
O
OCH2
CH2HO CH3
CH2
10.7.1.2 TranscutolCG 
IUPAC name Diethylene glycol monoethyl ether 
Molecular weight 134.2 
 
 
 
Chemical structure C6H14O3 
 
Properties 
Transcutol®CG is a hygroscopic liquid that is freely miscible with both polar and non-polar 
solvents. Transcutol®CG has been recognized as a potential transdermal permeation 
enhancer due to its non-toxicity, biocompatibility with skin and excellent solubilizing 
properties. However, Transcutol®CG has also been reported to increase the skin 
accumulation of topically applied compounds without a concomitant increase in transdermal 
permeation [185]. 
 
Transcutol®CG enhances penetration of several compounds prostaglandins , morphine base, 
and oestradiol [187]. It has been suggested that Transcutol®CG may enhance drug flux 
across SC by diffusing into it and altering its solubility parameters. Diffusion cell data show 
that Transcutol®CG can increase drug flux without an apparent change in lag time. This 
implies that Transcutol®CG acts by altering the solubility of a permeant in the skin [187]. This 
mechanism was demonstrated for the model compound, cyanophenol. 
 
Transcutol®CG is a vehicle used as a solvent/cosolvent in cosmetic and topical preparations 
and has been shown to form cutaneous depots in the skin with corticosteroids [186] and 
griseofulvin [188, 190].  
 
10.7.2 Determination of 4-MBC solubility 
10.7.2.1 Method 
The saturation solubility of 4-MBC in PEG 400 (F1), PEG 400 with 10% Transcutol®CG (F2) 
and PEG 400 with 50% Transcutol®CG (F3) was determined as described in section 
10.6.2.2. 
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10.7.2.2 Material  
• UV/VIS-spectrophotometer, Perkin Elmer, Lambda Bio 20 serial # 101N7062724; 
UVWinLab Software V2.85. 04 
• Magnetic stirrer, N.ZIVY & CIE SA, 4104 Oberwil, Switzerland 
• Pharmacopoeial thermometer (from -2 to +50°C), Ph. Helv., 1994, SCS3120.  
• Water-bath WTE var 3185 
• Labofuge I, Haereus Christ, Laborgeräte AG, Zürich, Switzerland, serial # 00100581. 
 
10.7.2.3 Results 
The influence of Transcutol®CG as a cosolvent is clearly visible in Figure 37. Adding 50% 
Transcutol®CG to PEG 400 augments the 4-MBC solubility greatly.  
 
Figure 37. Effect of Transcutol®CG concentration on the saturation solubility of 4-MBC. 
Legend.  The saturation solubility of 4-MBC was measured at 33°C; n=10 for 0%, n=5 for 10% and; n= 5 for 50% 
Transcutol®CG in polyethylene glycol 400. 
 0% Transcutol®CG : x = 7.7; SD = ± 0.4. 
 10% Transcutol®CG: x = 9.4; SD = ± 0.4. 
 50% Transcutol®CG: x = 19.6; SD = ± 0.6. 
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10.7.3 Study Design for Experiment 3 
All suitable test persons for this series of studies were selected according to inclusive and 
exclusive criteria (see section 10.6.4). 
Three formulations (F1, F2 and F3) were tested. Each of the three formulations contained    
4-MBC in a saturated concentration. Each test person was treated with two formulations (F1 
and F2 or F3) and each candidate received F1 application. Twice within one hour each 
formulation was applied to the skin of the forearm by means of an application chamber. Both 
application chambers were removed from both arms after one hour. The extra amount of 
formulation was removed with a dry cotton swab. The penetration of 4-MBC was measured 
on one arm immediately after application chamber removal (TI = 0 h) and on the other arm 
six hours later (TI = 6 h) (Table 35, Figure 38). 
 
 Table 35. Scheme for two test persons for Experiment 3. 
  F 1 F2 F3 
TI = 0 h F1, 0h F2, 0h  volunteer 
TI = 6 h F1, 6h F2, 6h  
TI = 0 h F1, 0h  F3, 0h volunteer 
TI = 6 h F1, 6h  F3, 6h 
 
F= formulation 
TI= Time interval between the moment of formulation removal and the  
tape stripping phase 
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F1, 0h 
F1, 6h 
F2, 6h 
F2, 0h 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. Treatment scheme for test person with different formulations (F). 
Legend.  F1, 0h = skin treated with PEG 400 saturated with 4-MBC and stripped directly after removing the formulation. 
F1, 6h = skin treated with PEG 400 saturated with 4-MBC and stripped 6 hours after removing the formulation. 
F2, 0h = skin treated with 10% Transcutol®CG in PEG 400 saturated with 4-MBC and stripped directly after 
removing the formulation. 
F2, 6h = skin treated with 10% Transcutol®CG in PEG 400 saturated with 4-MBC and stripped 6 hours after 
removing the formulation. 
 
On each arm two patches were treated during different time intervals (arm A: F1/TI = 0 h, 
F2/TI = 6 h, Arm B: F2/TI = 0 h, F1/TI = 6 h), and the time intervals on the arm were chosen 
at random. Two patches were treated simultaneously, one on each arm. 4 measurements 
were taken for each test person, the two formulations both at two different time intervals.  
 
  
10.7.4 Results 
10.7.4.1 Stratum Corneum Profiles 
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PEG 400, TI=0h, AUCconc-sc = 35.45 PEG 400, TI=6h, AUCconc-sc = 44.83 
  
TranscutolCG 10%, TI=0h, AUCconc-sc = 40.25 Transcutol
CG 10%, TI=6h, AUCconc-sc = 40.22 
  
S
C
 
t
h
i
c
k
n
e
s
s
 
i
n
 
%
 
T
ap
e
 n
u
m
b
e
r
 
S
C
 
 
t
h
i
c
k
n
e
s
s
 
i
n
 
%
 T
ap
e
 n
u
m
b
e
r
 
T
ap
e
 n
u
m
b
e
r
 
S
C
 
t
h
i
c
k
n
e
s
s
 
i
n
 
%
 
T
ap
e
 n
u
m
b
e
r
 
S
C
 
 
t
h
i
c
k
n
e
s
s
 
i
n
 
%
 
0 0,50,5 11 1,51,5 22 2,52,5 33 3,53,5 44 4,54,5 55
0
10
20
30
40
50
60
70
80
90
100
1
5
10
15
20
25
30
35
40
45
50
55
68
0 0,50,5 11 1,51,5 22 2,52,5 33 3,53,5 44 4,54,5 55
0
10
20
30
40
50
60
70
80
90
100
1
5
10
15
20
25
30
35
40
45
50
62
0 0,50,5 11 1,51,5 22 2,52,5 33 3,53,5 44 4,54,5 55
0
10
20
30
40
50
60
70
80
90
100
1
5
10
15
20
25
30
35
40
45
55
0 0,50,5 11 1,51,5 22 2,52,5 33 3,53,5 44 4,54,5 55
0
10
20
30
40
50
60
70
80
90
100
1
5
10
15
20
25
30
35
40
45
50
55
69
4-MBC [µg/cm2] 4-MBC [µg/cm2] 
4-MBC [µg/cm2] 4-MBC [µg/cm2] 
  
 
Volunteer 3 
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TranscutolCG 10%, TI=0h, AUCconc-sc = 57.15 TranscutolCG 10%, TI=6h, AUCconc-sc = 51.56 
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Volunteer 4 
PEG 400, TI=0h, AUCconc-sc = 38.65 PEG 400, TI=6h, AUCconc-sc = 20.90 
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Volunteer 5 
PEG 400, TI=0h, AUCconc-sc = 51.97 PEG 400, TI=6h, AUCconc-sc = 10.30 
  
TranscutolCG 10%, TI=0h, AUCconc-sc = 27.03 TranscutolCG 10%, TI=6h, AUCconc-sc = 32.81 
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Volunteer 6 
PEG 400, TI=0h, AUCconc-sc = 27.13 PEG 400, TI=6h, AUCconc-sc = 10.67 
  
TranscutolCG 50%, TI=0h, AUCconc-sc = 71.87 TranscutolCG 50%, TI=6h, AUCconc-sc = 34.55 
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Volunteer 7 
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Volunteer 8 
PEG 400, TI=0h, AUCconc-sc = 26.62 PEG 400, TI=6h, AUCconc-sc = 34.95 
  
TranscutolCG 50%, TI=0h, AUCconc-sc = 67.62 TranscutolCG 50%, TI=6h, AUCconc-sc = 59.15 
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Volunteer 9 
PEG 400, TI=0h, AUCconc-sc = 68.72 PEG 400, TI=6h, AUCconc-sc = 37.55 
  
TranscutolCG 50%, TI=0h, AUCconc-sc = 138.60 TranscutolCG 50%, TI=6h, AUCconc-sc = 88.37 
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Volunteer 10 
 
PEG 400, TI=0h, AUCconc-sc = 61.67 PEG 400, TI=6h, AUCconc-sc = 41.42 
  
TranscutolCG 50%, TI=0h, AUCconc-sc = 101.71 TranscutolCG 50%, TI=6h, AUCconc-sc = 32.32 
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10.7.4.2 Results for Experiment 3: AUCconc-sc 
For the calculation of the AUCconc-sc, the first tape collected was discarded due to potential 
drug remaining on the skin surface. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39.  AUCconc-sc-values of 4-MBC after treating skin with PEG 400 formulations containing various 
concentrations of Transcutol®CG. 
Legend.  x  ± SD expressed as AUCconc-sc in µg/tape, n=5 except for 0% Transcutol®CG (n=10). 
 
 
10.7.4.3  Statistical Analysis of results for Experiment 3 
In Experiment 3, two variance analyses were conducted, one for F2 vs F1, one for F3 vs F1.  
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Table 36. Logaritmic AUCconc-sc-values of Experiment 3. 
volunteer 0% Transcutol®CG  10% Transcutol®CG 50% Transcutol®CG 
 TI = 0h TI = 6h TI = 0h TI = 6h TI = 0h TI = 6h 
1 1.55 1.52 1.43 1.25 - - 
2 1.55 1.65 1.60 1.65 - - 
3 1.64 1.60 1.76 1.71 - - 
4 1.56 1.32 1.97 1.69 - - 
5 1.72 1.01 1.43 1.52 - - 
6 1.43 1.03 - - 1.86 1.54 
7 1.88 1.62 - - 2.12 2.00 
8 1.43 1.54 - - 1.83 1.77 
9 1.84 1.57 - - 2.14 1.95 
10 1.79 1.62 - - 2.01 1.51 
 
 
10.7.4.3.1 Formulation with 10% Transcutol®CG vs formulation with 0% Transcutol®CG  
None of the examined main factors showed a significant impact on the amount of 4-MBC 
which penetrated the stratum corneum (p>0.05). 
No interaction could be traced (p>0.05). 
Thus, no difference with respect to the penetrated 4-MBC amount could be deduced from 
this constellation of experiments between the formulations 0% Transcutol®CG and 10% 
Transcutol®CG at any time. 
 
Table 37. ANOVA for 4-MBC amount in SC from 0% and 10% Transcutol®CG formulations in Experiment 3 – 
Type III Sum of Squares. 
Source Sum of Squares Df Mean square F-ratio p value 
main effects 
A: fomulation 
B: time intervall 
C: volunteer 
 
0.0370 
0.0871 
0.2318 
 
1 
1 
4 
 
0.0370 
0.0871 
0.0580 
 
0.99 
2.33 
1.55 
 
0.3762 
0.2015 
0.3406 
interactions 
AB 
AC 
BC 
 
0.0168 
0.1676 
0.1033 
 
1 
4 
4 
 
0.0168 
0.0419 
0.0258 
 
0.45 
1.12 
0.69 
 
0.5390 
0.4571 
0.6356 
residual  0.1495 4 0.0374   
total 0.7931 19    
All F-ratios are based on the residual mean square error. 
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10.7.4.3.2 Formulation with 50% Transcutol®CG vs formulation with 0% Transcutol®CG 
The comparison of the formulation containing 50% Transcutol®CG and the formulation 
without Transcutol®CG by means of the variance analysis was statistically showed for the 
factors formulation (p<0.05), time interval (p<0.05) and volunteer (p<0.05). However, no 
significant data arose in the test for interaction.  
 
However, an addition of 50% Transcutol®CG caused a significant change in the amount of 
penetrating 4-MBC. The impact of the factor time interval shows that the amount of 4-MBC in 
the stratum corneum at TI = 6 h was significantly different from TI = 0 h. In contrast to other 
variance analyses, this comparison of formulations indicated a major difference among 
individual test persons (inter-individual distribution).  
 
Table 38. ANOVA for 4-MBC amount in SC from 0% and 50% Transcutol®CG formulations in Experiment 3 - 
Type III Sum of Squares. 
Source Sum of Squares Df Mean Square F-ratio p value 
main effects 
A: formulation 
B: time intervall 
C: volunteer 
 
0.4440 
0.2376 
0.5174 
 
1 
1 
4 
 
0.4440 
0.2376 
0.1294 
 
43.80 
23.44 
12.76 
 
0.0027 
0.0084 
0.0151 
interactions 
AB 
AC 
BC 
 
0.0020 
0.0908 
0.0938 
 
1 
4 
4 
 
0.0647 
0.0354 
0.0333 
 
0.20 
2.24 
2.31 
 
0.6799 
0.2270 
0.2182 
residual  0.0406 4 0.0162   
total 1.42628 19    
All F-ratios are based on the residual mean square error. 
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10.8 Calculation of intra–individual variance for determination of number of 
volunteers 
 
In a clinical test that involves a topical formulation a test person is often treated on different 
skin patches (placebo and verum). Both formulations are tested on a candidate. 
Subsequently, a calculation of a number of volunteers is necessary in order to conduct such 
a pair experiment. Still the inter–individual dispersion has no influence on such a test 
constellation.  
 
The intra-individual variance σ2 can be estimated by the results of the variance analyses as 
average Mean Square Error (the Mean Square Errors of the three variance analyses are 
assessed together with the degrees of freedom for the average calculation). Departing from 
a proportional, relevant difference D between two formulations, the selectivity can be 
calculated by means of this variance for a given test scope (nomogram [253]) which means 
one can discern the probability based on which a certain impact occurs with a definite 
number n of test persons. The proportional difference D has to be recalculated to the 
difference δ of the natural logarithmic values when applying the nomogram. On the other 
hand, the nomogram permits the assessment of the required test scope based on the 
calculated impact and the determined selectivity. 
Our estimated value for the intra-individual standard deviation σ equals 0.434. The required 
test scope can be read from the nomogram for definite, proportional differences at different 
selectivity.  
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Figure 40. Nomogramm for determination of number of volunteers needed in a population to obtain statistical 
significance for results.  
 
Table 39. Values read in the nomogram in order to assess the test scope based on known, relevant difference, D 
and selectivity. 
   
selectivity 
 δ b δ/σ c 20% 40% 50% 60% 80% 100% 
D a =10% 0.095 0.22 30 55 85 110 180 500 
D=20% 0.182 0.42 9 18 23 30 46 125 
D=30% 0.262 0.60 6 10 13 16 25 60 
D=40% 0.336 0.78 4 7 9 10 15 42 
D=50% 0.405 0.93 4 6 7 8 12 26 
D=60% 0.470 1.08 3 5 6 7 9 20 
D=70% 0.530 1.22 3 4 5 6 7 16 
D=80% 0.588 1.35 3 4 5 5 7 14 
D=90% 0.642 1.48 3 4 4 5 6 12 
D=100% 0.693 1.60 3 4 4 4 5 10 
 
a
 Relevant difference between 2 formulations 
b
 Difference of the natural logarithmic values 
c
 Relevant difference 
 
 
Relevant difference δ/σ 
Se
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